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C/EBP, CCAAT/enhancer-binding protein  
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CaMKKβ, Ca(2+)/CaM-dependent protein kinase kinase β 
CAR, cardamonin  
CD36, cluster of differentiation 36 
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CYP1A1, cytochrome P4501A1  
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ERK, extracellular signal-regulated kinase  
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FA, fatty acid 
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GLUT4, glucose transporter type 4 
GPAT-1, glycerol-3-phosphate acyl transferase-1  
GST, glutathione S-transferase  
HF, high fat 
JNK, c-jun amino-terminal kinase 
LC-MS/MS, liquid chromatography-mass spectrometry-mass spectrometry  
LKB1, liver kinase B1 
MAPK, mitogen-activated protein kinase  
MN assay, micronucleus assay 
NAFLD, nonalcoholic fat liver disease 
NEFA, non-esterified fatty acid  
Nrf2, nuclear factor-erythroid 2-related factor 2  
p38, p38 MAPK 
PC4-1, EC-(4β→6)-EC-(4β→8)-EC-(4β→8)-EC  
PC4-2, cinnamtannin A2 
PCB1, procyanidin B1  
PCB2, procyanidin B2 
PCC, procyanidin C 
PC-rich BE, procyanidin-rich BE  
PPARα, peroxisome proliferator-activated receptor alpha  
PPARγ, peroxisome proliferator-activated receptor gamma 
ROS, reactive oxygen species  
RXRα, retinoid X receptor α 
SREBP-1, sterol regulatory element binding protein-1 
UCPs, uncoupling proteins  
XAG, xanthoangelol 
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General introduction 
 
Preface 
Diet and lifestyle are closely related to human health [Hu et al., 2001; Knoops et al., 
2004]. For example, the associated genotoxic carcinogens for some types of cancers and heart 
diseases causation are produced during the broiling and frying of creatinine-containing foods 
such as meats: The fat intake is associated with a higher incidence of the nutritionally linked 
metabolic syndrome and cancers [Weisburger, 2002]. Resent years, the composition of diet is 
changing dramatically and associated with excess intake of energy-dense foods and physical 
inactivity. The proportion of energy from fats and oil, and animal proteins has increased. In 
contrast, the amount of time spent on physical activity has been decreasing year-by-year 
[Eaton, 2006]. These lifestyle changes lead to an increase in patients suffering from 
life-style-related disease including obesity, nonalcoholic fatty liver disease (NAFLD), insulin 
resistance and even cancers. To prevent life style-related disease, natural products offer a 
bonanza for the development of novel therapeutic agents used to treat a variety of human 
diseases [Williamson and Manach, 2005]. There is currently a growing interest in the use of 
compounds from natural sources. Especially, polyphenols showed the prevention of obesity, 
diabetes, cardivascular disease, cancers and other diseases [Scalbert et al., 2005].  
Among the polyphenols, the author focused on the chaclcones 4-hydroxyderricin (4HD), 
xanthoangelol (XAG), cardamonin (CAR) and flavokawain B (FKB). The chemical structures 
of these chalcones were shown in Fig. G1. Each has an aromatic ketone and an enone that 
forms the central core for a variety of important biological compounds. Chalcones were 
originally isolated from natural sources and have a variety of biological properties, including 
antioxidant, anti-inflammatory and anticancer activities [Dimmock et al., 1999; Birari et al., 
2011]. Several synthetic chalcone derivatives are also known to inhibit diabetic complications 
[Lim et al., 2001]. However, the molecular mechanisms of chalcones on prevention of obesity 
and insulin resistance are still not yet fully understood. In this dissertation, the author 
introduced the novel molecular targets of 4HD, XAG, CAR and FKB for prevention of 
obesity and insulin resistance. In the next part, the author explained obesity and metabolic 
syndrome briefly as a background of this dissertation. 
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Fig. G1. The chemical structures of 4-hydroxyderricin, xanthoangelol, cardamonin and 
flavokawain B.  
 
Obesity and metabolic syndrome 
Obesity has increased at an alarming rate in recent years and is now a worldwide public 
health problem. Obesity is defined as an abdomen increase in fat, though obtaining not 
necessarily in body weight gain. It may have an adverse effect on health, leading to reducing 
life expectancy and increased health problems [Haslam et al., 2005]. Obesity is not a single 
disorder but a heterogeneous group of conditions with multiple causes. Body weight is 
determined by an interaction between genetic, environmental and psychosocial factors acting 
through the physiological mediators of energy intake and expenditure [Friedman et al., 2000]. 
At an individual level, a combination of excessive food energy intake and a lack of physical 
activity are thought to explain most cases of obesity. A limited number of cases are due 
primarily to genetics, medical reasons or psychiatric illness [Bleich et al., 2008]. 
Obesity is a medical condition, in which body fatness is increasing accompanied by 
profound changes in physiological function of adipose tissue, skeletal muscle and liver. These 
changes are, to a certain extent, dependent on the regional distribution of adipose tissue. The 
intra-abdominal visceral deposition of fat in adipose tissue is a major contributor to the 
development of elevated plasma insulin and insulin resistance, diabetes, NAFLD and other 
metabolic disease [Friedman et al., 2000; Reaven et al., 2011]. Skeletal muscle is the most 
important tissue for maintaining glucose homeostasis under insulin-stimulated conditions 
[DeFronzo et al., 1988]. Moreover, it is known that skeletal muscle is a primary site of insulin 
resistance in type2 diabetes mellitus [Bogardus et al., 1984; Bonadonna et al., 1990, Bouzakri 
et al., 2005]. Under the condition of obesity, the inflammation adipockines and free fatty acids 
(FAs), which secreted from adipose tissue, decreased skeletal insulin sensitivity with reduced 
glucose uptake and increased the risk of insulin resistance, [Kim et al., 2004; Ueki et al., 
2004; Friedman et al., 2000]. Liver is a pivotal organ in regulating the metabolism especially 
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lipid metabolism. Obesity is associated with an increased risk of steatosis in liver. Under the 
conditions of obesity, the rate of hepatic FA uptake from plasmas and de novo FA synthesis 
are greater than the rate of FA oxidation and export. The excessive amount of intrahepatic 
triglyceride represents an imbalance between complex interactions of metabolic events, which 
increased the risk of NAFLD [Targher et al., 2007; Ahmed et al., 2009]. The obesity and the 
profound changes in physiological functions of adipose tissue, skeletal muscle and liver are 
leading to the metabolic syndrome.  
Diet
Exercise
Enviroment
Genetics
Obesity
Adipocyte differentiation
Adipogensis
Energy expenditure
Fatty acid synthesis
Enegy expenditure
Glucose intake
Skeletal Muscle White adipose tissue Liver
Metabolic
Syndrome
Hypertension
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Insulin resistance
Visceral fat obesity
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Fig. G2. Obesity and metabolic syndrome. 
 
The metabolic syndrome is a common metabolic disorder. The relationship of obesity 
and metabolic syndrome is illustrated in Fig. G2. The metabolic syndrome can be 
characterized by a cluster of manifestations, such as insulin resistance, hypertension, NAFLD, 
and glucose intolerance. These medical disorders increase a risk of developing cardiovascular 
diseases and diabetes mellitus [Eckel et al., 2005; Lakka et al., 2002; Marchesini et al., 2003]. 
Obesity is associated with a significant risk factor for metabolic syndrome [Hajer et al., 2008; 
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Ligibel, 2011]. Thus, weight loss has been recognized to the major health beneficial way for 
overweight people and also increases life expectancy in people having metabolic syndrome 
[Goldstein, 1992]. Weight control medications are becoming popular in today’s society, but 
all the medications controls have side effects [Bray et al., 2009]. Therefore, safe and effective 
weight loss methods are expected. Certain phytochemicals have been reported to prevent and 
reduce the risk of obesity [Gonzalez-Castejon and Rodriguez-Casado, 2011]. Dietary 
phytochemicals may be another cure for weight control and management of metabolic 
syndrome. 
 
Adipocyte differentiation 
Adipocyte differentiation is deeply involved in the onset of obesity. 3T3-L1 cells, 
isolated from non-clonal Swiss 3T3-L1 cells, supply for a well-characterized cell culture 
model for the study of adipocyte-specific differentiation [Green et. al., 1975]. During 
adipogenesis, fibroblast-like preadipocytes differentiate into lipid-laden and 
insulin-responsive adipocytes. This process occurs in several stages and involves a cascade of 
transcription factors. Among them, peroxisome proliferator-activated receptor gamma 
(PPARγ) and CCAAT/enhancer-binding proteins (C/EBPs) are considered to be the master 
regulator or the crucial determinants of adipocyte fate [Tontonoz et al., 1994; Lefterova et al., 
2009]. The role of PPARγ as the master regulator of adipogenesis is supported by 
overwhelming evidence from both in vivo and in vitro studies. Important early evidence of the 
critical role of PPARγ in regulating adipogenesis came from Spiegelman and collaborators 
[Tontonoz et al., 1994; Tontonoz et al., 1994], who had investigated to elucidate the 
transcription factors regulating expression of the adiposes pecific FA binding protein 
aP2/FABP4. Similar to a subset of other nuclear receptors, PPARγ binds DNA as a 
heterodimer with retinoid X receptor α (RXRα). Analysis of the regulatory regions of PPARγ 
target genes has identified a PPARγ-response element, the consensus sequence of which 
consists of two direct repeats of the hexamer ‘AGGTCA’ separated by a single nucleotide 
(called a ‘DR-1’ sequence) [Lefterova et al., 2009; Tontonoz and Spiegelma, 2008]. On the 
other hand, C/EBPα functions as a principal player in adipogenesis also resulted from 
gain-of-function studies in cultured cells [Freytag et al., 1994] as well as establishment of 
appropriate knockout mice. Whole-body C/EBPα-knock mice, which die shortly after birth 
because of liver defects and hypoglycemia, fail to accumulate lipid in white or brown 
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adipocytes [Wang et al., 1995]. Before the discovery of PPARγ and C/EBPα as the master 
regulators of adipogenesis, many researchers tried to identify the mechanism of adipocyte 
differentiation. The cascade of transcription factors eventually leads to expression of PPARγ 
and C/EBPα, which is established by McKnight and associates [Cao et al., 1991; Yeh et al., 
1995]: two other members of the C/EBP family, C/EBPβ and C/EBPδ, are expressed earlier 
than C/EBPα during adipogenesis in 3T3-L1 cells and they are responsible for regulating 
C/EBPα and PPARγ expression. The model of PPARγ and C/EBP transcriptional action 
during adipogenesis is illustrated in Fig. G3. [Lefterova et al., 2009] 
 
 
 
 
 
 
Fig. G3. Model of PPARγ and C/EBP transcriptional action during adipogenesis. During the 
early stages of adipogenesis, C/EBPβ and -δ activate expression of PPARγ, C/EBPα and 
probably other adipogenic genes. Downstream genes characteristic of terminally 
differentiated adipocytes are regulated by binding of PPARγ as aheterodimer with RXRα at 
thousands of locations, with C/EBPα and β frequently occupying C/EBP-response elements 
nearby. 
 
Hepatic steatosis 
Hepatic steatosis caused by the activation of FAs uptake, enhanced de novo lipogenesis, 
and lowing of lipid catabolism. The rate of transport of FAs is the first essential step in the 
accumulation of fat in the hepotocytes [Gasbarrini et al., 2005; Bradbury, 2006]. Cluster of 
differentiation 36 (CD36) is one of the characterized FA transporters for FAs uptake [Su et al., 
2009]. CD36 is expressed in a wide variety of cells including macrophages, adipocytes, 
myocytes, enterocytes and hepatocytes [Hajri et al., 2002]. Hepatic CD36 expression is 
normally weak, but its expression is increased in rodents with fatty liver [Bonen et al., 2007]. 
The expression of CD36 increased concomitantly with hepatic lipid content in different 
animal models of liver steatosis [Buque et al., 2010; Degrace et al., 2006]. De novo 
lipogenesis is mediated by sterol regulatory element binding protein-1 (SREBP-1) which is a 
C/EBPβC/EBPδ PPARγ RXRαC/EBPβC/EBPδ
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key lipogenic transcription factor, and nutritionally regulated by glucose and insulin 
[Goldstein et al., 2008; Zhou et al., 2001]. SREBP-1 preferentially regulates the lipogenic 
process by activating genes for FA and triglyceride synthesis, which are involved in hepatic 
steatosis [Sanyal, 2005]. It is also known that peroxisome proliferator-activated receptors 
(PPARs) mediate the critical transcriptional regulation of genes associated with lipid 
homeostasis [Lee et al., 2003]. Especially, PPARα is most abundantly expressed in the liver 
and has the effect of diminishing circulating triglycerides and preventing hepatic steatosis 
through increasing hepatic β-oxidation [Braissant and Wahli, 1998]. Therefore, the CD36, 
SREBP-1 and PPARα are the important molecular targets for prevention of hepatic steatosis. 
 
AMPK  
Adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) is a key 
modulator to maintain the cellular as well as whole-body energy balance. Fig. G4 shows the 
roles of AMPK in the control of whole-body energy metabolism and AMPK signaling 
pathway. In the liver and white adipose tissue, phosphorylation of AMPK reversibly and 
inactivates acetyl CoA carboxylase (ACC) through phosphorylation of this enzyme. 
Glycerol-3-phosphate acyl transferase-1 (GPAT-1) and carnitine palmitoyltransferase-1 
(CPT-1) are the enzymes involving in FA metabolism. GPAT-1 esterifies FAs to glycerol to 
form triglyceride for storage. The activation of AMPK phosphorylates GPAT-1 and inhibits 
an activity of this enzyme as the same as ACC. In contrast, CPT-1 transfers cytosolic 
long-chain fatty acyl CoA into the mitochondria for oxidation and is allosterically inhibited 
by malonyl CoA [Lage et al., 2008; Ejaz et al., 2009;]. AMPK also mediates suppression of 
lipogeneic gene expression such as FA synthase and ACC through decreasing the functions of 
transcription factors SREBP-1 [Foretz et al., 2005; Zhou et al., 2001] and 
carbohydrate-responsive element-binding protein (ChREBP) [Kawaguchi et al., 2002; Merrill 
et al., 1997]. In the skeletal muscle, AMPK is activated during exercise, which is involved in 
contraction-stimulated glucose transport and FA oxidation, as a result of acute decreases in 
the ratios of ATP/AMP and phosphocreatine/creatine. In the heart, AMPK activity increases 
during ischaemia and functions to sustain ATP, cardiac function and myocardial viability 
[Assifi et al., 2005]. AMPK represents a potential target for the treatment of obesity, insulin 
resistance and type II diabetes. Physiological, pharmacological and genetic data clearly 
demonstrate that manipulating the activity of AMPK and its upstream kinases, liver kinase B1 
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(LKB1) and Ca(2+)/CaM-dependent protein kinase kinase β (CaMKKβ), in different tissues 
has a profound impact on feeding, body weight, glucose homeostasis and insulin sensitivity in 
rodents and humans [Lage et al., 2008].  
 
(A) 
 
 
 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
 
 
Fig. G4. Roles of AMPK in the control of whole-body energy metabolism (A) and AMPK 
signaling pathway (B). 
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Fig. G5. Invovement of the MAPKs at the various steps of adipogenesis. 
 
MAPKs 
Mitogen-activated protein kinase (MAPK) signalling occurs in response to almost any 
change in the extracellular or intracellular milieu that affects the metabolism of the cell, organ 
or the entire organism [Gehart et al., 2010]. Most of the knowledge comes from the study of 
three groups of MAPKs: extracellular signal-regulated kinases (ERKs); c-Jun amino-terminal 
kinases (JNKs); and p38 MAPK (p38). These kinases are serine/threonine kinases regulated 
by phosphorylation cascades organized in specific modules. All modules comprise three 
additional protein kinases activated in series and leading to activation of a specific MAP 
kinase: a MAP kinase kinase, represented by MEK or MKK proteins, which phosphorylates a 
specific MAPK, and a MAP kinase kinase kinase (MAPKKK), represented by Raf and 
MEKK proteins, which phosphorylates a specific MAPKK [Robinson and Melanie, 1997; 
Gehart et al., 2010]. Activation of MAPKs is associated with detrimental events in obesity 
and diabetes that contribute to disease progression [Bost et al., 2005; Gehart et al., 2010]. 
MAPK pathways are able to regulate adipogenesis at each steps of the process, from stem 
cells to adipocytes (the various effects are summarized in Fig. G5) [Bost et al., 2005]. ERK 
pathway is involved in throughout adipogenesis, demonstrating both positive and negative 
ERK
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effects. Activation of ERK was necessary for adipocytes differentiation, and the reduction of 
ERK expression in pre-adipocytes led to decrease in adipocyte differentiation [Sale et al., 
1995]. However, the activation of ERK conversely attenuates differentiation by 
phosphorylation of PPARγ during adipocyte differentiation [Camp et al., 1999; Hu et al., 
1996]. Therefore, ERK activation is tightly and temporally controlled: it has to turn on for 
pre-adipocytes, while shut off to avoid PPARγ phosphorylation during adipocyte 
differentiation. It has been known that JNK is involved in insulin signaling pathway 
[Hirosumi et al., 2002; Sabio et al., 1996]. However, the effect of JNK on adipogenesis was 
still not clear, although the activation of JNK inhibits adipocyte differentiation through 
phosphorylation of PPARγ and negatively regulating its transcriptional activity [Camp et al., 
1999]. It is reported that p38 activity is required for adipocyte differentiation [Engelman et al., 
1998]. Obesity-related insulin resistance is an important contributor to the metabolic 
disturbance that define metabolic syndrome. Many studies have causally implicated MAPKs 
in the development of insulin resistance. ERK1 knokout mice are protected from diet-induced 
obesity and insulin resistance [Bost et al., 2005]. Global deletion of JNK or its specific 
deletion in adipose tissue, skeletal muscle and brain has been show to attenuate diet-induced 
insulin resistance in mice fed a high-fat (HF) diet [Sabio and Davis, 2010]. p38 is requited for 
glucose transporter type 4 (GLUT4)-mediated glucose uptake in response to insulin 
[Antonescu et al., 2005; Ribe et al., 2005]. p38 is required for glucagon- fasting-mediated 
suppression of hepatic lipogenesis, possibly through the inhibition of SREBP-1 transcription 
[Xiong et al., 2007]. These results indicate that MAPKs are important targets for regulating 
obesity and obesity-related disease.     
 
The aim and profile of this dissertation 
The aim of this dissertation is elucidation of molecular mechanisms behind the 
preventive effects of chalcones on obesity and insulin resistance. Briefly, the author 
investigated the mechanisms of chalcones 4HD, XAG, CAR and FKB on adipocyte 
differentiation in 3T3-L1 cells and FAs-induced steatosis in HepG2 cells. Moreover, the 
author demonstrated the preventive effects of Ashitaba extract, which contains two main 
chalcones 4HD and XAG, on HF diet-induced obesity and insulin resistance in C57BL/6 
mice. 
In Section A of Chapter 1, the author screened for the polyphenols, which decreased 
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intracellular lipid accumulation in 3T3-L1 cells. It was found that 6 effective polyphenols, 
namely 4HD, XAG, CAR, FKB, glabridin and 1,4-anthraquinone, inhibited lipid 
accumulation without cytotoxity. In Section B of Chapter 1, the mechanism of Ashitaba 
chalcones 4HD and XAG on adipocytes differentiation was investigated. The author, first, 
evaluated the anti-adipogenic effect of two chalcones 4HD and XAG on intracellular lipid 
accumulation during the differentiation of 3T3-L1 cells. To clarify the underlying molecular 
mechanisms, the author, further, investigated the effects of these chalcones on the expression 
of adipocyte-specific transcription factors, C/EBPs and PPARγ, and phosphorylation of 
AMPK and MAPK that involved in the expression of these transcription factors. As the 
results, 4HD and XAG inhibit adipocytes differentiation through AMPK and MAPK 
pathways, resulting in the down-expression of adipocyte-specific transcription factors. In 
order to confirm the inhibitory effects of chalcones on lipid accumulation, the author 
investigated another two chalcones CAR and FKB (a 4’-O-methoxylated CAR analog) and 
alpinetin (ALP) (an inactive flavonone) on adipocyte differentiation in Section C of Chapter 1. 
The author, first, evaluated the anti-adipogenic effect of CAR, FKB and ALP on intracellular 
lipid accumulation during the differentiation of 3T3-L1 cells. To clarify the underlying 
molecular mechanisms, the author, further, investigated the effects of these compounds on the 
expression of adipocyte-specific transcription factors, C/EBPα and PPARγ, and the 
phosphorylation level of ERK. As the results, CAR and FKB but not ALP inhibited lipid 
accumulation through down-expression of adipocyte-specific transcription factors. The 
inhibitory effects of the two chalcones are involved, at least in part, in ERK activation. 
In Chapter 2, the author established an experimental model of hepatocellular steatosis 
with a fat overaccumulation profile using a mixture of FAs [palmitic acid (C16:0) : oleic acid 
(C18:1) = 1:2]. Then the author studied the effect of 4HD, XAG, CAR and FKB on 
FAs-induced lipid accumulation. To clarify the underlying mechanism, the effects of these 
chalcones on the expression of SREBP-1 and PPARα, and the activation of LKB-1/AMPK 
and MAPKs were investigated. As the results, these chalcones decreased the expression of 
SREBP-1 and increased the expression of PPARα. These chalcones increased AMPK and 
LKB-1 activation without the activation of MAPKs.  
In Chapter 3, the author first detected the content of the two main chalcones 4HD and 
XAG in Ashitaba extract using LC-MS/MS. Then the author investigated whether Ashitaba 
extract prevented obesity and insulin resistance in HF diet-fed C57BL/6 mice. The effects of 
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Ashitaba extract on body, white adipose tissue weight, plasma and liver lipid levels, plasma 
glucose, insulin and adiponectin levels were investigated. Moreover the author demonstrated 
the underlying preventive molecular mechanism of Ashitaba extract on prevention of HF 
diet-induced obesity and insulin resistance.  
Based on the obtained results, the author assumes that 4HD, XAG, CAR and FKB 
suppress adipocytes differentiation and FAs-induced lipid accumulation in vitro. Ashitaba 
extract rich in 4HD and XAG is able to prevent HF diet-induced obesity and insulin resistance. 
Taken together the findings in this dissertation, the author concludes that chalcones should be 
of benefit to prevent obesity and insulin resistance. 
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Chapter 1 
Chalcones suppress differentiation of preadipocytes to adipocytes via AMPK and 
MAPK pathways 
CHAPTER INTRODUCTION 
Adipocytes differentiation is deeply involved in the onset of obesity. During 
fibroblast-like preadipocytes differentiate into lipid-laden adipocytes, peroxisome 
proliferator-activated receptor gamma (PPARγ) and CCAAT/enhancer-binding proteins 
(C/EBPs) are known to be the master regulators or the crucial determinants of adipocyte fate 
[Tontonoz et al., 1994; Lefterova et al., 2009]. Glucose transporter type 4 (GLUT4), of which 
expression is regulated by C/EBPs, plays an important role in glucose uptake in adipocytes 
[Kaestner et al., 1990]. Adenosine 5'-monophosphate activated protein kinase (AMPK) is a 
key modulator to maintain the cellular as well as whole-body energy balance. In adipocytes, 
phosphorylation of AMPK reversibly and inactivates acetyl CoA carboxylase (ACC) through 
phosphorylation of this enzyme. Glycerol-3-phosphate acyl transferase-1 (GPAT-1) and 
carnitine palmitoyltransferase-1 (CPT-1) are the enzymes involved in fatty acid metabolism. 
GPAT-1 esterifies fatty acids to glycerol to form triglyceride for storage. The activation of 
AMPK also phosphorylates GPAT-1 and inhibits an activity of this enzyme as the same as 
ACC. In contrast, CPT-1 transfers cytosolic long-chain fatty acyl CoA into the mitochondria 
for oxidation and is allosterically inhibited by malonyl CoA [Ejaz et al., 2009]. Moreover, the 
activation of AMPK also inhibited the differentiation of 3T3-L1 cells by down-regulating the 
expression of C/EBPβ, δ, α, and PPARγ [Gao et al., 2008]. The extracellular signal-regulated 
kinase (ERK), c-Jun amino-terminal kinase (JNK) and p38 MAPK (p38) are the members of 
Mitogen-activated protein kinases (MAPKs) that play a pivotal role in many essential cellular 
processes including adipocytes differentiation. ERK is necessary for preadipocytes 
differentiation into adipocytes, but the sustained activation of the ERK inhibits the 
differentiation [Sale et al., 1995; Sakaue et al., 2004]. Activation of JNK also inhibits 
adipocytes differentiation through phosphorylation of PPARγ and negatively regulating its 
transcriptional activity [Camp et al., 1999]. However, p38, not the same as ERK and JNK, is 
important for promotion of 3T3-L1 cells differentiation [Engelman et al., 1998]. 
Natural products, especial polyphenols, are expected for prevention and treatment of 
obesity and other human diseases [Williamson and Manach, 2005; Rayalam, et al., 2008; 
Scalbert, et al., 2005]. Chalcones, which have an aromatic ketone and an enone, are 
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containing in various plants and have been reported to have a variety of beneficial functions 
for health promotion, including antioxidant, anti-inflammatory and anticancer activities. 
Several synthetic chalcones also show a series of biological activity [Dimmock, et al., 1999; 
Bandgar, et al., 2009]. However, the preventive effects and molecular mechanisms of 
chalcones on obesity are not fully understood yet.  
This chapter was divided into 3 sections. In Section A, the author searched for the 
effective compounds capable of inhibiting the lipid accumulation in 3T3-L1 cells among 49 
polyphenols. Then in Section B, the author investigated inhibitory effect of Ashitaba 
chalcones 4HD and XAG on lipid accumulation and clarified the underlying molecular 
mechanisms of these two chalcones on adipocytes differentiation. In Section C, the author 
selected another two effective chalcones CAR and FKB, and alpinetin (ALP) as a reference 
compound to confirm the inhibitory effects of chalcones on adipocytes differentiation. 
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Section A 
Effects of polyphenols on lipid accumulation in 3T3-L1 adipocytes 
INTRODUCTION 
Obesity is a condition in which adipocytes accumulate a large amount of fat and become 
enlarged. It is characterized at the cellular level by an increase in the number and size of 
adipocytes differentiated from fibroblastic preadipocytes in adipose tissue. 3T3-L1 
preadipocytes are known to differentiate into mature adipocyte-like cells in vitro. It is a 
well-characterized cell culture model for the study of adipocyte specific differentiation [Green 
and Kehinde, 1975]. Intracellular accumulation of lipid droplets can be observed during cell 
differentiation.  
Polyphenols are the most abundant antioxidants in diet. The research on the effects of 
polyphenols on human health has developed considerably recent years. It strongly supports a 
role for polyphenols in the prevention of obesity and insulin resistance [Williamson and 
Manach, 2005; Rayalam, et al., 2008; Scalbert, et al., 2005]. Flavonoids, a class of plant 
secondary metabolites or yellow pigments, can be visualized as two benzene rings which are 
joined together with a short three carbon chain. The flavonoids consist of several major 
subgroups: chalcone, flavone, flavonol, flavanone and isoflavonoids [Peterson et al., 1998]. 
Research on dietary flavonoids has shown them to have a broad spectrum of biological 
activities including anti-cancer, antioxidant, anti-inflammatory [Cook et al., 1998]. The 
anthraquinones, with two ketone groups added at posi-tion C9 and position C10, occur 
naturally in plants. The anthraquinones are also reported to active against certain diseases 
[Choi et al., 2005; Huang et al., 1998; Malterud et al., 1993]. As mentioned above, 
polyphenols have shown many biological effects, but, the effect of polyphenols on lipid 
accumulation in adipocytes is not fully understood yet. Thus, the author searched for the 
effective compounds capable of inhibiting lipid accumulation in 3T3-L1 cells among 49 
polyphenols (Section A). 
 
MATERIAL AND METHODS 
Materials 
Dulbecco’s modified Eagle’s medium (DMEM) was obtained from Nissui 
Pharmaceutical (Tokyo, Japan). Calf serum and fetal bovine serum (FBS) were purchased 
from Gibco BRL (Gaithersburg, MD) and Biological industries (Kibbutz Beit Haemek, Israel), 
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respectively. The cell proliferation reagent WST-1 substrate was from Roche Diagnostics 
(Mannheim, Germany). 4HD and XAG were purified from “Ashitaba Chalcone Powder” as a 
commercial product of Japan Bio Science Laboratory (Osaka, Japan). CAR and ALP were 
isolated from the seeds of Alpinia katsumadai Hayata, while FKB was synthesized by direct 
aldol condensation of acetophenone with benzaldehyde as described previously [Yamamoto et 
al., 2011]. Biochanin A, caffeic acid and chalcone were purchased from LKT Laboratories (St. 
Paul, MN) and xanthohumol were obtained from Alexis Biochemicals (San Diego, CA). 
Chlorogenic acid and prunetin were from Sigma (St. Louis, MO) and eupatilin was from 
PhytoLab (Vestenbergsgreuth, Germany). Other polyphenols were products of Extrasyntese 
(Genay, France).  
 
Cell culture and treatments 
3T3-L1 cells were maintained and differentiated in a CO2 incubator with 5% CO2/95% 
air at 37°C. Adipocytes differentiation was induced as described previously [Huang et al., 
2006]. Briefly, the cells were grown up to the contact inhibition stage in DMEM containing 
10% (v/v) calf serum. The cells were cells maintained at post-confluent stage for 24 h in 
DMEM containing 10% (v/v) FBS. Differentiation was than induced by a MDI (0.5 mM 
3-isobutyl-1-methylxanthine, 1 µM dexamethasone and 10 µg/mL insulin) cocktail and 100 
µM ascorbic acid phosphate for 3 days in the same medium. Then, the cells were cultured in 
DMEM containing 10% FBS, 10 µg/mL insulin and 100 µM ascorbic acid phosphate for 
another 3 days. Thereafter, the cells were cultured in DMEM containing 10% FBS and 100 
µM ascorbic acid phosphate. 
To search for polyphenols capable of inhibiting intracellular lipid accumulation, 
post-confluent 3T3-L1 cells in the 96-well plates were first treated with the 49 polyphenols or 
DMSO alone as a vehicle control at a final concentration of 0.25% for 3 or 8 days. The cell 
viability assays and sudan II staining were carried out at Day 3 and 8, respectively.  
 
Sudan II staining 
Post-confluent 3T3-L1 cells were plated in 96-well plates and were treated with the 
indicated polyphenol or DMSO alone as a vehicle at a final concentration of 0.25%. The cells 
were washed twice with ice-cold phosphate-buffered saline (PBS), fixed with 100 μL of 4% 
(w/v) paraformaldehyde in PBS for 1 h at 4°C, and stained with 100 μL of 0.5% (w/v) Sudan 
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II solution in 60% (v/v) isopropanol for 1 h at room temperature. The cells were washed twice 
with distilled water to remove excess stain and a photograph was taken at a magnification of 
200×. Thereafter, oil droplets present in the stained cells were dissolved in isopropanol 
containing 4% (v/v) Nonidet P-40, and absorbance of the dissolved solution was measured at 
a wavelength of 490 nm. 
 
Cell viability assay 
The cell viability was determined by WST-1 assay and crystal violet staining assay, as 
previously described [Zhang et al., 2013]. After treating the cells with 1, 5, 10, or 30 μM of 
the indicated polyphenol, the cells were incubated with WST-1 reagent in DMEM medium for 
3 h. The absorbance of the medium was measured at 450 nm with a reference wavelength of 
630 nm using a Wallac multilabel counter (1420 ARVO Sx; PerkinElmer, Waltham, MA, 
USA). Then, the cells were washed three times with PBS and stained with 0.2% (w/v) crystal 
violet in 2% (v/v) ethanol for 10 min. The cells were washed three times with distilled water, 
and the stained dye was dissolved in 0.5% (w/v) sodium dodecyl sulfate in 50% (v/v) ethanol. 
Absorbance was measured at 570 nm with a reference wavelength of 630 nm using a Wallac 
multilabel counter. 
 
Statistical analysis 
All data are expressed as the mean ± standard deviation (SD) of at least three 
independent determinations for each experiment. Statistical significance was analyzed using 
the Dunnett’s test, and probability levels of 0.05 and 0.01 were considered to indicate 
statistical significance. 
 
RESULTS 
Inhibitory effects of polyphenols on lipid accumulation in 3T3-L1 cells with treatment 
for 8 days 
The author initially searched for the inhibitory effect of polyphenols on the intracellular 
lipid accumulation in 3T3-L1 cells by Sudan II staining. The author tested 46 compounds, 
including 7 chalcons (4HD, XAG, CAR, FKB, xanthohumol, butein, and chalcone), 6 
flavones (tangeretin, luteolin, diosmetin, apigenin, baicalein, chrysin, and eupatilin), 7 
flavonols (3-hydroxyflavone, fisetin, quercetin, galangin, robinetin, isorhamnetin, and 
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kaempferol), 7 isoflavones (glabridin, prunetin, genistein, daidzein, equol, daidzin, and 
biochanin A), 8 flavanones (bavachinin, sakuranetin, pinostrobin, ALP, isosakuranetin, 
eriodictyol, flavanone, and naringenin), 8 anthraquinones [1,4-anthraquinone, 
1,4-dimethylanthraquinone (1,4-DAQ), rhein, emodin, sennoside A, aloe-emodin, 
chrysophanol, and danthron], 1 quinone (shikonin), 1 stilbene (resveratrol), 1 
phenylpropanoid (caffeic acid), 1 quinic acid (chlorogenic acid), and 1 hydroxycinnamic acid 
(artepillin C). The cells were treated with each of these compounds at concentrations of 10 or 
30 μM for 8 days. As the results, all chalcones tested, tangeretin, luteolin, 3-hydroxyflavone, 
glabridin, prunetin, bavachinin, sakuranetin, 1,4-anthraquinone, 1,4-DAQ, rhein and shikonin 
significantly suppressed lipid accumulation (Fig. 1A-1.). However, some of these active 
compounds were thought to be cytotoxic based on the morphological features observed under 
a microscope. Moreover, it has been known that expression of adipocyte-specific transcription 
factors play an important role in the early stage of adipocytes differentiation [Lefterova and 
Lazar, 2009]. Hence, the author further investigated the effects of active compounds (at 1, 5, 
10, and 30 μM) on lipid accumulation in 3T3-L1 cells during the first 3 days of treatment. 
 
Inhibitory effects of polyphenols on lipid accumulation in 3T3-L1 cells with treatment 
for 3 days 
During the differentiation of preadipocytes to adipocytes, the cells were treated with 
effective compounds (1, 5, 10, 30 µM) for the first 3 days. As shown in Fig 1A-2, 4HD, XAG, 
CAR, FKB, xanthohumol, butein, glabridin, bavachinin, 1,4-anthraquinone, 
1,4-dimethylanthraquinone and shikonin dose-dependently decreased the lipid accumulation. 
4HD, XAG, CAR, FKB, glabridin and 1,4-anthraquinone at 5 μM significantly decreased the 
lipid accumulation to 67%, 74%, 71%, 76%, 76% and 67%, respectively. 
 
Cell viability assay of effective compounds in 3T3-L1 cells  
3T3-L1 cells were treated with 18 effective compounds at 1, 5, 10 and 30 μM during 
MDI-induced differentiation. After treatment, cell viability was determined by both WST-1 
assay and crystal violet staining assay. As shown in Fig. 1A-3, Both WST-1 assay and crystal 
violet staining assay revealed that some compounds caused a reduction in cell viability at 30 
μM, but 5 μM and lower than 5 μM, neither compound showed any cytotoxicity except 
shikonin.  
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Fig. 1A-1. Inhibitory effects of polyphenols 
on lipid accumulation in 3T3-L1 cells over 8 
days of treatment. During differentiation, the 
cells were treated with the indicated compounds at 
concentrations of 10 or 30 µM, or DMSO as a 
vehicle control, for 8 days. The intracellular lipid 
accumulation was determined by Sudan II staining. 
(A) Chalcones; (B) flavones; (C) flavonols; (D) 
isoflavones; (E) favanones; (F) anthraquinones; (G) 
others. The results are presented as the mean ± SD 
of three independent experiments. *P<0.05 and 
**P<0.01 vs. DMSO-treated cells (Dunnett’s test). 
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DISCUSSION 
Obesity is associated with a significant risk factor for metabolic syndrome [Hajer et al., 
2008; Ligibel, 2011]. Certain polyphenols have been reported to prevent and reduce the risk 
of obesity [Gonzalez-Castejon and Rodriguez-Casado, 2011]. In this section, the author 
searched for effective polyphenols capable of inhibiting lipid accumulation in 3T3-L1 cells. 
Of 49 polyphenols tested, the author found 4HD, XAG, CAR, FKB, glabridin and 
1,4-anthraquinone inhibited lipid accumulation in 3T3-L1 cells without cytotoxity at 5 μM. 
4HD, XAG, CAR and FKB, which are chalcones, showed strong inhibitory effects on lipid 
accumulation. The α,β-unsaturated carbonyl group in the 4HD, XAG, CAR and FKB 
structures may play an important role in the inhibition of lipid accumulation, because the 
α,β-unsaturated carbonyl group in chalcones is known to regulate cell functions, such as the 
NF-E2-related factor 2/Kelch-like ECH-associated protein system [Kim and Surh, 2006]. 
Fig. 1A-2. Effects of polyphenols on lipid accumulation and viability of 3T3-L1 cells 
over 3 days of treatment. The cells were treated with the indicated compounds at concentrations 
of 1, 5, 10, or 30 µM, or DMSO as a vehicle control, for the first 3 days. Intracellular lipid 
accumulation was determined by Sudan II straining at Day 8. The results are presented as the mean ± 
SD of three independent experiments. *P<0.05 and **P<0.01 vs. DMSO-treated cells (Dunnett’s 
test). 
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The author’s finding indicates that α, β-unsaturated chalcones may be potential target 
molecules capable of inhibiting adipocytes differentiation and obesity. Broader screening tests 
are needed to determine the structure–activity relationship. To clarify the effect chalcones on 
differentiation of predadipocytes to adipocytes, the author demonstrated the underlying 
Fig. 1A-3. Effects of polyphenols on viability of 3T3-L1 cells over 3 days of treatment. 
The cells were treated with the indicated compounds at concentrations of 1, 5, 10, or 30 µM, or 
DMSO as a vehicle control, for the first 3 days. Cell viability was measured by WST-1 assays (A) 
and crystal violet staining assays (B), respectively. The results are presented as the mean ± SD of 
three independent experiments. *P<0.05 and **P<0.01 vs. DMSO-treated cells (Dunnett’s test). 
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molecular mechanism of 4HD, XAG, CAR and FKB on adipocyte differentiaton in following 
Section B and C.  
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Section B 
4-Hydroxyderricin and xanthoangelol from Ashitaba (Angelica keiskei) suppress 
differentiation of preadiopocytes to adipocytes via AMPK and MAPK pathways. 
INTRODUCTION 
Certain phytochemicals have been reported to reduce the risk of obesity [Rayalam et al., 
2008; Lu et al., 2012; Alappat and Awad, 2010; Gourineni et al., 2012]. Angelica keiskei, a 
Japanese herb and Japanese name is “Ashidaba”, has been used as a traditional medicine for 
so many years. It contains two main phytochemicals 4HD and XAG, and they have been 
reported to exert various biological activities such as anti-tumor [Kimura et al., 2004; Akihisa 
et al., 2012], anti-inflammatory [Ohkura et al., 2011] and anti-diabetes [Enoki et al., 2007; 
Kawabata et al., 2011] activities. However, the preventive effects of 4HD and XAG on 
obesity are not yet reported to date. 
Results in the Section A showed that two chalcones 4HD and XAG inhibited lipid 
accumulation effectively. In this section B, the author, first, evaluated the anti-adipogenic 
effect of 4HD and XAG on intracellular lipid accumulation during the differentiation of 
3T3-L1 cells. To clarify the underlying molecular mechanisms, we, further, investigated the 
effects of these chalcones on the expression of adipocyte-specific transcription factors, 
C/EBPs and PPARγ, and phosphorylation of AMPK and MAPKs that involved in the 
expression of these transcription factors. 
 
MATERIAL AND METHODS 
Materials 
Antibodies for β-actin, PPARγ, C/EBPα, C/EBPβ, C/EBPδ, GLUT4, horseradish 
peroxidase-conjugated anti-rabbit IgG and anti-goat IgG were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA), p-AMPK, AMPK, p-ACC, ACC, p-ERK, ERK, p-JNK, 
JNK, p-p38, p38 Compound C, PD98059 and SP600125 were purchased from Cell Signaling 
Technology (Beverly, MA). The PCR primer pairs were synthesized as shown in Table 1B-1. 
 
Cell culture and treatments 
Cell culture was performed as described in Chapter 1A. To search for the inhibitory 
effect of 4HD and XAG on the intracellular lipid accumulation , post-confluent 3T3-L1 cells 
in the 96-well plates were first treated with 4HD and XAG or DMSO alone as a vehicle 
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control (a final concentration at 0.25%) for 3 days. Sudan II staining was carried out at Day 0, 
3, 6, 8, and 10. To investigate the molecular mechanism by which the compounds inhibited 
adipocyte differentiation, 3T3-L1 cells were plated on a 35-mm dish and were treated with 
each compound for 3 days. Then, cells were prepared for protein and mRNA analysis at the 
times indicated in each figure. For treatments with the inhibitors for kinases, post-confluent 
3T3-L1 cells were simultaneously treated with the chalcones and inhibitors [PD98059 (20 
µM), SP600125 (5 µM), and compound C (5 µM), respectively], during MDI-induced 
adipocytes differentiation. Expression level of C/EBPβ mRNA was determined on Day 1, 
while that of C/EBPα and PPARγ was determined on Day 5. Lipid accumulation was assessed 
on Day 7. 
 
 
Table 1B-1. Primer sequences used for real-time PCR amplification 
Gene  5’-3’ primer sequence       Reference  
PPARγ         F: ACGTGCAGCTACTGCATGTGA      [Ejaz et al., 2009] 
R: AGAAGGAACACGTTGTCAGCG 
C/EBPα       F: GGAACTTGAAGCACAATCGATC    [Ejaz et al., 2009] 
R: TGGTTTAGCATAGACGTGCACA 
C/EBPβ        F: GGGGTTGTTGATGTTTTTGG        [Gao, et al., 2008] 
              R: CGAAACGGAAAAGGTTCTCA  
C/EBPδ F: GATCTGCACGGCCTGTTGTA       [Huang, et al., 2006] 
 R: CTCCACTGCCCACCTGTCA 
GAPT-1 F: GGCATCTCGTATGATCGCAT        [Ejaz et al., 2009] 
 R: GCAAAATCCACTCGGACGTA 
CPT-1 F: AGAGAAGCCTGCCAGTTTGT      [Ejaz et al., 2009] 
 R: AAAGAGGTGACGGTCAATCC 
18S rRNA F: CATGGCCGTTCTTAGTTGGT       [Ferguson et al., 2010] 
 R: CGCTGAGCCAGTCAGTGTAG  
 
Sudan II staining 
Sudan II staining was performed as described in Chapter 1A. 
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RNA isolation and real-time quantitative PCR analysis 
The 3T3-L1 cells plated in 35-mm dishes were harvested with 200 μL of TRlzol Reagent 
(Invitrogen, Carlsbad, CA, USA), transferred to a microtube, and homogenized. The 
homogenate was mixed with 100 μL chloroform and incubated at room temperature for 10 
min. The mixture was centrifuged at 12,000 × g for 15 min at 4°C and the aqueous phase was 
transferred to another microtube. To precipitate RNA, the aqueous phase was mixed with 400 
μL of isopropyl and incubated for 10 min at room temperature. The mixture was centrifuged 
at 12,000 × g for 10 min at 4°C. The supernatant was discarded, and the pellet containing 
RNA was dried at room temperature. The pellet was dissolved in 30 μL of deionized-distilled 
water. After isopropanol precipitation, RNA was re-dissolved in 40 μL of deionized-distilled 
water. The dissolved samples were purified by digesting the residual DNA using DNase I 
(Roche, Basel, Switzerland) according to the manufacturer’s instructions. The quality and 
concentration of total RNA were measured by a spectrophotometer. Purified RNA (20 ng) was 
subjected to a quantitative RT-PCR amplification using One Step SYBR® PrimeScriptTM Plus 
PCR-RT Kit (Takara Bio, Shiga, Japan). Reactions were run in a RT-PCR system (TaKaRa 
PCR Thermal Cycler Dice, Takara Bio Inc). The relative gene expression level was calculated 
using the comparative cycle threshold method (Livak and Schmittgen, 2001), using the 
expression of the ribosomal RNA (18S rRNA) gene as an internal control. 
 
Western blotting analysis 
Preparation of the cell lysate and western blotting were performed according to 
the previous report [Furuyashiki et al., 2004]. Specific immune complexes were detected 
with the ATTO Light-Capture II Western Blotting Detection System. The density of specific 
bands was calculated using ImageJ image analysis software (NIH, Bethesda, MD, USA). 
 
Statistical analysis 
All data are expressed as the mean ± standard deviation (SD) of at least three 
independent determinations for each experiment. Statistical significance was analyzed using 
the Dunnett’s test, and probability levels of 0.05 and 0.01 were considered to indicate 
statistical significance 
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RESULTS 
4HD and XAG inhibited lipid accumulation during differentiation of 3T3-L1 adipocytes 
In order to examine the effects of 4HD and XAG on the adipocytes differentiation, 
3T3-L1 cells undergoing MDI-induced differentiation were treated with 4HD and XAG (5 
µM). Sudan II staining revealed that 4HD and XAG significantly inhibited the lipid 
accumulation (Fig. 1B-1A). When the sudan II staining was also carried out at Day 0, 3, 6, 8 
and 10, it was confirmed that 4HD and XAG significantly suppressed lipid accumulation after 
Day 6, and accumulated lipids decreased to approximately 40% and 70%, respectively, on 
Day 10 (Fig. 1B-1). 
 
 
 
 
 
 
 
Fig. 1B-1. Suppression of 4HD and XAG on lipid accumulation in 3T3-L1 cells. 3T3-L1 
cells were treated with 4HD, XAG at 5 µM or DMSO as a vehicle control during MDI-induced 
adipocytes differentiation. (A) The intracellular lipid accumulation was determined by sudan II 
straining at Day 8. (B) The intracellular lipid accumulation was stained by Sudan II straining at Day 
0, 3, 6, 8 and 10. The results represent as the mean ± SD from three independent experiments. 
Asterisks indicate significant difference from control treated with DMSO alone at each time point by 
Dunnett’s test. * p<0.05; * * p<0.01. 
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Effects of 4HD and XAG on adipocyte-specific transcription factors expression during 
differentiation of 3T3-L1 adipocytes 
To determine whether the decrease in the lipid droplet accumulation was due to 
down-regulation of adipocyte-specific differentiation markers, the expression of C/EBPα, 
PPARγ and GLUT4 were determined by quantitative RT-PCR and western blotting analysis. 
4HD and XAG at 5 μM significantly down-regulated mRNA levels of C/EBPα and PPARγ 
from 48 h (Fig. 1B-2A). Moreover, these two chalcones decreased C/EBPα (27-74%) and 
PPARγ (9-83%) on both Day 3 and 8. Meanwhile, 4HD and XAG also significantly 
down-regulated the protein expression of a late stage maker GLUT4 on Day 8 by 17% and 
44%, respectively (Fig. 1B-2B). It was noteworthy that inhibition effect of 4HD was higher 
than that of XAG, consisting with their inhibitory degree of lipid accumulation (Fig. 1B-1). 
The author, then, evaluated the effects of 4HD and XAG on expression of C/EBPβ and 
C/EBPδ transcription factors that are upstream of C/EBPα and PPARγ. The author found that 
these two chalcones decreased the C/EBPβ expression not only mRNA level from 6 hours to 
24 hours (Fig. 1B-3A) but also the protein level by 56%  and 43%, respectively, at 24 hours 
(Fig. 1B-3B). However, there is no different changes between in C/EBPδ expression neither 
mRNA nor protein level. 
 
4HD and XAG modulation of energy and lipid metabolism related enzymes. 
AMPK is a major regulator of energy metabolism, and its phosphorylation is involved in 
regulation of adipocytes differentiation [Ejaz et al., 2009]. The author, therefore, investigated 
whether 4HD and XAG regulated adipocytes differentiation and energy metabolism through 
AMPK pathway in 3T3-L1 cells. Western blotting analysis revealed that these chalcones 
enhanced the activation of AMPK by phosphorylation of its α-subunit (4HD: 1.63-fold on 
Day 1; 1.35-fold on Day 3 and XAG: 1.45-fold on Day 1; 1.31-fold on Day 3 compared with 
DMSO treated cells at each time point) (Fig. 1B-4A). In turn, activation of AMPK 
significantly increased the phosphorylation level of ACC (4HD: 1.45-fold on Day 3; 1.67-fold 
on Day 8 and XAG: 1.33-fold on Day 3; 1.37-foldon Day 8) (Fig. 1B-4B), down-regulated its 
down-stream events GAPT 1 mRNA (4HD: 71 %; 75 %; 92 % and XAG: 81 %; 79 %; 88 % 
on Day 1, 3 and 8, respectively) (Fig. 1B-4C), while up-regulated CPT-1 mRNA (4HD: 
1.16-fold; 1.25-fold; 1.23-fold and XAG: 1.14-fold; 1.24-fold; 1.27-fold on Day 1, 3 and 8, 
respectively) (Fig. 1B-4D). 
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Fig. 1B-2. 4HD and XAG down-regulated the expression of C/EBPα, PPARγ and 
GLUT4 during 3T3-L1 adipocytes differentiation. The cells were treated with 4HD and XAG 
at 5 µM or DMSO as a vehicle control during MDI-induced adipocytes. (A) mRNA expression of 
C/EBPα and PPARγ were detected by quantitative RT-PCR. (B) Protein expression of C/EBPα, 
PPARγ and GLUT4 was determined by western blotting analysis. Typical results are shown from 
representative three independent experiments. Band density was quantified and normalized with 
β-actin. The results represent as the mean ± SD from three independent experiments. Asterisks 
indicate significant difference from control treated with DMSO alone at each time point by Dunnett’s 
test. * p<0.05; * * p<0.01. 
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Fig. 1B-3. Effect of 4HD and XAG on expression of C/EBPβ and C/EBPδ during 
3T3-L1 adipocytes differentiation. The cells were treated with 4HD and XAG at 5 µM or 
DMSO as a vehicle control for the first 24 h. (A) mRNA expression of C/EBPβ and C/EBPδ were 
detected by quantitative RT-PCR. (B) Protein expression of C/EBPβ and C/EBPδ was determined by 
western blotting analysis. Typical results are shown from representative three independent 
experiments. Band density was quantified and normalized with β-actin. The results represent as the 
mean ± SD from three independent experiments. Asterisks indicate significant difference from 
control treated with DMSO alone at each time point by Dunnett’s test. * p<0.05; * * p<0.01. 
 
30 
 
 
 
 
 
 
 
Fig. 1B-4. Effects of 4HD and XAG on activation of AMPK signaling in 3T3-L1 
adipocytes. The cells were treated with compounds at 5 µM or DMSO as a vehicle control 
during MDI-induced adipocytes. (A and B) AMPK, p-AMPK, p-ACC and ACC were examined by 
western blotting. Typical results are shown from representative three independent experiments. Band 
density of p-AMPK and p-ACC was quantified and normalized with AMPK and ACC, respectively. 
(C and D) The mRNA expression of enzymes GPAT-1 and CPT-1 were examined using quantitative 
RT-PCR. The results represent as the mean ± SD from three independent experiments. Asterisks 
indicate significant difference from control treated with DMSO alone at each time point by Dunnett’s 
test. * p<0.05; * * p<0.01. 
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Fig. 1B-5. Effects of 4HD and XAG on activation of MAPK signaling in 3T3-L1 
adipocytes. The cells were treated with compounds at 5 µM during MDI-induced adipocytes. ERK, 
JNK and p38 MAPK and their phophorylation level were examined by western blotting. Typical 
results are shown from representative three independent experiments. Band density of p-ERK, p-JNK 
and p-p38 MAPK was quantified and normalized with ERK, JNK and p38 MAPK, respectively. The 
results represent as the mean ± SD from three independent experiments. Asterisks indicate significant 
difference from control treated with DMSO alone at each time point by Dunnett’s test. * p<0.05; * * 
p<0.01. 
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The effect of 4HD and XAG on MAPK pathway during adipocytes differentiation 
MAPK pathway is required for series of metabolic events and is associated with 
modulation effect on obesity including adipocytes differentiation. To investigate the role of 
the MAPK pathway in 4HD- and XAG-inhibiting adipocytes differentiation, phosphorylation 
levels of ERK, JNK and p38 were estimated by western blotting analysis. These chalcones 
increased the level of ERK phosphorylation (4HD: 1.28 to 1.71-fold and XAG: 1.26 to 
1.64-folds) on both Day 1 and 3 (Fig. 1B-5A). Moreover, they also enhanced the level of JNK 
phosphorylation (4HD: 1.69 to 2.79-fold and XAG: 1.00 to 2.33-folds on Day 1, 3 and 8) (Fig. 
1B-5B) during the differentiation of 3T3-L1 cells. However, they did not bring any alter to 
p38 phosphorylation level (Fig. 1B-5C). 
 
AMPK, ERK, JNK inhibitors blocked inhibition effects of 4HD and XAG on adipocytes 
differentiation. 
To confirm the involvement of AMPK, ERK and JNK in 4HD- and XAG-inhibiting 
adipocytes differentiation accurately, the author employed Compound C (AMPK inhibitor, 
5µM), PD98059 (ERK inhibitor, 20 µM) and SP600125 (JNK inhibitor, 5µM) and treated to 
the cells. The author have found that 4HD and XAG decreased the C/EBPβ expression both 
mRNA and protein level on Day 1 (Fig. 1B-3). These chalcones significantly down-regulated 
the expression of C/EBPα and PPARγ from Day 2 (Fig. 1B-2), thereby significantly decreased 
the lipid acuumulation from Day 6 (Fig 1B-1B). Moreover, it has been known that C/EBPβ is 
the initial event that subsequently leads to increase the expression of C/EBPα, PPARγ and 
probably other adipogenic factors [Tontonoz et al., 1994; Wu et al., 1999]. Thus, the author 
determined the mRNA level of C/EBPβ mRNA on Day 1 and that of C/EBPα and PPARγ was 
determined on Day 5 (Fig. 1B-7). Lipid accumulation was also assessed on Day 7 (Fig. 1B-6). 
The author found that treatment with the inhibitors for AMPK, ERK and JNK increased the 
lipid accumulation comparing with control group. In addition, these inhibitors abolished 
effects the 4HD- and XAG-caused suppression of lipid accumulation (Fig. 1B-6). 
Furthermore, the author found that the inhibitors increased the expression of C/EBPα 
(Compound C: 3.92-fold; PD98059: 3.12-fold; SP600125: 3.11-fold and PD+SP: 4.56-fold) 
and PPARγ (Compound C: 2.87-fold, PD98059: 2.18-fold, SP600125: 2.65-fold and PD+SP: 
2.86-fold). The 4HD- and XAG-caused down-regulation of the expression of C/EBPα (4HD: 
41 % and XAG: 58 % compared with DMSO treated cells in Control group) and PPARγ 
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(4HD: 24 % and XAG: 62%) was canceled by treatment with Compound C, PD98059 and 
SP600125 (Fig. 1B-7 upper and middle panels). In addition, Compound C and PD98059 but 
not SP600125 increased the expression of C/EBPβ (Compound C: 1.76-folds; PD98059: 
1.53-folds; SP600125: 1.09-folds and PD+SP: 1.34-folds). The 4HD- and XAG-caused 
down-regulation of the expression of C/EBPβ (4HD: 34 % and XAG: 39 %) was also 
canceled by treatment with Compound C and PD98059, but not SP600125 (Fig.1B-7 bottom 
panel). These results strongly suggested that 4HD and XAG inhibited adipocytes 
differentiation via AMPK, ERK and JNK signaling pathways. 
 
4. Discussion 
Obesity is the main reason for metabolic syndrome. Many studies have been documented 
that adipocytes differentiation and lipid accumulation are associated with the development of 
obesity. Certain dietary phytochemicals are considered to be a prescription for anti-obesity by 
inhibition of differentiation and regulation of lipid metabolism [Rayalam et al., 2008; Lu et 
al., 2012; Alappat and Awad, 2010; Gourineni et al., 2012]. In this section, the author 
demonstrated that 4HD and XAG, the major active chalcones of the Japanese herb Ashitaba, 
reduced lipid accumulation during differentiation of 3T3-L1 cells (Fig. 1B-1) through 
down-regulation of adipocyte-specific transcription factors, C/EBPs and PPARγ (Figs. 1B-3 
and 4), involving in the activation of AMPK and MAPK signaling pathways (Figs. 1B 5-7). 
C/EBPs and PPARγ are the master regulators during the adipocyte differentiation. PPARγ 
forms a heterodimer with retinoic acid X-receptor (RXR) [Kliewer et al., 1992], and regulates 
the transcription of adipocyte-specific genes [Tontonoz et al., 1994]. C/EBPα functions as 
another principal player in adipogenesis and is most abundant in mature adipocytes, where 
plays a crucial role in insulin-dependent glucose uptake [Wu et al., 1999]. In this adipogenic 
process, GLUT4, which is regulated by C/EBPα, participates in glucose uptake in adipocytes 
[Lu et al., 2012]. At the early stage of adipocyte differentiation, activations of C/EBPβ and 
C/EBPδ are the initial events that subsequently lead to increase the expression of C/EBPα, 
PPARγ and probably other adipogenic factors [Cao et al., 1991; Yeh et al., 1995]. The 
author’s founding revealed that 4HD and XAG dramatically down-regulated C/EBPα, PPARγ 
and GLUT4 expression accompanied by the decreased C/EBPβ but not C/EBPδ expression 
(Figs. 1B-2 and 3). However, there is no evidence to make clear that down-regulated C/EBPα 
and PPARγ expression directly associates with reducing C/EBPβ expression level. Further 
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study is needed to investigate this issue. These results indicated that 4HD and XAG 
suppressed C/EBPβ expression at the early stage, thereafter suppressed PPARγ, C/EBPα and 
GLUT4 expression during adipocytes differentiation. 
AMPK is a key enzyme to maintain cellular as well as body energy balance. Intense 
research in recent years has revealed the critical roles that AMPK plays in modulating 
ever-expanding many biological pathways. The broad spectrum of activities of AMPK in lipid 
and glucose metabolism makes it a very attractive target for obesity, diabetes and metabolic 
syndrome [Zhang et al., 2009; Luo et al., 2005]. ACC, which is one of the targets molecular 
of AMPK [Ejaz et al., 2009], is an essential enzyme for the synthesis and consumption of 
fatty acids. The author’s results revealed that 4HD and XAG enhanced the phosphorylation of 
AMPK and ACC during the MDI-induced adipocytes differentiation (Fig. 1B-4A and B). In 
the downstream events, GPAT-1 and CPT-1 are the enzymes involved in synthesis of glycerol 
lipids and in oxidation of fatty acid, respectively [Ejaz et al., 2009]. The author’s results 
showed that these chalcones caused down-regulating GPAT-1 and up-regulating CPT-1 
expression (Fig. 1B-4C and D), respectively. These results suggested that 4HD and XAG 
inhibited adipogenesis through AMPK activation, thereby suppressed ACC activation and 
affected the gene expression of GPAT-1 and CPT-1, which in turn inhibited lipid 
accumulation in adipocytes. To clarify whether the 4HD- and XAG- inhibited adipocytes 
differentiation was dependent on the AMPK activation, the author employed Compound C as 
an AMPK inhibitor. The results showed that Compound C entirely cancelled the inhibitory 
effects of 4HD and XAG on lipid accumulation of adipocytes (Fig. 1B-6). In addition, the 
effects of down-regulation of C/EBPβ, C/EBPα, and PPARγ were also cancelled by treatment 
with compound C. The previous study showed that the activation of AMPK inhibited the 
differentiation of 3T3-L1 cells by down-regulating the expression of C/EBPs and PPARγ 
[Kimura et al., 2004]. Thus, the author’s findings strongly proved that 4HD- and XAG- 
driven inhibition of adipocytes differentiation was involved in AMPK activation. 
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Fig. 1B-6. Effect of AMPK, ERK, JNK inhibitors on 4HD- and XAG-caused 
suppression of lipid accumulation in 3T3-L1 cells. Post-confluent 3T3-L1 cells were treated 
with 4HD and XAG (5 µM) and simultaneously treated with Compound C (5 µM), PD98059 (20 
µM), SP600125 (5 µM) and PD98059 + SP500125 (PD+SP), respectively, for first 3 days. Lipid 
accumulation was assessed by Sudan II staining at Day 7.  
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Fig. 1B-7. Effects of AMPK, ERK, JNK inhibitors on 4HD- and XAG- caused 
suppression of CEBPβ, C/EBPα and PPARγ expression. Post-confluent 3T3-L1 cells were 
treated with 4HD and XAG (5 µM) and simultaneously treated with Compound C (5 µM), PD98059 
(20 µM), SP600125 (5 µM) and PD98059 + SP500125 (PD+SP), respectively, for first 3 days. 
mRNA levels of C/EBPα and PPARγ were determined at Day 5 while mRNA level of C/EBPβ was 
determined at Day 1. The results represent as the mean ± SD from three independent experiments. 
Asterisks indicate significant difference from DMSO treated cells in each group by Dunnett’s test. * 
p<0.05; * * p<0.01. Octothorpes indicate significant difference between inhibitors treated cells to 
DMSO treated cells of Control group. # p<0.05; ##p<0.01. 
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MAPKs are intracellular signaling pathways that play a pivotal role in many essential 
cellular processes including differentiation [Sakaue et al., 2004]. Most of the knowledge 
comes from the study of three groups of MAPKs: ERK, JNKs and p38 MAPK [Bost et al., 
2005]. It was reported that ERK activation was necessary for adipocytes differentiation, and 
the reduction of ERK expression in pre-adipocytes led to decrease in adipocytes 
differentiation [Kimura et al., 2004]. However, the activation of ERK conversely attenuates 
differentiation by phosphorylation of PPARγ during adipocytes differentiation [Akihisa et al., 
2012; Hu et al., 1996]. Therefore, ERK activation is tightly and temporally controlled: it has 
to turn on for pre-adipocytes, while shut off to avoid PPARγ phosphorylation during 
adipocytes differentiation. The author’s results showed that 4HD and XAG enhanced ERK 
phosphorylation during MDI-induced adipocytes differentiation (Fig. 1B-5A), while they 
brought no effect to ERK activation in preadipocytes (data was not shown). When the ERK 
inhibitor PD98059 was treated to the cells with the chalcones during MDI-induced 
differentiation, the inhibition effects of 4HD and XAG on lipid accumulation (Fig. 1B-6) and 
on the expression of C/EBPβ, C/EBPα and PPARγ were reserved (Figs. 1B-7). It has been 
known that JNK is involved in insulin signaling pathway [Hirosumi et al., 2002; Sabio et al., 
2009]. However, the effect of JNK on adipocytes differentiation was still not clear. In the 
present study, the author attempted to clarify this effect using a JNK inhibitor SP600125 and 
found phosphorylation of JNK inhibited adipocytes differentiation. In addition, the author 
also found that SP600125 abolished the inhibitory effects of 4HD and XAG on lipid 
accumulation (Fig. 1B-6) and on the expression of C/EBPα and PPARγ but not C/EBPβ (Fig. 
1B-7). Previous studies reported that activation of JNK inhibits adipocyte differentiation by 
enhancing phosphorylation of PPARγ and negatively regulating its transcriptional activity 
[Ohkura et al., 2011; Hu et al., 1996]. These results indicate that the inhibitory effects of 4HD 
and XAG on adipocytes differentiation is also depend on enhancing phosphorylation of JNK 
and decreasing expression of C/EBPα and PPARγ. p38 MAPK positively regulates 
adipocytes differentiation through the phosphorylation of C/EBPβ [Enoki et al., 2007]. 
However, 4HD and XAG did not alter p38 MAPK activation. Taken together all the results, 
4HD and XAG inhibited adipocytes differentiation through activating ERK and JNK resulting 
in down-regulation of adipocyte-specific transcription factors, C/EBPs and PPARγ. 
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The author’s study demonstrated the inhibition effects of Ashitaba chalcones 4HD and 
XAG on adipocytes differentiation which is deeply involved in the onset of obesity. Obesity 
is associated with certain metabolic disorder diseases such as type 2 diabetes, cardiovascular 
diseases, hypertension, and the certain forms of cancer [Kaul et al., 2012; Vernooij et al., 
2012; Vucenik and Stains, 2012; Ligibel, 2011]. The author’s founding indicates that 4HD 
and XAG should be effective compounds for prevention and improvement of obesity and 
obesity-induced metabolic disorder diseases. Moreover, the author found 4HD and XAG 
regulated adipocytes differentiation through activation of AMPK, ERK and JNK. These 
Fig. 1B-8. The hypothetical scheme of mechanism that 4HD and XAG inhibit 
adipocytes differentiation by AMPK and MAPK pathways. (Upper part) 4HD and XAG 
enhanced ERK and JNK activation by increasing their phosphorylation level but did not alter p38 
activation. (Bottom part) 4HD and XAG enhanced AMPK and ACC activities by increasing their 
phosphorylation levels. The phosphorylated AMPK suppresses expression of GPAT-1 while increases 
expression of CPT-1. The phosphorylated ERK, JNK and AMPK result in suppression of 
adipocyte-specific transcription factors expression. 
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factors could be available as the molecular targets for anti-obesity therapeutics. However, the 
mechanisms of between these factors for modulating adipocytes differentiation did not 
elucidate in present study. It should be an issue for the future study. In addition, to apply the 
anti-obesity effects to clinical treatment, animal studies should also be performed in the 
future. 
In conclusion, 4HD and XAG are able to inhibit adipocytes differentiation through 
down-regulating expression of C/EBPβ, C/EBPα and PPARγ in 3T3-L1 adipocytes. As 
shown in Fig.1B-8, these effects are involved in activation of AMPK, ERK and JNK signal 
pathways. On the one hand, 4HD and XAG enhanced ERK and JNK activation by increasing 
their phosphorylation levels. On the other hand, 4HD and XAG enhanced phosphorylation of 
AMPK and its downstream ACC. The phosphorylation of AMPK also suppressed the 
expression of glycerol synthesis enzyme GPAT-1 and increased expression of fatty acid 
oxidative enzyme CPT-1. The phosphorylation of ERK, JNK and AMPK result in suppression 
of adipocyte-specific transcription factors, C/EBPs and PPARγ. The author’s finding provide 
a possibility that 4HD and XAG are of great benefit to prevent obesity and obesity-related 
disorders. 
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Section C 
The chalcones cardamonin and flavokawain B inhibit the differentiation of 
preadipocytes to adipocytes by activating ERK 
INTRODUCTION 
In Section B, the author demonstrated the underlying mechanism of two chalcones 4HD 
and XAG on adipocyte differentiation. To confirm the inhibitory effects of chalcones on 
adipocytes differentiation, the author focused on another two effective chalcones CAR and 
FKB in this section. In addition to these chalcones, the author also evaluated ALP, a 
flavanone with the same molecular weight with CAR, used as a reference compound. CAR 
and FKB were reported to have some biological activity [Kuroyanagi et al., 2011; Tang et al., 
2012; He et al., 2005; Chen et al., 2013]. However the effects of these chalcones on adipocyte 
differentiation and obesity are still not clear to date.  
In this section, the author determine the underlying molecular mechanism of CAR and 
FKB on adipocyte differentiation, the author examined the effects of these chalcones on the 
expression of the adipocyte-specific transcription factors PPARγ and C/EBPα, and on ERK 
phosphorylation in differentiating 3T3-L1 cells.  
 
MATERIAL AND METHODS 
Materials 
The PCR primer pairs were synthesized as shown in Table 1C-1. Other materials were 
performed as described in Section A and B. 
 
Table 1C-1. Primer sequences used for RT-PCR amplification 
Gene  5’-3’ primer sequence Reference  
PPARγ         F: ACGTGCAGCTACTGCATGTGA       [Ejaz et al., 2009] 
R: AGAAGGAACACGTTGTCAGCG 
C/EBPα       F: GGAACTTGAAGCACAATCGATC     [Ejaz et al., 2009] 
R: TGGTTTAGCATAGACGTGCACA 
GAPDH F: ACAACTTTGGCATTGTGGAA    [Kanamoto, et al. 2011] 
 R: GATGCAGGGATGATGTTCTG  
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Cell culture and treatments 
Cell culture was performed as described in Section A. To search for the inhibitory effect 
of CAR and FKB on the intracellular lipid accumulation , post-confluent 3T3-L1 cells in the 
96-well plates were first treated with CAR, FKB and ALP or DMSO alone as a vehicle 
control (a final concentration at 0.25%) for 3 days. sudan II staining were carried out at Days 
0, 3, 6, 8, and 10. To investigate the molecular mechanism by which the CAR and FKB 
inhibited adipocyte differentiation, 3T3-L1 cells were plated on a 35-mm dish and were 
treated with each compound for 3 days. Then, cells were prepared for protein and mRNA 
analyses at the times indicated in each figure. For treatment with the ERK inhibitor, 3T3-L1 
cells were plated in a 35-mm dish, and were simultaneously treated with the indicated 
chalcone plus 20 μM PD98059 during MDI-induced adipocyte differentiation. 
 
Sudan II staining 
Sudan II staining was performed as described in Section A. 
 
RNA isolation and real-time quantitative PCR (RT-PCR) analysis 
RNA isolation and RT-PCR analysis were performed as described in Chapter 1B.  
 
Western blotting analysis 
Preparation of the cell lysate and western blotting were performed according to 
the previous report [Furuyashiki et al., 2004]. Specific immune complexes were detected 
with the ATTO Light-Capture II Western Blotting Detection System. The density of specific 
bands was calculated using ImageJ image analysis software (NIH, Bethesda, MD, USA). 
 
Statistical analysis 
All data are expressed as the mean ± standard deviation (SD) of at least three 
independent determinations for each experiment. Statistical significance was analyzed using 
the Dunnett’s test, and probability levels of 0.05 and 0.01 were considered to indicate 
statistical significance. 
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RESULTS 
CAR and FKB inhibited lipid accumulation during differentiation of 3T3-L1 adipocytes 
Morphological analysis showed that treatment with 5 μM CAR and FKB significantly 
inhibited lipid accumulation, whereas ALP did not (Fig. 1C-1A). Sudan II staining at Days 0, 
3, 6, 8, and 10, revealed that 5 μM CAR and FKB suppressed lipid accumulation in a 
time-dependent manner (Fig. 1C-1B). Lipid accumulation was significant suppressed from 
Day 6 onwards, and lipid accumulation at Day 10 had decreased to approximately 55% and 
66% in cells treated with CAR and FKB, respectively. ALP did not significantly affect lipid 
accumulation under the same experimental conditions. 
 
 
 
 
 
 
 
Fig. 1C-1. Inhibitory effects of CAR and FKB on lipid accumulation in 3T3-L1 cells. 
The cells were treated with 5 µM CAR and FKB, or ALP, or DMSO as a vehicle control, 
for first 3 days. (A) Intracellular lipid accumulation was determined by Sudan II straining 
at Day 8. The stained cells were photographed at a magnification of 200×. (B) Intracellular 
lipid accumulation was measured at Days 0, 3, 6, 8, and 10 after Sudan II straining. The 
results are presented as the mean ± SD of three independent experiments. *P<0.05 and 
**P<0.01 vs. DMSO alone at each time-point (Dunnett’s test). 
43 
 
 
 
Effect of CAR and FKB on the expression of adipocyte-specific transcription factors 
during 3T3-L1 adipocytes differentiation 
To determine whether the suppression of lipid accumulation was due to downregulation 
of adipocyte-specific differentiation markers, the quantitative RT-PCR and western blotting 
were conducted to determine the mRNA and protein expression levels of C/EBPα, PPARγ, 
and GLUT4. As shown in Figure 1C-2, treatment with 5 μM CAR and FKB decreased the 
expression of C/EBPα (42–83%) and PPARγ (36–70%) at Days 3 and 8, respectively, whereas 
Fig. 1C-2. CAR and FKB 
downregulated the protein 
expression of C/EBPα, PPARγ, 
and GLUT4 during 3T3-L1 
adipocyte differentiation. The 
cells were treated with 5 µM CAR, 
FKB and ALP or DMSO as a 
vehicle control, for the first 3 days. 
(A) The protein expression levels 
of C/EBPα, PPARγ, and GLUT4 
were determined by western 
blotting. Typical results of three 
representative, independent 
experiments are shown. (B) 
Densitometric analysis of specific 
bands after normalization for 
β-actin. The results are presented as 
the mean ± SD of three 
independent experiments. *P<0.05 
and **P<.001 vs. DMSO alone at 
each time-point (Dunnett’s test). 
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ALP did not significantly affect their expression levels. CAR and FKB also significantly 
downregulated the protein expression of GLUT4, a late-stage marker of differentiation, at 
Day 3 by 31% and 38%, respectively, and at Day 8 by 37% and 59%, respectively. ALP 
decreased GLUT4 expression by 39% at Day 3, but its effect was diminished at Day 8, at 
which time the expression level was 95% of that in the DMSO control group. CAR and FKB, 
but not ALP, significantly downregulated the mRNA levels of C/EBPα (CAR: 31%; FKB: 
72%) and PPARγ (CAR: 51%; FKB: 77%) at Day 5 (Fig. 1C-3). 
 
 
 
 
Effects of CAR and FKB on ERK activation during adipocyte differentiation 
ERK activation is associated with a modulatory effect on obesity, including adipocyte 
differentiation [Sakaue et al., 2004]. To investigate whether ERK activation was involved in 
the inhibitory effects of CAR and FKB on adipocyte differentiation, the phosphorylated level 
of ERK was determined by western blotting analysis. These chalcones increased the 
phosphorylation level of ERK: CAR increased ERK phosphorylation (1.28– to 1.82–fold) on 
both Days 1 and 3, and FKB (1.33– to 1.61–fold), respectively (Fig. 1C-4). Both chalcones 
increased ERK phosphorylation in a dose-dependent manner at Day 2 of adipocyte 
differentiation. By contrast, ALP did not significantly affect ERK phosphorylation. 
 
Fig. 1C-3. CAR and FKB downregulated the mRNA expression levels of C/EBPα and 
PPARγ during 3T3-L1 adipocyte differentiation. The cells were treated with 5 µM CAR, 
FKB and ALP, or DMSO as a vehicle control, for the first 3 days. The mRNA expression levels of 
C/EBPα and PPARγ were determined by quantitative RT-PCR at Day 3. The results are presented 
as the mean ± SD of three independent experiments. *P<0.05 and **P<0.01 vs. DMSO-treated 
cells (Dunnett’s test). 
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Fig. 1C-4. Effects of CAR and FKB on ERK activation in 3T3-L1 cells. (A) The cells 
were treated with 5 µM of CAR, FKB and ALP during MDI-induced adipocytes. ERK and p-ERK 
protein expression levels were determined by western blotting at Days 1, 3, and 8. (B) The 
dose-dependent effects of cardamonin and flavokawain B on ERK phosphorylation were estimated 
at Day 2. Typical results of three representative, independent experiments are shown. 
Densitometric analysis of p-ERK was conducted after normalization for ERK. The results are 
presented as the mean ± SD of three independent experiments. *P<0.05 and **P<0.01 vs. DMSO 
alone at each time-point (Dunnett’s test). 
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Fig. 1C-5. Effects of the ERK inhibitor PD98059 on the suppressive effects of CAR 
and FKB on PPARγ expression and lipid accumulation. 3T3-L1 cells were treated with 5 
µM CAR and FKB in the presence of 20 µM PD98059 for first 3 days. (A) ERK and p-ERK 
protein expression levels were examined at Day 3. (B) The expression of PPARγ was determined 
at Day 6. (C) Lipid accumulation was assessed at Day 7. Typical results of three representative, 
independent experiments are shown. Densitometric analysis of p-ERK was conducted after 
normalization for ERK, while that of PPARγ was normalized for β-actin. The results are presented 
as the mean ± SD of three independent experiments. *P<0.05 and **P<0.01 vs. DMSO alone at 
each time-point (Dunnett’s test). 
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The ERK inhibitor PD98059 restored CAR- and FKB-inhibiting adipocytes 
differentiation. 
To confirm that ERK activation was involved in the inhibitory effects of CAR and FKB 
on adipocyte differentiation, the author treated cells with 20 μM of PD98059, an ERK 
inhibitor. The author confirmed that PD09059 restored CAR- and FKB-induced ERK 
phspharylation at Day 3 (Fig. 1C-4A). PPARγ expression at Day 6 was downregulated by 
CAR (53 kDa: 23%; 57 kDa: 45%) and FKB (53 kDa: 35%; 57 kDa: 47%) compared with 
DMSO-treated cells. These effects were abolished by treatment with PD98059 (Fig. 1C-5B). 
PD98059 also abolished the inhibitory effects of CAR and FKB on lipid accumulation (Fig. 
1C-5C). Treatment with PD98059 alone slightly increased PPARγ expression and lipid 
accumulation (Fig. 1C-5B,C). These results strongly indicated that CAR and FKB inhibit 
adipocyte differentiation by activating ERK. 
 
DISCUSSION  
In the Section A, the author found that CAR and FKB inhibited lipid accumulation in 
3T3-L1 cells without cytotoxic effects when administered at a concentration of 5 μM. In this 
section, the author further analyses CAR and FKB, and found that their inhibitory effects on 
lipid accumulation in 3T3-L1 cells involved downregulation of the adipocyte-specific 
transcription factors PPARγ and C/EBPα (Fig. 1C-2 and 3) as a consequence of ERK 
activation (Fig. 1C-4 and 5). 
CAR is one of the main constituents of the seeds of Alpinia katsumadai Hayata, which 
has been used as a traditional Chinese herbal antiemetic and gastric drug [Kuroyanagi et al., 
2011]. ALP, a flavonoe also contained in Alpinia katsumadai Hayata, was also reported to 
have antibacterial, antitumor, and anti-inflammatory effects [Tang et al., 2012; He et al., 2005; 
Chen et al., 2013]. ALP and CAR have the same molecular weight but different molecular 
structures. In this section, ALP was used as a reference compound to investigate the effects of 
chalcones on the differentiation of 3T3-L1 cells. FKB, an active constituent in Alpia pricei 
Hayata and Kava, also has antioxidant, anti-inflammatory, and antidiabetic effects 
[Yamamoto et al., 2011; Zhou et al., 2009; Yu et al., 2009; Lin et al., 2009]. The author found 
that CAR and FKB, but not ALP, inhibited lipid accumulation in 3T3-L1 cells (Fig. 1C-1). 
These results showed that the α, β-unsaturated carbonyl moiety in CAR and FKB might play 
an important role in the inhibition of lipid accumulation.  
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It is well known that C/EBPα and PPARγ are master regulators of adipocyte 
differentiation. PPARγ forms a heterodimer with retinoic acid X-receptor [Tontonoz et al., 
1994], and regulates the transcription of adipocyte-specific genes [Wu, et al., 1999]. C/EBPα 
is another key mediator of adipogenesis and is very abundant in mature adipocytes, where it 
plays a crucial role in regulating adipocyte differentiation and glucose uptake [Cao et al., 
1991]. In this adipogenic process, GLUT4, which is regulated by C/EBPα, is responsible for 
glucose uptake in adipocytes [Kaestner et al., 1990]. Through the coordinated regulation of 
these adipocyte-specific transcription factors and GLUT4, adipocytes accumulate lipids 
during differentiation. This study demonstrated that CAR and FKB, but not ALP, significantly 
downregulated the expression of C/EBPα, PPARγ, and GLUT4 (Fig. 1C-2 and 3). These 
results indicate that downregulation of C/EBPα and PPARγ inhibits lipid accumulation in 
3T3-L1 adipocytes. Thereafter, the author determined whether ERK activation was involved 
in the inhibitory effects of CAR and FKB on adipocyte differentiation. The author found that 
CAR and FKB, but not ALP, enhanced ERK phosphorylation during MDI-induced adipocyte 
differentiation (Fig. 1C-4), and this enhancement was canceled by the ERK inhibitor 
PD98059 (Fig. 1C-5). ERK is a member of the mitogen-activated protein kinase family and 
plays a pivotal role in many essential cellular processes [Sakaue et al., 2004]. It was reported 
that ERK activation was necessary for adipocyte differentiation, and that a reduction in ERK 
expression in preadipocytes decreases adipocyte differentiation [Sale et al., 1995]. However, 
ERK activation also attenuates differentiation by inducing PPARγ phosphorylation during 
adipocyte differentiation [Camp et al., 1999; Hu et al., 1996]. It seems that ERK activation is 
tightly controlled in a temporal manner, being activated in preadipocytes and deactivated 
during adipocyte differentiation to prevent PPARγ phosphorylation. Recent studies showed 
that ERK activation is required for cell mitosis in the early stage of adipogenesis, and that 
activated (phosphorylated) ERK needs to be dephosphorylated thereafter because ERK might 
enhance PPARγ efflux from nucleus, suppress PPARγ degradation, and inhibit adipocyte 
differentiation [Burgermeister et al., 2007; Wang et al., 2009; Kim et al., 2009]. Moreover, 
diallyl trisulfide suppresses the adipogenesis of 3T3-L1 cells by activating ERK, and 
evodiamine improved diet-induced obesity by inhibiting adipocyte differentiation via ERK 
activation [Lii et al., 2012; Wang et al., 2009]. Therefore, the author’s results showing that 
CAR and FKB inhibit adipocyte differentiation through ERK activation are consistent with 
those of prior studies.  
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In conclusion, the author found that CAR and FKB effectively suppressed lipid 
accumulation in 3T3-L1 cells. CAR and FKB inhibited the differentiation of preadipocytes 
into adipocytes. The inhibitory effects of these chalcones were at least partly regulated by 
ERK activation, which downregulated the expression of adipocyte-specific transcription 
factors. The author’s findings suggest that CAR and FKB might be valuable for preventing 
obesity and obesity-related metabolic syndrome. 
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CHAPTER DISCUSSION 
The prevalence of obesity has increased dramatically in recent years. Obese individuals 
are more likely than lean individuals to develop type 2 diabetes mellitus, cardiovascular 
diseases, and some types of cancer [Kaul et al., 2012; Vernooij et al., 2012; Vucenik and 
Stains, 2012]. Obesity is recognized as a disease state that requires a range of interventions to 
treat and prevent the progression of obesity. Polyphenols are expected to be useful to treat and 
prevent obesity and other diseases [Williamson et al., 2005; Rayalam et al., 2008]. In this 
chapter, the author searched for a panel of 49 polyphenols capable of inhibiting lipid 
accumulation in 3T3-L1 cells. Six of these polyphenols, including four chalcones 4HD, XAG, 
CAR and FKB inhibited lipid accumulation in 3T3-L1 cells without cytotoxic effects when 
administered at a concentration of 5 μM (Section A). The author conducted further analyses in 
4HD, XAG, CAR and FKB inhibiting adipocyte differentiation and attempted to clarify the 
underlying molecular mechanism in Section B and C.  
During adipogenesis, fibroblast-like preadipocytes differentiate into adipocytes, the 
process occurs in several stages and involves a cascade of transcription factors. Among them, 
PPARγ and C/EBPs are considered to be the master regulators or the crucial determinants of 
adipocyte fate [Tontonoz et al., 1994; Lefterova et al., 2009]. AMPK is a key enzyme to 
maintain cellular as well as body energy balance. Intense research in recent years has revealed 
the critical roles that AMPK plays in modulating ever-expanding many biological pathways. 
The broad spectrum of activities of AMPK in lipid and glucose metabolism makes it a very 
attractive target for obesity, diabetes and metabolic syndrome [Zhang et al., 2009; Luo et al., 
2005]. MAPKs are intracellular signaling pathways that play a pivotal role in many essential 
cellular processes including differentiation [Sakaue et al., 2004]. Most of the knowledge 
comes from the study of three groups of MAPKs: ERK, JNK and p38 MAPK [Bost et al., 
2005]. In Section B, the author demonstrated the mechanism of Ashitaba chalcones 4HD and 
XAG on adipocyte differentiation which is deeply involed in the onset of obesity. The results 
showed that 4HD and XAG are able to inhibit adipocytes differentiation through 
down-regulating expression of C/EBPβ, C/EBPα and PPARγ in 3T3-L1 adipocytes. 
Moreover, the author found 4HD and XAG regulated adipocyte differentiation though 
activation of AMPK, ERK and JNK. These factors could be available as the molecular targets 
for anti-obesity therapeutics. In Section C, the author selected another two chalcones CAR 
and FKB, and a flavonone ALP as a reference compound to confirm the inhibitory effects of 
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chalcones on adipocyte differentiaton. The author found that CAR and FKB but not ALP 
effectively suppressed lipid accumulation in 3T3-L1 cells. CAR and FKB also inhibited the 
differentiation of preadipocytes into adipocytes. The inhibitory effects of these chalcones 
were at least partly regulated by ERK activation, which downregulated the expression of 
adipocyte-specific transcription factors.  
In conclusion, the author found that chalcones 4HD, XAG, CAR and FKB effectively 
suppressed lipid accumulation in adipocytes. These chalcones are able to inhibit adipocyte 
differentiation through down-regulating expression of C/EBPs and PPARγ. Moreover, the 
author found chalcones regulated adipocyte differentiation though AMPK and MAPK 
pathways. These findings provide a possibility that chalcones are of great benefit to prevent 
obesity and obesity-related disorders. 
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Chapter 2 
Chalcones suppress fatty acids-induced lipid accumulation through LKB1/AMPK 
signaling pathway in hepatocytes. 
INTRODUCTION 
The liver is an important organ that maintains whole-body energy homeostasis though 
metabolizing fatty acids (FAs) and glucose [Cheung and sanyal, 2008]. Nonalcoholic fatty 
liver disease (NAFLD) is one of the most common liver diseases worldwide and characterized 
by hepatic lipid accumulation in the absence of significant ethanol consumption. It comprises 
of a broad spectrum of the liver diseases ranging from hepatic steatosis to steatohepatitis and 
latter progressing to cirrhosis [Matteoni et al. 1999]. Several studies suggest that excessive 
intake of calories, visceral obesity, and insulin resistance will burden liver function and be 
important risk factors for NAFLD development [Browning and Horton, 2004]. 
Over-accumulation of lipids in hepatocytes is currently recognized as the most common cause 
of chronic liver disease and an increase in the risk of other diseases [Targher et al. 2007; 
Ahmed et al. 2009]. 
Lipid accumulation in the liver is caused by enhancing de novo lipogenesis, and lowing 
of lipid catabolism. Studies have shown that sterol regulatory element binding protein-1 
(SREBP-1) regulates lipid metabolism. SREBP-1 plays an essential role in the regulation of 
lipogenesis in FA and triglycerides synthesis [Brown and Goldstein, 1997; Sanyal, 2005]. It is 
also known that peroxisome proliferators-activated receptors (PPARs), which are 
ligand-activated nuclear receptors, mediate the critical transcriptional regulation of genes 
associated with lipid homeostasis [Lee et al., 2003]. Especially, PPARα is the most 
abundantly expressed in the liver and has the effect of diminishing circulating triglycerides 
and prevent hepatic steatosis involving in increasing hepatic FA oxidation [Braissant and 
Wahli, 1998]. A lot of evidences indicates that AMP-activated protein kinase (AMPK) is 
involved in regulating hepatic lipogenesis [Schimmack et al., 2006]. Activation of hepatic 
AMPK attenuates FA synthesis and promotes FA oxidation [Hardie, 2007; McGarry and 
Brown, 1997]. Recent studies revealed that liver kinase B1 (LKB1) is one of the important 
upstream kinases of AMPK [Hawley et al., 2003; Woods et al., 2003]. LKB1 can activate 
AMPK by phosphorylation at Thr172 in mammalian cells. The activation of AMPK leads to 
the phosphrylation and inhibition of acetyl-CoA carboxylase activity and leads to an increase 
in FA oxidation [Park et al., 2002]. It is also reported that activated AMPK interacted with 
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SREBP-1 and inhibited its transcriptional activity, leading to reduced lipogenesis and lipid 
accumulation [Li et al., 2011]. Thus, AMPK should be a therapeutic target for treating fatty 
liver diseases. The mitogen-activated protein kinases (MAPKs) signaling occurs in response 
to almost any change in the extracellular or intracellular milieu that affects the metabolism of 
the cell, organ or the entire organism [Gehart et al., 2010]. MAPKs play an important role in 
cellular metabolism including regulating in insulin signaling, adipocyte development as well 
as hepatic lipid metabolism [Gehart et al., 2010; Deak et al., 1998; Xiong et al., 2007; Malhi 
et al., 2006]. 
Chalcones are containing in various plants and have a variety of health-promoting effects. 
Several synthetic chalcones also showed biologically active [Dimmock et al., 1999; Bandgar 
et al., 2009]. 4HD and XAG are two major chalcones in Angelica keiskei Ashitaba, a Japanese 
herb, which has been used as a traditional medicine for long time. They have been reported to 
exert various biological effects such as anti-tumor [Kimura et al., 2004; Akihisa et al., 2011], 
anti-inflammatory [Ohkura et al., 2011] and anti-diabetes [Kawabata et al., 2011, Enoki et al., 
2007] effects. CAR is one of the main constituents of the seeds of Alpinia katsumadai Hayata, 
which has been used as a traditional Chinese herbal antiemetic and stomachic drug 
[Kuroyanagi et al., 1983]. FKB, a 4’-O-methylated analog of CAR, is an active constituent in 
Alpia pricei Hayata and Kava. These two chalcones are also reported to possess antioxidant, 
antiinflammatory, antidiabetic and other important therapeutic activities of significant potency 
[Lee et al., 2003; Yu et al., 2009; Lin et al., 2009]. In Chapter 1, the author found that these 
chalcones also showed strong inhibitory effect on adipocytes differentiation. However, the 
inhibitory effects of these chalcones on hepatic steatosis are unknown yet. 
In this chapter, the author first designed to define an experimental model of hepatic 
steatosis without cytotoxicity using unsaturated and saturated FAs in human HepG2 cells. 
Then, the author used this model to investigate the preventive effect of 4HD, XAG, CAR and 
FKB on FAs-induced lipid accumulation. To clarify the underlying molecular mechanisms, 
the author, further, investigated the effect of these chalcones on the expression of SREBP-1, 
PPARα and phosphorylation of LKB1, AMPK and MAPKs. 
 
MATERIALS METHODS  
Reagents  
4HD and XAG were purified from “Ashitaba Chalcone Powder” as a commercial 
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product of Japan Bio Science Laboratory (Osaka, Japan). CAR was isolated from the seeds of 
A. katsumadai Hayata, and FKB was synthesized by direct aldol condensation of 
acetophenone with benzaldehyde, as previously described [Yamamoto et al., 2011]. The cell 
proliferation reagent WST-1 substrate was purchased from Roche Diagnostics (Mannheim, 
Germany). Antibodies for PPARα, horseradish peroxidase-conjugated anti-rabbit IgG, 
anti-mouse IgG and anti-goat IgG were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA), β-actin, p-AMPK, AMPK, p-LKB1, LKB, p-ERK1/2, ERK1/2, p-JNK, JNK, 
p-p38 and p38 were from Cell Signaling Technology (Beverly, MA), and for SREBP-1 was 
from Abcam (Cambrige, MA). Palmitic acid, oleic acid, linoleic acid and linolenic acid were 
purchased from Wako (Osaka, Japan), and stearic acid was from sigma (St. Louis, MO). 
Bovine serum albumin (BSA) was from Nakarai Tesque (Kyoto, Japan). 
 
Cell culture  
HepG2 cells were cultured in Dulbecco’s modified Eagle’s medium (Nissui 
Pharmaceutical, Tokyo, Japan) containing 10% fetal bovine serum (Sigma, USA), 4 mM 
L-glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin under a humidified 
atmosphere of 95% air and 5% CO2 at 37 °C. The cells were grown to 80% confluence and 
incubated in serum free medium overnight before treatments. The cells were exposed to FAs 
and simultaneously treated with various concentrations of chalcones (4HD, XAG, CAR or 
FKB) or to vehicle (DMSO) for 24h. Stock solution of each FA was dissolved in 99% MetOH 
and diluted in culture medium containing 1% BSA to obtain the desired final concentrations.  
 
Cell viability assay 
The cell viability was determined by WST-1 assay. To detect the effects of FAs on 
HepG2 cells viability, the cells were treated with the each FA at 0.5 or 1 mM for 24h, 
respectively. To detect the effects of chalcones on HepG2 cells viability, the cells were treated 
with the each chalcones at 1, 5, 10 and 20 μM or DMSO alone as a vehicle control (final 
concentration, 0.25%) for 24h in culture medium. The WST-1 assay was performed as 
described in Section A of Chapter 1. 
 
Determination of intracellular lipid content 
To detect the effects of FAs on lipid accumulation in HepG2 cells, the cells were treated 
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with the each FA at 0.5 or 1 mM for 24h, respectively. To detect the effects of chalcones on 
FAs-induced lipid accumulation in HepG2 cells, the cells were exposed to a mixture of FAs 
(palmitic acid : oleic acid = 1:2 ratio), and simultaneously treated with the each chalcones 
with various concentrations as indicated in each figure or DMSO alone as a vehicle (final 
concentration, 0.25%) for 24h. Then Sudan II straining was carried out as described in 
Section A of Chapter 1. 
 
Western blotting analysis 
Preparation of the cell lysate and western blotting were performed according to previous 
report [Furuyashiki et al., 2004].  Specific immune complexes were detected with the ATTO 
Light-Capture II Western Blotting Detection System. The density of specific bands was 
calculated using ImageJ image analysis software. 
 
Statistical analysis 
All data are expressed as the mean ± standard deviation (SD) of at least three 
independent determinations for each experiment. Statistical significance was analyzed using 
the Dunnett’s test, and probability levels of 0.05 and 0.01 were considered to indicate 
statistical significance. 
 
RESULTS 
Efffects of FA on lipid accumulation and cells viability in HepG2 cells. 
The lipid accumulation (Fig. 2-1A) and the cell viability (Fig. 2-1B) were investigated 
after treatment with palmitic acid, stearic acid, oleic acid, linoleic acid and linolenic acid at 
0.5 or 1 mM to HepG2 cells for 24h. The author found that all FAs significantly increased 
lipid accumulation in HepG2 cells (Fig. 2-1A). Under the same conditions, linoleic acid and 
linolenic acid showed cytotoxity at both 0.5 and 1 mM (Fig. 2-1B). Palmitic acid and stearic 
acid also showed cytotoxicity at 1 mM. Palmitic and oleic acids are the most abundant FAs in 
liver triglycerides in both normal subjects and patients with NAFLD [Araya et al., 2004]. 
Therefore, HepG2 cells were incubated with a mixture of palmitic acid and oleic acid with 
different proportions to induce fat-overloading. Results from lipid accumulation (Fig. 2-1C) 
and cells viability (Fig. 2-1D) assays showed that palmitic acid was easy to increase lipid 
accumulation but exhibited cytotoxicity over 1.2 mM. Although lipid accumulation of oleic 
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acid was weaker than that of palmitic acid, oleic acid did not exhibit cytotoxicity. To achieve 
maximal fat overaccumulation without cytotoxicity, a FAs mixture consisting of a low 
proportion of palmitic acid (palmitic acid : oleic acid = 1:2 ratio) was selected for further 
experiments. 
 
4HD, XAG, CAR and FKB inhibited FAs-induced cellular lipid accumulation in HepG2 
cells. 
The author first investigated that the effect of 4HD, XAG, CAR and FKB on cell 
viability of HepG2 cells by WST-1 assay and found that all chalcones did not show any 
cytotoxicity up to 20 μM (Fig. 2-2A). To investigate the inhibitory effect of chalcones on the 
lipid accumulation in HepG2 cells, 5 μM of each chalcone and various concentrations of FAs 
mixture were simultaneously treated to HepG2 cells for 24h and the lipid contents were 
determined by Sudan II staining. As showed in Fig. 2-2B, the FAs mixture dose-dependently 
increased lipid accumulation in HepG2 cells compared with DMSO-treated control cells. 
Simultaneous with 4HD, XAG, CAR and FKB at 5μM decreased the FAs mixture-induced 
lipid accumulation: CAR and FKB showed significant effect at 0.3, 0.6 and 1.2 mM, 4HD at 
0.6 and 1.2 mM, and XAG at 1.2 mM. Thus, the author selected 1.2 mM FAs mixture and 
investigated the dose-dependent effect of chalcones on FAs mixture-induced lipid 
accumulation. As showed in Fig. 2-2C, these chalcones decreased lipid accumulation in a 
dose-dependent manner. All chalcones tested significantly inhibited the FAs mixture-induced 
lipid accumulation at 5, 10 and 20 μM.  
 
4HD, XAG, CAR and FKB down-regulated SREBP-1 and up-regulated PPARα 
expression in HepG2 cells 
To determine the mechanism by which 4HD, XAG, CAR and FKB decreased the 
FAs-induced lipid accumulation in HepG2 cells, western blotting analysis was performed to 
evaluate the expression levels of important factors SREBP-1 and PPARα. These proteins are 
involved in hepatic lipogenesis and FA oxidation, respectively [Brown and Goldstein, 1997; 
Sanyal, 2005; Braissant and Wahli, 1998]. As shown in Fig. 2-3, the author confirmed that the 
FAs mixture enhanced expression of SREBP-1 but did not affect expression of PPARα. 4HD 
and XAG dose dependently decreased expression of SREBP-1, while they increased 
expression of PPARα. Significant differences were observed over 5 μM (Fig. 2-3A). The 
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same trends were observed by treatment with CAR and FKB; ie, they dose dependently 
decreased expression of SREBP-1 while increased that of PPARα (Fig. 2-3B).  
 
 Fig. 2-1. Effects of FA on lipid accumulation and cells viability in HepG2 cells. (A, B) 
Effects FA on lipid accumulation and cytotoxicity in HepG2 cells. The cells were incubated with 
each FA at 0.5 or 1 mM for 24h. MetOH was used as a vehicle control. (C, D) Effects of different 
ratio of palmitic acid and oleic acid on lipid accumulation and cytotoxicity in HepG2 cells. The 
cells were incubated with palmitic acid and oleic acid mixture with different ratios (1:0, 2:1, 1:1, 
1:2 and 0:1) for 24h. Intracellular lipid accumulation was determined by Sudan II staining (A, C). 
Cell viability was measured by WST-1 assays (B, D). The results are presented as the mean ± SD 
from three independent experiments. *P<0.05 and **P<0.01 vs. MetOH-treated control cells 
(Dunnett’s test). 
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Fig. 2-2. 4HD, XAG, CAR and FKB suppressed a FAs mixture-induced lipid 
accumulation in HepG2 cells. (A) The cells were treated with each chalcone at concentrations 
of 1, 5, 10, or 20 µM for 24h. Cell viability was measured by WST-1 assays. (B) The cells were 
exposed to 0, 0.3, 0.6, 1.2 and 2.4 mM FAs mixture (palmitic acid : oleic acid =1:2 ratio) with or 
without 5 µM each chalcone for 24h. (C) The cells were exposed to 1.2 mM FAs mixture 
consisting of 0.4 mM palmitic acid and 0.8 mM oleic acid with or without each chalcone at 1, 5, 
10, or 20 µM for 24h. In these experiments, DMSO was used as a vehicle control. Intracellular 
lipid content was determined by Sudan II staining. The results are presented as the mean ± SD from 
three independent experiments. *P<0.05 and **P<0.01 vs. DMSO-treated control cells at each 
dose of FA (Dunnett’s test).A 
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Fig. 2-3. 4HD, XAG, CAR and FKB downregulated SREBP-1 expression and 
upregulated PPARα xpression in HepG2. The cells were exposed to 1.2 mM FAs mixture 
consisting of 0.4 mM palmitic acid and 0.8 mM oleic acid with or without (A) 4HD or XAG, and (B) 
CAR or FKB at 5 µM for 24h. DMSO was used as a vehicle control. The protein expression levels of 
SREBP-1 and PPARα were determined by western blotting. Typical representative result was shown 
from three independent experiments. Densitometric analysis of specific bands was also shown after 
normalization by β-actin expression. The results are presented as the mean ± SD from three 
independent experiments. *P<0.05 and **P<0.01 vs. DMSO-treated cells (Dunnett’s test). 
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Effects of 4HD, XAG, CAR and FKB on LKB1/AMPK and MAPKs pathways in HepG2 
cells 
AMPK is a key regulator of lipogenesis and FA oxidation in metabolic tissues including 
the liver. The change of AMPK activity in HepG2 cells is strongly associated with 
intracellular lipid metabolism [Schimmack et al., 2006]. To investigate the effects of 
chalcones on the phosphrylation of AMPK and its upstream kinase LKB1, HepG2 cells were 
treated with 1.2 mM FAs mixture and 5 μM chalcone for 24 h. As shown in Fig. 2-4 A and B, 
all chalcones significantly simulated phosphorylation of AMPK (4HD, 2.18-fold; XAG, 
2.08-fold; CAR, 1.74-fold; and FKB, 1.85-fold) and that of LKB1 (4HD, 1.58-fold; XAG, 
1.52-fold; CAR, 1.72-fold; and FKB, 1.64-fold). To confirm that AMPK activation was 
involved in the inhibitory effects of chalcones on the FAs mixture-induced lipid accumulation, 
an AMPK inhibitor, compound C was introduced (Fig. 2-5 A and B). Compound C decreased 
chalcones-caused AMPK activation. 4HD, XAG (Fig. 2-5A) and CAR, FKB (Fig. 2-5B) 
down-regulated expression of SREBP-1 (4HD, 67%; XAG 67%; CAR, 70%; and FKB, 74%) 
and up-regulated PPARα (4HD, 1.80-fold; XAG, 1.69-fold; CAR, 1.56-fold; and FKB, 
1.54-fold) as the same manner as the results in Fig. 2-3. In the same series of cultures, these 
effects were abolished by treatment with compound C. These results indicated that the 
activation of LKB1/AMPK pathway by chalcones is involved in the FAs mixture-induced 
lipid accumulation. 
MAPKs play an important role in various cellular metabolism including regulation of 
hepatic lipid metabolism [Malhi et al., 2006]. Thus, the author investigated whether chalcones 
active MAPKs. However, 4HD, XAG, CAR and FKB did not alter the MAPKs activation 
under the present experimental conditions (Fig. 2-6). 
 
Discussion 
In this Chapter, the author found that the treatment with a FAs mixture consisting of 
palmitic acid and oleic acid (1:2 ratio) to HepG2 cells is suitable in vitro model for hepatic 
steatosis (Fig. 2-1). Using this model, the author found that chalcones 4HD, XAG, CAR and 
FKB significantly decreased the FA mixture-induced lipid accumulation in HepG2 cells 
without cytotoxicity (Fig. 2-2). These results indicated that 4HD, XAG, CAR and FKB will 
be effective compounds to prevent hepatic steatosis. The author conducted further 
experiments and found that their inhibitory effect on the FAs mixture-induced lipid 
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accumulation is involved in down-regulation of the SREBP-1 and up-regulation of PPARα 
(Fig. 2-3) as a consequence of LKB1/AMPK activation (Figs. 2-4 and 5) but not MAPKs (Fig. 
2-6). 
 
 
 
 
 
 
Fig. 2-4. 4HD, XAG, CAR and FKB simulated the phosphorylation of AMPK and 
LKB1 in HepG2 cells. The cells were exposed to 1.2 mM FAs mixture consisting of 0.4 mM 
palmitic acid and 0.8 mM oleic acid with or without (A) 4HD or XAG, and (B) CAR or FKB at 5 µM 
for 24h. DMSO was used as a vehicle control. The phosphorylation levels of AMPK and LKB1, and 
the expression levels of AMPK, LKB1 and β-actin were determined by western blotting. Typical 
representative result was shown from three independent experiments. Densitometric analysis of 
specific bands for pAMPK and pLKB1 was also shown after normalization by corresponding protein 
expression. The results are presented as the mean ± SD from three independent experiments. *P<0.05 
and **P<0.01 vs. DMSO-treated cells (Dunnett’s test). 
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Fig. 2-5. The AMPK inhibitor compound C restored the effects of 4HD, XAG, CAR 
and FKB on SREBP-1 and PPARα expression. The cells were exposed to 1.2 mM FAs 
mixture consisting of 0.4 mM palmitic acid and 0.8 mM oleic acid with or without (A) 4HD or 
XAG, and (B) CAR or FKB at 5 µM for 24h. Compound C at 20 µM was simultaneously treated to 
the cells. DMSO was used as a vehicle control. The phosphorylation levels of AMPK, and the 
expression levels of AMPK, SREBP-1, PPARα and β-actin were determined by western blotting. 
Typical representative result was shown from three independent experiments. Densitometric analysis 
of specific bands for pAMPK was shown after after normalization by AMPK expression, and that of 
SREBP-1 and PPARα was also shown after normalization by β-actin expression. The results are 
presented as the mean ± SD from three independent experiments. *P<0.05 and **P<0.01 vs. 
DMSO-treated cells (Dunnett’s test). 
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Intracellular lipid accumulatin is the main pathological characteristic of a human liver 
with NAFLD [Wu et al., 2008]. FAs are the main substrates for synthesis of triglycerides in 
hepatocytes. It is known that twenty five percent of liver triglycerides is derived from 
increased de novo lipogenesis [Donnelly et al., 2005]. De novo lipogenesis is mediated by 
SREBP-1 that is a key lipogenic transcription factor and nutritionally regulated by glucose 
and insulin [Goldstein et al., 2008; Zhou et al., 2001]. SREBP-1 preferentially regulates the 
lipogenic process by activating genes involved in FA and triglyceride synthesis which 
contribute to hepatic steatosis [Sanyal, 2005]. SREBP-1 plays a considerable role in the 
pathogenesis of NAFLD [Ahmed and Byrne, 2007]. Increased SREBP-1 levels have been 
found in patients with histologically diagnosed NAFLD [Kohjima et al., 2008], and in the 
fatty livers of obese (ob/ob) mice [Ahmed and Byrne, 2007] and obese rats induced by fat-diet 
feeding [Madsen et al., 2003]. The author found that 4HD, XAG, CAR and FKB decreased 
Fig. 2-6. Effects of 4HD, XAG, CAR and FKB on the phosphorylation of MAPKs in 
HepG2 cells. The cells were exposed to 1.2 mM FAs mixture consisting of 0.4 mM palmitic 
acid and 0.8 mM oleic acid with or without (A) 4HD or XAG, and (B) CAR or FKB at 5 µM for 
24h. DMSO was used as a vehicle control. The phosphorylation and total levels of ERK, JNK and 
p38 were determined by western blotting. Typical representative result was shown from three 
independent experiments. 
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the FAs mixture-induced SREBP-1 expression in HepG2 cells (Fig.2-3). The results in this 
chapter indicate that 4HD, XAG, CAR and FKB prevent hepatic steatosis by down-expression 
of SREBP-1. Moreover, the author also found that 4HD, XAG, CAR and FKB increased 
expression of PPARα in HepG2 cells. PPARα is expressed at high levels in tissues with high 
rates of FA oxidation, such as brown fat, liver and heart [Braissant and Wahli, 1998]. 
PPARα-mediated responses have been well studied in the liver. It has been reported PPARα 
agonist normalized fatty livers in fat-fed rats [Braissant and Wahli, 1998] and markedly 
improved lipid accumulation in the liver of rats [Ye et al., 2003]. Curcumin also decreases 
oleic acid-induced lipid accumulation through enhancing the expression of PPARα [Kang et 
al., 2013]. The author’s findings and these previous results indicate that 4HD, XAG, CAR and 
FKB prevent hepatic steatosis by up-expression of PPARα, which involved in FA oxidation. 
Collectively, 4HD, XAG, CAR and FKB reduces the FAs mixture-induced hepatic lipid 
accumulation by down regulating de novo lipogenesis and up regulating FA oxidation. 
To determine the signaling mechanism underlying down-regulation of SREBP-1 and 
up-regulation of PPARα by 4HD, XAG, CAR and FKB, the author investigated the effects of 
these chalcones on LKB1/AMPK activation in HepG2 hepatocytes. It is known that AMPK 
plays a key role in regulating carbohydrate and fat metabolism, serving as a metabolic master 
switch response to alterations in cellular energy charge [Schimmack et al., 2006; Winder and 
Hardie, 1999]. AMPK is expected to be a therapeutic target for treating fatty liver disease. 
AMPK is involved in regulating hepatic lipogenesis [Schimmack et al., 2006]. Activation of 
hepatic AMPK turn off a switch for FA synthesis via decreasing expression of SREBP-1 
which regulating genes involved in de novo lipogenesis [Hardie, 2007]. The author’s founding 
showed that 4HD, XAG, CAR and FKB increased AMPK activation (Fig. 2-4). When an 
AMPK inhibitor compound C was treated to the cells, the expression of SREBP-1 was 
increased and the inhibitory effect of chalcones on SREBP-1 expression was canceled (Fig. 
2-6). In addition, AMPK also simulates FA oxidation by up-regulating expression of proteins 
involved in FAs oxidation, including PPARα [Lee et al., 2006;]. The author’s founding 
showed that 4HD, XAG, CAR and FKB increased expression of PPARα (Fig. 2-3) and 
phophorylation of AMPK (Fig. 2-4) simultaneously. AMPK inhibitor compound C partly 
canceled the increase in the expression of PPARα by chalcones (Fig. 2-5). These results 
indicate that 4HD, XAG, CAR and FKB have an ability to activate AMPK then reduce 
SREBP-1 expression and enhance PPARα expression, finally leading to inhibit hepatic 
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steatosis. AMPK activity is regulated by phosphorylation at Thr172 by the upstream 
serine/threonine kinase LKB1 [Hawley et al., 2003; Shaw et al., 2004; Woods et al., 2003]. 
Consistent with phosphorylation of AMPK α at Thr172, 4HD, XAG, CAR and FKB 
phosphorylated LKB1 at Ser428 in HepG2 cells (Fig. 2-4). These results indicate that 4HD, 
XAG, CAR and FKB inhibit the FAs mixture-induced lipid accumulation by the activation of 
LKB1/AMPK pathway. MAPKs are involved in regulating lipid metabolism [Gehart et al., 
2010]. It was reported that SREBP-1 expression is linked to the MAPK cascade [Kotzka et al., 
2000]. However, the author found that 4HD, XAG, CAR and FKB did not altered the 
phosphorylation levels of ERK, JNK and p38 under this experimental condition (Fig. 2-6). 
In conclusion, the author established an in vitro model of hepatic steatosis using a 
mixture of palmitic acid oleic acid mixtures. Using this model, the author found that 
chalcones 4HD, XAG, CAR and FKB inhibit the FAs mixture-induced lipid accumulation in 
HepG2 cells. The inhibitory mechanism is, at least in part, dependent on down-regulation of 
SREBP-1 and up-regulation of PPARα expressions though the activation of LKB1/AMPK 
signaling pathway. The author’s findings suggest that 4HD, XAG, CAR and FKB might be 
valuable for preventing NAFLD and NAFLD-related metabolic syndrome. 
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Chapter 3 
Ashitaba (Angelica keiskei) extract prevent obesity and insulin resistance in high-fat 
diet-fed C57BL/6 mice. 
INTRODUCTION  
The rates of obesity have increased dramatically in recent years [Friedman, 2000]. 
Obesity usually results from an energy imbalance [Takahashi et al., 2000]: Excessive energy 
storage and insufficient energy expenditure induced lipid accumulation in both adipose tissue 
and liver leading to type II diabetes, cardiovascular disease, nonalcoholic fatty liver disease 
(NALFD) and other metabolic disorders [Lois et al., 2008; Despres et al., 2008; Friedman, 
2000]. Dietary fat is considered to be one of the most important factors in the 
pathophysiology of obesity. C57/BL/6 mice are obesity-prone and develop obesity, 
hyperglycemia, and hyperlipidemia when fed on a high-fat (HF) diet. C57/BL/6 mice are, 
therefore, commonly used for obesity and obesity-related diseases research [Nishikawa et al., 
2007; Surwit et al., 1995].  
Lipid accumulation and energy metabolism are tightly controlled in the adipose tissue 
and liver. Adipogenesis is a differentiation process by which undifferentiated preadipocytes 
are converted to fully differentiated adipocytes. This process is regulated by a highly 
organized cascade of transcription factors such as members of the peroxisome 
proliferator-activated receptor gamma (PPARγ), the CCAAT/enhancer-binding proteins 
(C/EBPs), and sterol regulatory element binding protein-1 (SREBP-1) [Lefterova and Lazar, 
2009]. Differentiation of adipocytes stores FAs in the cytoplasm, leading to visceral fat 
accumulation. There is a metabolic rationale linking the expanded abdominal to 
hyperglycemia, hyperlipidemia and insulin resistance, which are often accompanied with 
impaired metabolic regulation in adipose tissue, leading to an overproduction of free FAs 
[Despres, 2006]. Such flux of free FAs toward the liver results in an increase of triglyceride 
deposition and secretion of triglyceride-rich lipoproteins, which in turn affect the lipo-lipase 
activity and the distribution of lipoprotein subtypes [Peng et al., 2011]. During this process, 
SREBP-1 plays an essential role in the regulating genes in liver, including FA synthase (FAS) 
as an enzyme for lipogenesis, in the liver [Brown and Goldstein, 1997; Sanyal, 2005]. On the 
other hand, the expressions of carnitine palmitoyltransferase-1 (CPT-1), acy-CoA oxidase 
(ACO) and peroxisome proliferator-activated receptor gamma (PPARα) were critically 
associated with the process of FAs oxidation. [Bonnefont et al., 2004; Miyazawa et al., 1987; 
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Wanders et al., 2001; Braissant and Wahli, 1998]. In addition, uncoupling proteins (UCPs) 
have attracted considerable interest in the context of energy expenditure. UCP-2 is one of the 
members of UCP family, and involved in energy metabolism in the adipose tissue and liver 
[Boss et al., 1998; Ricquier, 2000]. AMPK is a key modulator to maintain the cellular as well 
as whole-body energy balance. There increased an interest in developing AMPK activators as 
potential therapies for obesity, diabetes and hepatic steatosis [Carling et al., 2012, O'Neill et 
al., 2012]. 
A Japanese herb Ashitaba, an umbelliferous perennial plant found along the Pacific coast 
from the Bousou peninsula to the Kii peninsula and on the Izu islands of Japan, is drunk as a 
tea and used as a vegetable as well as the folk medicine as a diuretic, laxative, analeptic and 
galactagogue [Kim et al., 1992]. Several of the compounds in this plant have been identified 
including coumarins, flavanones and chalcones. Among them, 4HD and XAG are considered 
to be major active compounds [Kozawa et al., 1977]. In the previous chapters, the author 
found that 4HD and XAG inhibited the differentiation of preadipocytes into adipocytes via 
the activation of AMPK, ERK and JNK signal pathways leading to down-regulating 
expression of C/EBPβ, C/EBPα and PPARγ (Chapter 1). The author also found that 4HD and 
XAG also suppressed FAs mixture-induced lipid accumulation through LKB1-AMPK 
signaling pathway in HepG2 cells (Chapter 2). However, the effects of AE on the HF 
diet-induced obesity, hepatic steatosis and insulin resistance are still lack information. 
In this chapter, AE was given to C57BL/6 mice fed a control or HF diet for 16 weeks to 
examine whether AE could prevent HF diet-induced obesity and insulin resistance. The author 
further examined its effects on lipid metabolism in adipose and liver tissues to identify the 
underlying molecular mechanisms.  
 
MATERIAL AND METHODS 
Materials 
AE was prepared from Ashitaba Chalcone Powder supplied by Japan Bio Science 
Laboratory (Osaka, Japan), as previously described [Kawabata, K., et al., 2011]. The powder 
(10 g) was treated with ethyl acetate (100 mL × 3 times) at room temperature, and the solution 
was evaporated. The yield of AE is 17%. Antibodies for PPARγ, C/EBPα, PPARα, ACC 
horseradish peroxidase-conjugated anti-rabbit IgG, anti-mouse IgG and anti-goat IgG were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA), β-actin, p-AMPK, AMPK and 
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p-ACC were from Cell Signaling Technology (Beverly, MA). SREBP-1 CPT-1A and 
ACOX1 were from Abcam (Cambrige, MA) and UCP-2 was from BioLegend Inc. (San 
Diego, CA). All other reagents used were of the highest grade available from a commercial 
source. 
 
Measurement of 4HD and XAG in AE by Liquid Chromatography-Tandem Mass 
Spectrometry (LC-MS/MS)  
Detection and quantification of 4HD and XAG were performed with LC-MS/MS (4000 
Q TRAP, AB Sciex, Foster City, CA, USA) using electrospray ionization. HPLC separation 
was done with a gradient system using solvent A (0.1% formic acid) and solvent B 
(acetonitrile) using a L-column-2 ODS (2.1×150 mm) column (Chemicals Evaluation and 
Research Institute, Tokyo, Japan) at a flow rate of 0.2 mL/min. The column oven was 
maintained at 40 °C. The gradient program was: 0-2 min, 45% A; 2-7 min, linear gradient to 
0% A; 7-8 min, 0% A hold; 8-8.1 min, linear gradient to 45% A; and 8.1-15 min, 45% A hold. 
The chalcones were detected by multiple reaction monitoring as follows: 4HD 339.2/163.1 
[M + H]+, xanthoangelol 393.2/131.0 [M + H] +, chalcone 209.1/131.0 [M + H] +. For 
quantification, standard curves of Ashitaba chalcones from 0.05 to 500 fmol/5 μL injection 
were generated as described in previously study [Nakamura et al., 2012]. Concentrations of 
4HD and XAG were corrected by the comparison between a peak area of these compounds 
and that of an internal standard. Concentrations of 4HD and XAG in AE were showed in 
Table 3-1. 
Table 3-1. 4HD and XAG in an extract of  
Ashitaba (AE) identified by LC-MS/MS 
Name Concentration in AE 
(mg/g) 
4HD 64.89 
XAG 84.86 
 
Animal treatment 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee (Permission #25-04-02) and were carried out according to the guidelines for 
Animal Experiments at Kobe University. Male C57BL/6 mice (5 weeks old, n = 36) were 
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obtained from Japan SLC (Shizuoka, Japan) and maintained in a temperature-controlled room 
(22°C) as described above. The mice had free access to tap water and an AIM-93M laboratory 
purified diet (Oriental Yeast, Tokyo, Japan), and were acclimatized for 7 days before the 
experiments. They were then randomly divided into six groups of six mice each and fed a 
control (AIN-93M) or high-fat diet containing 30% (w/w) lard for 16 weeks. The 
compositions of the diets and energy densities are shown in Table 3-2. The diets were 
supplemented with 0% (C-0 and HF-0 groups), 0.01% (C-0.01 and HF-0.01 groups) or 0.1% 
(C-0.1 and HF-0.1 groups) AE. Food and water intake were measured, and the diets replaced 
every 2 days. Body weight was measured weekly. After 16 weeks of feeding, the mice were 
fasted for 18 h and sacrificed under anesthesia with sodium pentobarbital, blood was collected 
from cardiac puncture using a heparinized syringe. The liver, white adipose tissue 
(subcutaneous, epididymal, mesenteric and retroperitoneal adipose tissues) and brown adipose 
tissue were also collected. Plasma and tissue samples were washed with 1.15% (w/v) KCl, 
weighed, immediately frozen using liquid nitrogen, and kept at −80°C until use. 
 
Table 3-2. Composition of the control and high-fat diets 
 Control High-fat 
Ingredients (g/100 g diet) 
 Casein 14 14  
 L-Cystin 0.2 0.2  
 Cornstarch 46.6 16.6  
 Dextrin 15.5 15.5  
 Sucrose 10 10  
 Soybean oil 4 4  
 Cellulose 5 5  
 Mineral mixture 3.5 3.5  
 Vitamin mixture 1 1  
 Choline bitartate 0.3 0.3 
 Tertiary butyl hydroxyl quinone 0.0008 0.0014 
 Lard 0 30  
  (kcal/100 g diet) 
Energy density           348 518  
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Measurement of plasma parameters related to lipid and glucose metabolism  
Plasma triglyceride, total cholesterol, non-esterified fatty acid (NEFA) and glucose levels 
were measured using the commercial assay kits s according to the instructions (Triglyceride-E 
test, Cholesterol-E test, NEFA-C test, and Glucose CII-test, respectively, Wako Pure 
Chemical). Plasma insulin and adiponectin levels were measured by the commercial ELISA 
assay kits according to the manufacturer’s instructions (mouse insulin ELISA kit, Shibayagi, 
Gunma, Japan; and mouse/rat adiponectin ELISA kit, Otsuka Pharmaceutical, Tokyo, Japan, 
respectively). The index of the homeostasis model assessment of insulin resistance 
(HOMA-IR) was calculated using the relationships between the plasma glucose and insulin 
levels, according to the following formula [Trout et al., 2007]: 14 HOMA-IR = fasting 
glucose (mg per 100 mL) × fasting insulin (μU per mL)/405. 
 
Measurement of hepatic lipid levels 
An aliquot of 100 mg of liver was homogenized with 0.35 mL of distilled water, and the 
homogenate was extracted three times with 0.7 mL of chloroform–methanol (2 : 1, v/v) 
solution. The chloroform layer was collected by centrifugation at 1800 × g for 10 min, and 
washed with a 1/4 volume of 0.88% (w/v) KCl. The obtained chloroform layer was 
evaporated, and measured the weight of the residue as total lipids. The residue was dissolved 
in isopropanol containing 10% (v/v) Triton-X, and triglyceride and cholesterol levels were 
measured using the commercial kits as described above. 
 
Western blotting 
Preparation of the cell lysate was performed according to the previous study 
[Nishiumi and Ashida, 2007]. Proteins in the cell lysate fractions of adipose tissue and liver 
were separated by SDS-polyacrylamide gels and transferred to polyvinylidene difluoride 
membranes. After blocking with commercial Blocking One solution (Nacalai Tesque), The 
membrane was incubated with primary antibodies for PPARγ (1:20000), C/EBPα (1:10000), 
SREBP-1 (1:10000), PPARα (1:20000), CPT-1A (1:5000), ACOX1 (1:20000), UCP-2 
(1:20000), β-actin (1:20000), AMPK (1:10000), p-AMPK 1:5000), ACC (1:10000) and 
p-ACC (1:5000) overnight at 4 °C, followed by the corresponding HRP-conjugated secondary 
antibody for 1 h at room temperature. Specific immune complexes were detected with the 
ATTO Light-Capture II Western Blotting Detection System. The density of specific bands 
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was calculated using ImageJ image analysis software. 
 
Statistical analysis 
Data are represented as the means ± SD. The statistical significance of experimental 
observations was determined using the Tukey-Kramer multiple comparison test. The level of 
significance was set at p <0.05. 
 
RESULTS 
Effect of AE on body weight and adipose tissue weight 
During the feeding period, body weight was significantly lowered in the 0.01%AE and 
0.1%AE groups compared with the HF-0%AE group from week 10 to 16, respectively (Fig. 
3-1). At the end of experiment (week 16), the author confirmed that the body weight of the 
mice was significantly higher in the HF-0 group than in C-0%AE group, and 0.01%AE and 
0.1%AE significantly lowered body weight compared with the HF-0 group (Table 3-3). The 
weight of white adipose tissue (epididymal, mesenteric, retroperitoneal, and subcutaneous 
adipose tissue) was greater in the HF-0%AE group than in C-0%AE group. AE suppressed an 
increase in adipose tissue weight compared with the HF-0%AE group. In the groups given the 
control diet, AE did not affect body weight or adipose tissue weights (Table 3-2). AE has the 
potential to reduce body weight and white adipose weight gain induced by the HF diet. 
 
 
 
Fig. 3-1. Changes in body weight of mice fed the control and HF diets 
containing AE for 16 weeks. Open symbols represent control diet-fed groups, while 
closed symbols HF diet-fed groups. Values are the mean ± SD (n=6). Significant 
differences between the 0%AE group (Diamonds) and 0.01%AE (spuares) or 0.1%AE 
(triangles) group are shown (p<0.05, Tukey-Kramer multiple comparison test). 
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Table 3-3. Effects of AE on body weight, and adipose tissue weights of mice fed control and high fat for 16 weeks 
                 Group 
 Control  HF 
Ashitaba extract(%) 0 0.01 0.1  0 0.01 0.1 
Final body weight (g) 30.8±2.2a  32.8±1.1 ab  29.2±2.21 a   35.9±3.34 b 31.5±2.11a 31.5±1.64a 
Tissue weight (g per 100 g body weight) 
Liver   3.79±0.36 a  3.71±0.33 a  3.88±0.47 a   3.74±0.27 a 3.91±0.32 a  3.62±0.56 a 
White adipose tissue weight 
Total 10.91±4.06 a 13.98±1.18a  9.75±2.60 a  19.90±4.79b 11.99±2.8a 12.25±1.48a 
Epididymal  3.22±0.65a  4.31±0.49ab  2.94±0.74a   5.50±1.26b 3.60±1.26a  3.85±0.56a 
Mesenteric  1.47±0.45ab  2.10±0.32ab  1.36±0.24ac   2.40±0.30b 1.71±1.03ab  1.31±0.21ac 
Retroperitoneal  1.62±0.61a  2.22±0.32ab  1.59±0.42 a   3.10±1.00b 1.72±0.69a  2.10±0.73ab 
Subcutaneous  4.59±2.47a  5.53±0.53ab  3.85±1.61a   8.90±3.37b 4.97±1.71a  4.98±0.87a 
Brown adipose tissue  0.73±0.16 a  0.72±0.09 a  0.55±0.12 a   0.47±0.11 a 0.56±0.20 a 0.70±0.19 a 
                                                                                       
 
 
 
 
Mice were fed the control or high-fat diet containing AE for 16 weeks. At the end of the experiment, body weight and adipose 
tissue weights were measured after 18 hours fasting. Values are the mean ± SD (n=6). Values without a common letter in a row 
differ significantly among groups (p<0.05) by the Tukey-Kramer multiple comparison test. 
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Effects of AE on lipid metabolism 
Plasma levels of cholesterol, triglyceride, and NEFA were shown in Fig.3-2. Total 
plasma cholesterol level was significantly increased in the HF-0%AE group compared with 
the C-0%AE group. HF-0.01%AE and -0.1%AE group significantly lowered plasma 
cholesterol level to the almost same level as the control diet-fed groups. On the other hand, 
AE did not affect plasma triglyceride and NEFA levels in both the control and high-fat 
diet-fed groups. Intake of a HF diet is reported to induce hepatic lipid accumulation, which 
are involved in systemic insulin resistance [Korenblat et al., 2008; Hwang et al., 2007]. As 
Fig. 3-2. Eeffect of AE on the levels 
of plasma lipid levels. Mice were fed 
the control or HF diet containing AE for 
16 weeks. At the end of the experiment, 
the plasma levels of cholesterol (A), 
triglyceride (B) and NEFA (C) levels 
were measured. Values are the mean ± 
SD (n=6). The same letters represent no 
significant differences according to the 
Tukey-Kramer multiple comparison test. 
p< 0.05 was considered significant. 
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shown in Fig. 3-3, the hepatic total lipids, triglyceride and cholesterol levels in HF-0%AE 
group were significantly higher than those in the C-0%AE group. The hepatic total lipid, 
triglyceride and cholesterol levels were significantly lower in HF-0.01% AE and HF-0.1%AE 
groups than in the HF-0%AE group. In the groups given the control diet, AE did not affect 
hepatic total lipid triglyceride and cholesterol levels. These results indicate that AE has the 
ability to prevent HF diet-induced hepatic lipid accumulation. 
 
 
Effect of AE on plasma glucose, insulin and adiponectin levels.  
The plasma glucose level at the end of the experiment was significantly higher in the 
HF-0%AE group, compared with the C-0%AE group (Fig. 3-4A). Supplementation of the HF 
diet with 0.01% and 0.1% of AE reduced the plasma glucose levels significantly. The plasma 
insulin level in the HF-0%AE group was also higher than that in the C-0%AE group. 
Supplementation of the HF diet with 0.01% and 0.1% of AE also reduced the insulin levels 
Fig. 3-3. Effects of AE on the 
hepatic lipid levels. Mice were fed the 
control or HF diet containing AE for 16 
weeks. At the end of the experiment 
Total lipid (A), cholesterol (B) and 
triglyceride (C) levels were measured. 
Values are the mean ± SD (n=6). The 
same letters represent no significant 
differences according to the 
Tukey-Kramer multiple comparison test. 
p < 0.05 was considered significant. 
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compare with HF-0%AE group. The insulin levels in the HF-0.01%AE and HF-0.1%AE 
groups were normalized, the level in the control diet group (Fig. 3-4B). Neither glucose nor 
insulin levels significantly changed in the control diet groups. HOMA-IR is a good predictor 
of total insulin sensitivity, and was significantly higher in the HF-0%AE group than that in 
the C-0%AE group (Fig. 3-4C). Supplementation of the HF diet with 0.01% and 0.1% AE 
significantly attenuated the HF diet-induced increase in HOMA-IR. 
White adipose tissue is a major endocrine tissue that releases various adipocytokines into 
the bloodstream. Because adiponectin is one of the major adipocytokines associated with 
maintaining glucose homeostasis [Tilg and Moschen, 2008], the author measured the plasma 
level of adiponectin (Fig. 3-4D). The plasma adiponectin level was lower in the HF-0%AE 
than that in control diet groups, AE dose-dependently increased: 0.1%AE group significantly 
increased adiponectin level compared with HF-0%AE and recovered the same level in the 
control diet groups.  
 
Effect of AE on expression of adipogenesis- and energy metablism-proteins in the 
adipose tissue 
Since PPARγ, C/EBPα, and SREBP-1 are associated with adipogenesis [Lefterova and 
Lazar, 2009], the expression of these proteins levels in white adipose tissue were determined 
by western blotting. As shown in Fig. 3-5, the expression of PPARγ, C/EBPα, and SREBP-1 
were significantly increased in HF-0%AE group compared with those in the control diet 
groups. Both 0.01%AE and 0.1%AE significantly decreased HF diet evoked these 
adipogenesis-related protein expression. In the groups given the control diet, AE did not affect 
the expression of PPARγ, C/EBPα, and SREBP-1. AE also did not affect the expression 
UCP-2 in both control diet and HF diet groups. It has been known that HF diet suppresses 
AMPK activation [Pang et al., 2008; Kim et al., 2008]. Interestingly, the author found AE 
supplentation restored AMPK phosphorylation in HF diet mice (Fig. 3-5). 
 
Effect of AE on expression of adipogenesis- and energy metabolism-proteins in the liver 
To investigate whether the reduction of fat mass in AE-dosed mice is accompanied by 
changes in lipogenesis in the liver, western blotting was performed. As shown in Fig. 3-6, HF 
diet significantly increased the expression of SREBP-1 and FAS and AE was significantly 
decreased HF-diet induced expression of these proteins in HF diet groups. Then, the author 
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investigated the expression of protein responsible for FA oxidation and thermogenesis in the 
liver. HF diet tended to decrease the expression of CPT1, ACOX1 and PPARα and AE was 
significantly increased HF diet depressed expression of these proteins in HF diet groups. AE 
did not alter the expression of these proteins in the control diet groups. Similar to the adipose 
tissue, AE also did not alter UCP-2 expression in the liver. Interestingly, HF-0.01%AE and 
HF-0.1%AE groups also increased in phosphorylation of AMPK and ACC compared with 
HF-0%AE group.  
 
 
 
Fig. 3-4. Effects of AE on plasma glucose, insulin and adiponecitn levels. Mice were 
fed the control or HF diet containing AE for 16 weeks. At the end of the experiment on the levels 
of glucose (A) and insulin (B) levels were measured and the homeostasis model assessment of 
insulin resistance index (HOMA-IR) was calculated (C). The plasma adiponectin was also 
measured (D). Values are the mean ± SD (n=6). The same letters represent no significant 
differences according to the Tukey-Kramer multiple comparison test. p< 0.05 was considered 
significant. 
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Fig. 3-5. Effects of AE on expression of adipogenesis- and energy 
metabolism-proteins in adipose tissue. Mice were fed the control or HF diet containing AE 
for 16 weeks. The expression of C/EBPα, PPARγ, SREBP-1, UCP2, AMPK and p-AMPK in white 
adipose tissue was evaluated by western blotting. Densitometric analysis of specific bands for 
C/EBPα, PPARγ, SREBP-1 and UCP-2 was shown after normalization by β-actin expression, 
p-AMPK was also shown after after normalization by AMPK expression. Values are the mean ± 
SD (n=6). The same letters represent no significant differences according to the Tukey-Kramer 
multiple comparison test. p< 0.05 was considered significant. 
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Fig. 3-6. Effects of AE on expression of adipogenesis- and energy 
metabolism-proteins in liver tissue. Mice were fed the control or HF diet containing AE for 
16 weeks. The expression of SREBP-1, FAS, CPT-1A, ACOX1, PPARα, UCP-2, ACC, p-ACC, 
AMPK and p-AMPK in liver tissue was evaluated by western blotting. Densitometric analysis of 
specific bands for SREBP-1, FAS, CPT-1A, ACOX1, PPARα and UCP-2 was shown after 
normalization by β-actin expression, p-AMPK, p-ACC was also shown after normalization by 
AMPK and ACC expression, respectively. Values are the mean ± SD (n=6). The same letters 
represent no significant differences according to the Tukey-Kramer multiple comparison test. p< 
0.05 was considered significant. 
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DISCUSSION 
In this chapter, AE showed their good ability to lowering body weight and body fat 
(Table 3-1 and Fig. 3-1), accompanied with the prevention of hyperglycemia, and 
hyperlipidemia effects, as estimated by reducing serum levels of cholesterol, glucose, insulin 
and enhancing adiponectin (Figs. 3-2 and 3-4). AE decreased the hepatic contents of 
triglyceride and cholesterol AE also protected the liver from HF diet-induced dysfunctions 
(Fig. 3-3). AE decreased expression of PPARγ, C/EBPα and SREBP-1, which were involved 
in adipogenesis in the adipose tissue (Fig. 3-5). AE also decreased the expression of SREBP-1 
and FAS, and increased the hepatic expression of CPT-1, ACOX1 and PPARα (Fig. 3-6). It 
was noteworthy that AE restored HF-diet-induced inactivation of AMPK in both adipose 
tissue and liver (Figs. 3-5 and 3-6).  
AE significantly suppressed lipid accumulation in the white adipose tissue, including 
visceral adipose tissue. As decreased in the previous chapters, PPARγ and C/EBPα are 
considered to be the master regulators or the crucial determinants of adipocyte fate and play 
an important role in adipogenesis [Tontonoz, et al., 1994; Lefterova et al., 2009]. For instance, 
immortalized fibroblasts lacking PPARγ lose the potential for differentiation to mature 
adipocytes [Rosen et al., 2002]. C/EBPα functions as a principal player in adipogenesis also 
resulted from gain-of-function studies in cultured cells [Freytag et al., 1994] as well as 
establishment of appropriate knockout mice [Wang et al., 1995]. Whole-body C/EBPα-knock 
mice, which die shortly after birth because of liver defects and hypoglycemia, fail to 
accumulate lipid in white or brown adipocytes [Wang et al., 1995]. SREBP-1 regulate lipid 
metabolism and play an essential role in the regulation of lipogenesis in FA and triglyceride 
synthesis [Brown and Goldstein, 1997]. This study found that AE effectively decreased the 
expression of C/EBPα, PPARγ and SREBP-1 in HF-diet group (Fig. 3-5). The results in 
Chapter 1 showed that 4HD and XAG, which are two major components in AE, inhibited 
adipocytes differentiation by down-regulating C/EBPs and PPARγ expression. These results 
indicated that AE suppressed the lipid accumulation in the white adipose tissue by decreasing 
adipocyte differentiation and lipogenesis.  
AE normalized hepatic lipid content in the HF-diet groups, suggesting that it could 
prevent HF diet-induced fatty liver. Lipid accumulation in the liver is caused by enhancing de 
novo lipogenesis, and lowing of lipid catabolism. It is known that 25% of liver triglyceride is 
derived from increased de novo lipogenesis [Donnelly et al., 2005]. De novo lipogenesis is 
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mediated by SREBP-1 that is a key lipogenic transcription factor and nutritionally regulated 
by glucose and insulin [Goldstein et al., 2008; Zhou et al., 2001]. SREBP-1 preferentially 
regulates the lipogenic process by activating genes including FAS, involved in FA and 
triglyceride synthesis, which contribute to hepatic steatosis. The author found that AE 
significantly decreased SREBP-1 and FAS expression in HF-diet treated mice (Fig. 3-6). 
Moreover AE also increased CPT-1A, ACOX1 and PPARα expression in HF-diet treated 
mice. CPT-1, ACO X1 and PPAR α were critically associated with the process of FAs 
oxidation. [Bonnefont et al., 2004; Miyazawa et al., 1987; Wanders et al., 2001; Braissant 
and Wahli, 1998]. The oxidation of intra-hepatocellular FAs occurs mainly in mitochondria, 
and to a much lesser extent in peroxisomes and microsomes. CPT regulates the transport of 
FAs from the cytoplasm to the mitochondrial matrix across the membrane [Bonnefont et al., 
2004], while ACO is the initial enzyme in the peroxisomal β-oxidation system [Miyazawa et 
al., 1987; Wanders et al., 2001]. PPARα-mediated responses have been well studied in the 
liver. It has been reported PPARα agonist normalized fatty livers in fat-fed rats [Braissant and 
Wahli, 1998] and markedly improved lipid accumulation in the liver of rats [Ye et al., 2003]. 
The author’s results in Chapter 2 showed that 4HD and XAG, the major components in AE, 
inhibited the FAs-mixture induced lipid accumulation by down-regulating SREBP-1 and 
up-regulating PPARα expression. These results indicated that AE suppressed the lipid 
accumulation of liver tissue by decreasing lipogenesis and increasing FA oxidation. 
AMPK is a key modulator to maintain the cellular as well as whole-body energy balance. 
AMPK is activated in response to an increase in the AMP: ATP ratio within the cell and 
therefore acts as a sensor for cellular energy regulation. Binding of AMP with AMPK 
allosterically phosphorylates and activates AMPK [Ruderman et al., 1999], which in turn 
shuts down anabolic pathways and supports catabolic pathways through regulating the 
expression of several key enzymes of energy metabolism. The activation of AMPK interacted 
with SREBP-1 and inhibited SREBP-1 target including FAS expression, leading to reduced 
lipogenesis and lipid accumulation [Brown and Goldstein, 1997; Sanyal, 2005]. Moreover, the 
activation of AMPK also leads to the phosphrylation and inhibition of ACC activity and an 
increase in FA oxidation. Phosphorylation of AMPK reversibly and inactivates ACC through 
phosphorylation of this enzyme [Ejaz et al., 2009]. Inactivation of ACC reduces the synthesis 
of malonyl-CoA, which in turn de-represses CPT-1A and ACOX1, and activates FA oxidation 
[McGarry and Brown, 1997]. In addition, AMPK also simulates FA oxidation by 
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up-regulating expression of PPARα [Lee, 2006]. It is also reported that the activation of 
AMPK also inhibites the differentiation of adipocytes by down-regulating the expression of 
C/EBPα and PPARγ [Gao et al., 2008]. It has been known that HF diet suppresses AMPK 
activation [Pang et al., 2008; Kim et al., 2008]. Noticeably, AE treatment restored AMPK 
phosphorylation in HF diet mice in both adipose and liver tissues (Fig. 3-5 and 3-6). These 
results indicated that AE regulated lipid metabolism in adipose and liver through activation of 
AMPK. 
Visceral adipose tissue is an important predictor of insulin resistance, hyperglycemia and 
other metabolic risk factors [Gastaldelli et al., 2002; Després et al., 2008]. Increased adipose 
tissue weights are accompanied by the induction of inflammatory cytokines involved in 
insulin resistance [Hotamisligil, 2006; You et al., 2005]. In addition, visceral adipose tissue 
has been correlated with intrahepatic triglyceride content, and an increase in intrahepatic 
triglycerides is associated with the metabolic abnormalities [Korenblat et al., 2008; Hwang, 
Korenblat et al., 2007; Fabbrini et al., 2009]. The inhibition of fat accumulation in the white 
adipose and liver tissue by AE may, therefore, also contribute to its prevention of 
hyperglycemia and insulin resistance. The author found that AE decreased plasma glucose 
and insulin levels and increasing adiponectin level (Fig. 3-4). Adiponectin is one of the major 
adipocytokines associated with maintaining glucose homeostasis [Tilg and Moschen, 2008]. 
The previous study also showed that AE suppressed acute hyperglycemia in oral glucose 
tolerance test of mice, and 4HD and XAG, major polyphenols in AE stimulate glucose uptake 
in skeletal muscles cells [Kawabata et al., 2011]. These results indicate that AE should be 
effective material for inhibition of hyperglycemia and insulin resistance.  
In conclusion, the author found that administration of AE to mice with HF-diet-induced 
obesity reduced body weight gain, adipose tissue weight, serum levels of cholesterol, glucose, 
insulin and enhanced the level of adiponectin, thereby inhibiting lipogenesis both in the 
adipose tissue and liver. In addition, AE promote FA oxidation in the liver. These effects are 
involved in AMPK activation. Together, these findings demonstrate that AE should be of 
benefit to improve HF diet-induced obesity and insulin resistance.  
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Conclusion Remarks 
 
Obesity has increased at an alarming rate in recent years and is now a worldwide public 
health problem [Friedman, 2000]. Obesity is defined as an abnormal increase in fat, even 
without necessarily in body weight gain. Obesity is a significant risk factor for certain 
metabolic disorder diseases, including type 2 diabetes, cardiovascular diseases and the certain 
forms of cancers [Kaul et al., 2012; Vernooij et al., 2012; Vucenik and Stains, 2012; Ligibel, 
2011]. Thus, weight loss has been recognized to a major health beneficial way for overweight 
people and also increases life expectancy in people having obesity-related complications. The 
diets as well as energy intake and nutritional balance are major causes for obesity and insulin 
resistance [Eaton, 2006]. Certain food components are used as the ingredient of medicine, 
which have been established for over 4000 years by a natural or traditional herbal medicine. 
Thus, extensive researches have been carried out to clarify the cellular and molecular 
mechanism of functional foods that have the prevention and/or amelioration effects on obesity 
and insulin resistance [Pinent, 2004 & 2006; Hanhineva, 2010; Holt, 2012; Montagut, 2010].  
Chalcones are containing in various plants and have a variety of health-promoting effects. 
Several synthetic chalcones also showed biologically active [Dimmock et al., 1999; Bandgar 
et al., 2009]. In this dissertation, the author clarified the mechanisms of 4HD, XAG, CAR and 
FKB on adipocytes differentiation (Chapter 1) and FAs-mixture-induced steatosis in HepG2 
cells (Chapter 2). Moreover, the author demonstrated the preventive effects of Ashitaba 
(Angelica keiskei) extract, which contains two main phytochemicals 4HD and XAG, on 
high-fat diet-induced obesity and insulin resistance in C57BL/6 (Chapter 3). 
Adipocytes differentiation is deeply involved in the onset of obesity. In this dissertation, 
the author found that chalcones 4HD, XAG, CAR and FKB effectively suppressed lipid 
accumulation in adipocytes. These chalcones are able to inhibit adipocyte differentiation 
through down-regulating expression of CCAAT/enhancer-binding proteins (C/EBPs) and 
peroxisome proliferator-activated receptor gamma (PPARγ) (Chapter 1). The Ashitaba extract, 
which contains two main chalcones 4HD and XAG, also inhibited high-fat diet-induced 
C/EBPa and PPARγ expression in white adipose tissue of C57BL/6 (Chapter 3). C/EBPs and 
PPARγ are master regulators during the adipocyte differentiation. PPARγ forms a heterodimer 
with retinoic acid X-receptor (RXR) [Kliewer et al., 1992], and regulates the transcription of 
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adipocyte-specific genes [Tontonoz et al., 1994]. C/EBPα functions as another principal 
player in adipogenesis and is most abundant in mature adipocytes, where plays a crucial role 
in insulin-dependent glucose uptake [Wu et al., 1999]. At the early stage of adipocyte 
differentiation, activations of C/EBPβ and C/EBPδ are the initial events that subsequently 
lead to increase expression of C/EBPα, PPARγ and probably other adipogenic factors [Cao et 
al., 1991; Yeh et al., 1995]. Previous study also showed that tea catechin [Furuyashiki et al., 
2004] and crucumim [Ejaz et al., 2009] also inhibited adipocyte differentiation and obesity in 
mice by down-regulating of C/EBPs and PPARγ. These results indicated that chalcones 
should be an effective compounds for prevent obesity and obesity-related disorders. Moreover, 
the author found chalcones regulated adipocyte differentiation though AMP-activated protein 
kinase (AMPK) activation (Section B of Chapter 1). AMPK is a key enzyme to maintain 
cellular as well as body energy balance. Intense research in recent years has revealed the 
critical roles that AMPK plays in modulating ever-expanding many biological pathways 
[Zhang et al., 2009; Luo et al., 2005]. The author’s results showed that an inhibitor of AMPK, 
compound C enhanced the expression of C/EBPs and PPARγ, leading to increasing lipid 
accumulation in adipocytes (Section B of Chapter 1). Previous study showed that the 
activation of AMPK also inhibited the differentiation of 3T3-L1 cells by down-regulating the 
expression of C/EBPβ, δ, α, and PPARγ [Gao et al., 2008]. These results indicated that should 
be a molecular target for anti-obesity therapeutics. In Chapter 1, the author found that 
chalcones regulated adipocyte differentiation by extracellular signal-regulated kinase (ERK) 
and c-Jun amino-terminal kinases (JNK) activation. It was reported that ERK activation was 
necessary for adipocyte differentiation, and that a reduction in ERK expression in 
preadipocytes decreases adipocyte differentiation [Sale, et al., 1995]. However, ERK 
activation also attenuates differentiation by inducing PPARγ phosphorylation during 
adipocyte differentiation [Camp, et al., 1999; Hu, et al., 1996]. It seems that ERK activation 
is tightly controlled in a temporal manner, being activated in preadipocytes and deactivated 
during adipocyte differentiation to prevent PPARγ phosphorylation. Recent studies showed 
that ERK activation is required for cell mitosis in the early stage of adipogenesis, and that 
activated (phosphorylated) ERK needs to be dephosphorylated thereafter because ERK might 
enhance PPARγ efflux from nucleus, suppress PPARγ degradation, and inhibit adipocyte 
differentiation [Burgermeister, et al., 2007; Wang, et al., 2009; Kim, et al., 2009]. Moreover, 
diallyl trisulfide suppresses the adipogenesis of 3T3-L1 cells by activating ERK, and 
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evodiamine improved diet-induced obesity by inhibiting adipocyte differentiation via ERK 
activation [Lii, et al., 2012; Wang, et al., 2009]. Therefore, our results, showing that 
chalcones inhibit adipocyte differentiation through ERK activation, are consistent with those 
of prior studies. It has been known that JNK is involved in insulin signaling pathway 
[Hirosumi et al., 2002; Sabio et al., 2009]. However, the effect of JNK on adipocytes 
differentiation was still not clear. In the present study, we attempted to clarify this effect using 
a JNK inhibitor SP600125 and found phosphorylation of JNK inhibited adipocytes 
differentiation. In addition, we also found that SP600125 abolished the inhibitory effects of 
4HD and XAG on lipid accumulation and on the expression of C/EBPα and PPARγ but not 
C/EBPβ (Chapter 1). Previous studies reported that activation of JNK inhibits adipocyte 
differentiation by enhancing phosphorylation of PPARγ and negatively regulating its 
transcriptional activity [Ohkura et al., 2011; Hu et al., 1996]. These results indicate that the 
inhibitory effects of chalcones on adipocytes differentiation is also depend on enhancing 
phosphorylation of JNK and decreasing expression of C/EBPα and PPARγ. It is interesting 
that the author found 4HD and XAG regulated adipocytes differentiation through activation of 
AMPK, ERK and JNK multiple signaling pathways. These factors could be available as the 
molecular targets for anti-obesity therapeutics. However, the mechanisms of between these 
factors for modulating adipocytes differentiation did not elucidate in present study. It should 
be an issue for the future study. 
Hepatic steatosis is caused by enhancing de novo lipogenesis, and lowing of lipid 
catabolism. The author found the expression of (sterol regulatory element binding protein-1) 
SREBP-1 was attenuated while peroxisome proliferator-activated receptor alpha (PPARα) 
was increased in these chalcones-treated cells (Chapter 2). The author also found that AE 
efficiently inhibited hepatic lipid lipogenesis via suppressing expression of SREBP-1 and its 
target enzyme Fatty acid synthase (FAS), and increased fatty acid (FA) oxidation via 
promoting expression of carnitine palmitoyltransferase-1(CPT-1A), acy-CoA oxidase (ACO) 
and peroxisome proliferator-activated receptor alpha (PPARα) in the liver (Chapter 3). De 
novo lipogenesis is mediated by SREBP-1 that is a key lipogenic transcription factor and 
nutritionally regulated by glucose and insulin. SREBP-1 preferentially regulates the lipogenic 
process by activating genes including FAS, involved in FA and triglyceride synthesis, which 
contribute to hepatic steatosis [Goldstein et al., 2008; Zhou et al., 2001]. On the other hand, 
CPT-1, ACOX1 and PPAR α were critically associated with the process of FAs oxidation. 
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[Bonnefont et al., 2004; Miyazawa et al., 1987; Wanders et al., 2001; Braissant and Wahli, 
1998]. The oxidation of intra-hepatocellular FAs occurs mainly in mitochondria, and to a 
much lesser extent in peroxisomes and microsomes. CPT-1 regulates the transport of FAs 
from the cytoplasm to the mitochondrial matrix across the membrane [Bonnefont et al., 2004], 
while ACO is the initial enzyme in the peroxisomal β-oxidation system [Miyazawa et al., 
1987; Wanders et al., 2001]. PPARα-mediated responses have been well studied in the liver. It 
has been reported PPARα agonist normalized fatty livers in fat-fed rats [Braissant and Wahli, 
1998] and markedly improved lipid accumulation in the liver of rats [Ye et al., 2003]. It is 
noteworthy that chalcones not only inhibited FAs mixture-induced lipid accumulation in the 
HepG2 cells (Chapter 2), but also HF diet-induced lipid accumulation in liver of mice 
(Chapter 3) through decreasing de novo lipogenesis while increasing FA oxidation. These 
results indicate that chalcones should be the effective materials for prevention of hepatic 
steatosis. 
The author also found that AE significantly lowered plasma glucose and insulin levels, 
and increased adiponectin level compared to the HFD group (Chapter 3). Visceral adipose 
tissue is an important predictor of insulin resistance, hyperglycemia and other metabolic risk 
factors [Gastaldelli et al., 2002; Després et al., 2008]. Increased adipose tissue weights are 
accompanied by the induction of inflammatory cytokines involved in insulin resistance 
[Hotamisligil, 2006; You et al., 2005]. In addition, visceral adipose tissue has been correlated 
with intrahepatic triglyceride content, and an increase in intrahepatic triglycerides is 
associated with the metabolic abnormalities [Korenblat et al., 2008; Hwang, Korenblat et al., 
2007; Fabbrini et al., 2009]. The inhibition of fat accumulation in the white adipose tissue and 
liver by AE may, therefore, also contribute to its prevention of hyperglycemia and insulin 
resistance. The author found that AE decreased plasma glucose and insulin levels and 
increasing adiponectin level. Adiponectin is one of the major adipocytokines associated with 
maintaining glucose homeostasis [Tilg and Moschen, 2008]. The previous study also showed 
that AE suppressed acute hyperglycemia in oral glucose tolerance test of mice, and 4HD and 
XAG, major polyphenols in AE, stimulate glucose uptake in skeletal muscles cells [Kawabata 
et al., 2011]. These results indicate that chalcones-rich AE should be effective material for 
inhibition of hyperglycemia and insulin resistance.  
It is noteworthy that chalcones regulate lipid metabolism though increasing 
phosphorylation of AMPK in adipocytes (Chapter 1), HepG2 cells (Chapter 2) and C57BL/6 
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mice (Chapter 3). AMPK is a key modulator to maintain the cellular as well as whole-body 
energy balance. AMPK is activated in response to an increase in the AMP: ATP ratio within 
the cell and therefore acts as a sensor for cellular energy regulation. Binding of AMP with 
AMPK allosterically phosphorylates and activates AMPK [Ruderman et al., 1999], which in 
turn shuts down anabolic pathways and supports catabolic pathways through regulating the 
expression of several key enzymes of energy metabolism. The activation of AMPK interacted 
with SREBP-1 and inhibited SREBP-1 target including FAS expression, leading to reduced 
lipogenesis and lipid accumulation [Brown and Goldstein, 1997; Sanyal, 2005]. Moreover, the 
activation of AMPK also leads to the phosphrylation and inhibition of ACC activity and an 
increase in FA oxidation. Phosphorylation of AMPK reversibly and inactivates ACC through 
phosphorylation of this enzyme [Ejaz et al., 2009]. Inactivation of ACC reduces the synthesis 
of malonyl-CoA, which in turn derepresses CPT-1A and ACOX1, and activates FA oxidation 
[McGarry and Brown, 1997]. In addition, AMPK also simulates FA oxidation by upregulating 
expression of PPARα [Lee, 2006]. It is also reported that the activation of AMPK also 
inhibites the differentiation of adipocytes by down-regulating the expression of C/EBPα and 
PPARγ [Gao et al., 2008]. These results indicated that AMPK should be the core molecular 
target for chalcones prevents obesity and insulin resistance. Recent studies revealed that liver 
kinase B1 (LKB1) is one of the important upstream kinases of AMPK [Hawley et al., 2003; 
Woods et al., 2003]. LKB1 can active AMPK by phosphorylation at Thr172 in mammalian 
cells. chalcones phosphorylated LKB1 at Ser428 in HepG2 cells (Chapter 2). 
Ca(2+)/CaM-dependent protein kinase kinase β, is another upstream kinase of AMPK, has a 
profound impact on feeding, body weight, glucose homeostasis and insulin sensitivity in 
rodents and humans [Lage et al., 2008]. However, in this dissertation, the author did not pay 
attention to this kinase for chalcones preventing obesity and insulin resistance. It should be an 
interest issue for the future study. 
In Chapter 3, the author found HF diet supplementary of 0.01%AE and 0.1%AE 
significantly promoted HF diet-induced obesity and insulin resistance. To understand the 
beneficial effects of functional compounds, it is essential to determine their bioavailability 
and metabolism in vivo. The previous study [Nkamura et al., 2012] demonstrated that 4HD 
and XAG are rapidly absorbed into plasma and are distributed to various tissues in mice 
orally administered with Ashitaba extract. Similar to other polyphenols [Mullen et al., 2006; 
Kawai, et al., 2008; Zhang et al., 1999], it is thought that Ashitaba chalcones are metabolized 
88 
 
 
by phase 2 drug-metabolizing enzymes. Although we could not identified exact chemical 
structure of metabolite, previous reports demonstrated the structure of metabolite. For 
example, in the case of naringenin chalcone, which is one of the well-researched chalcones 
containing tomato, it was reported that glucuronide conjugated C-2′ hydroxyl group was 
major metabolites in the plasma and urine in rat [Yoshimura et al., 2009]. As expected, 4-HD 
and XAG were absorbed and conjugated after oral administration of Ashitaba extract. 
Thereafter, the aglycones and metabolites of these compounds were distributed to many 
tissues including the liver, kidney, spleen, muscle, perirenal fat and epididymal fat. It is 
interesting that prenylated chalcones, particularly 4-HD, mainly exist as aglycones, rather 
than metabolites, in plasma and tissues, indicating that these compounds contribute to the 
beneficial effects of Ashitaba extract [Nakamura et al., 2012]. These studies provide strong 
evidences that chalcones 4-HD and XAG should be the active compounds in AE for prevent 
obesity and insulin resistance. 
In conclusion, 4HD, XAG, CAR and FKB suppressed 3T3-L1 adipocytes differentiation 
though AMPK and MAPK pathways, resulting in the down-expression of adipocyte-specific 
transcription factors. These chalcones also decreased FAs-induced lipid accumulation through 
LKB1/AMPK signaling pathway accompanying with decreasing down-expression of 
SREBP1 and up-expression of PPARα in HepG2 cells. Moreover, the author found that 
administration of AE to mice with HF diet-induced obesity reduced body weight gain, adipose 
tissue weight, serum levels of cholesterol, glucose, insulin and enhanced the level of 
adiponectin, thereby inhibiting lipogenesis both in adipose and liver tissue. In addition, AE 
also promote FA oxidation in liver. These effects are involved in AMPK activation. The 
hypothetical chalcones in the prevention of obesity and hyperglycemia is shown in Fig. Concl. 
Together, these results indicate that chalcones should be of great benefit to prevent obesity 
and insulin resistance.  
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Fig. Concl. The mechanism of chalcones in the prevention of obesity and insulin  
resistance. 
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Future Research  
In this dissertation, the author demonstrated that chalcones are attractive food 
components for prevention of obesity and insulin resistanc through modulation of the central 
and peripheral functions. To elucidate the functions of food components, clarification of 
bioavailability for the target compound is important. Regarding bioavailability of chalcones, 
extent of absorption and metabolism are controversial. It was reported that Ashitaba 
chalcones are rapidly absorbed into plasma and are distributed to various tissues in mice 
orally administered with Ashitaba extract [Nakamura et al., 2012], but absorption and 
metabolism of Ashitaba chalcones is still not clear under the long time feeding at low 
concentration. Further study is needed to clarify this important issue. In addition, in the 
Chapter 1, the author found that chalcones modulated adipocyte differentiation through 
multiple signaling pathways. However, the mechanisms of between these factors for 
modulating adipocytes differentiation still not clear. It should be another issue for the future 
study.  
In generally, it is common that the patients with insulin resistance, NAFLD and extreme 
extent of obesity are treated with medicine. However, the pharmaceutically treatments have 
certain risk of adverse effects. In addition, it is impossible for normal people to use 
pharmaceutically treatments to maintain and improve their health. Recently, much attention 
has paid to functional foods from the view point of preventive medicine, because of lower 
adverse effects with less cost. Dietary phytochemicals may be another cure for weight control 
and management of metabolic syndrome. The findings of this dissertation are little evidences 
for prevention of obesity and insulin resistance by chalcones. More attention should be pay to 
the scientific evidences for understanding the functions and safety of foods. Therefore, the 
author expects to continue the studies on the function of chalcones to improve human health.  
 
 
91 
 
 
Appendix 
 
Preventive effects of black soybean seed coat polyphenols on DNA damage. 
 
APPENDIX INTRODUCTION  
DNA damage can lead to degenerative diseases including cancer, diabetes and 
cardiovascular disease [Ames, 1989; Reardon et al., 1992; Lee and Blair, 2001]. 
Environmental pollution and some dietary habits have been associated with genetic damage 
[Ames and Gold, 1998]. Several studies have reported that certain extracts of fruits and 
vegetables modify DNA damage [Godits et al, 1985; Freedman et al., 2008]. 
Black soybean has been a functional food for many years in East Asia [Inagaki et al., 
2005]. Recently, many studies have focused on the bioactivities of the color coats, which are 
rich in various polyphenols, such as catechins, anthocyanins, procyanidins and other 
flavonoids. Constituents in black soybean seed coat have been reported to possess various 
physiological functions, such as antioxidant activity in vitro [Ignasius et al., 2009], inhibition 
of inflammatory [Kim et al., 2008] and anti-obesity and anti-diabetic activity in mice 
[Kanamoto et al., 2011]. However, information concerning the preventative effect of 
compounds from black soybean seed coat extract against DNA damage is still lacking, though 
it has been reported that black soybean components have prevented genetic damage induced 
by chemical mutagens in mice [Azevedo et al., 2003]. 
The appendix was divided into 3 parts. In appendix A, Ames test were carried out to 
investigate the safety of black soybean seed coat extract (BE). Then, the author investigated 
contribution of the antimutagenic compounds from BE in Salmonella tyhimurium TA 98 and 
TA 100. In appendix B, the author investigated the protective effects of BE and its 
components on benzo[a]pyrene [B(a)P]-induced DNA damage in HepG2 cells and ICR mice. 
Moreover, the author clarified the underlying protective mechanism of BE on B(a)P-induced 
DNA damage by examining drug metabolism enzymes system. In appendix C, the author, 
further, investigated the protective effect of BE and its polyphenols on oxidative DNA 
damage by estimating the levels of 8-OHdG in human hepatoma HepG2 cells.  
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Table appendix A-1. Composition of 
polyphenols in BE and PC-rich BE. 
Compounds BE PC-rich BE 
 % (w/w) 
Total polyphenols 67 85.4 
Total flavanols 45.9 80.6 
Total isoflavones 0.96 0.69 
   
Cyanidin-3-glucoside 9.2 0.9 
Epicatechin 6.2 13.8 
Procyanidin 39.7 66.8 
Dimer 6.1 11.8 
Trimer 3.4 7.8 
Tetramer 0.5 3.1 
 
Appendix A 
Preventive effects of black soybean seed coat polyphenols against mutagens-induced 
DNA damage in Salmonella typhimurium. 
INTRODUCTION 
Among the methods for evaluating DNA damage, the Ames test serves as a quick assay 
to estimate the mutagenic and anti-mutagenic potential of compounds (Mortelmans and 
Zeiger, 2000). B(a)P is a polycyclic aromatic hydrocarbon and is widespread in the 
environment (Hattemer-Frey and Travis, 1991). It is an indirect mutagen that exhibits 
biological activity by P450-dependent monooxygenase enzymes (Schoket et al., 2001). B(a)P 
metabolites, such as epoxides, can bind to DNA to form B(a)P-DNA adducts that can 
interfere with or alter DNA replication, increasing the risk of several cancers (Rodriguez et 
al., 1999). 4-Nitroquinoline-1-oxide (4NQO) is a direct mutagen and binds covalently to 
DNA. 4NQO also plays a role as an oxidative mutagen that generates superoxide radicals and 
reactive oxygen species by redox recycling (Nunoshiba and Demple, 1993). 
BE is rich in various polyphenols, such as catechins, anthocyanins and procyanidins. In 
appendix A, mutagenic and cytotoxicity assays were performed to investigate the safety of 
BE. Then, the author investigated the contribution of the anti-mutagenic compounds from BE 
in Salmonella typhimurium stains TA 98 and TA 100.  
 
MATERIAL AND METHODS 
Materials 
Strains of S. typhimurium (TA 98 and TA 100) were used for mutagenic and 
anti-mutagenic assays. S9 mix (S9 
fraction of liver homogenate with 
cofactor I) was purchased from 
Oriental Yeast Co. Ltd (Tokyo, Japan). 
2-Aminoanthracene (2-AA), 
2-(2-furyl-3-(5-nitro-2-furyl) 
acrylamide (AF-2), 
4-nitroquinoline-1-oxide (4NQO), and 
benzo[a]pyrene [B(a)P] were 
purchased from Sigma (St. Louis, MD). 
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Black soybean seed coat extract (BE) and procyanidin-rich BE (PC-rich BE) were gifts from 
Fujico Co. Ltd (Kobe, Japan); their compositions are shown in Table appendix A-1. Cyanidin 
3-glucoside (C3G), procyanidin B1 (PCB1) and procyanidin B2 (PCB2) were purchased 
from Funakoshi (Tokyo, Japan). Procyanidin C (PCC), 
EC-(4β→6)-EC-(4β→8)-EC-(4β→8)-EC (PC4-1) and cinnamtannin A2 (PC4-2) were 
obtained from Fujico Co. Ltd. (+)-Catechin and (-)-epicatechin (EC) were purchased from 
Wako Pure Chemical Industries (Osaka, Japan). The chemical structures of the major 
polyphenols are shown in Fig. appendix A-1. All other reagents used were of the highest 
grade available from a commercial source. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cyanidin 3-glucoside             
(C3G)
(+)-catechin (-)-epicatechin
(EC)
procyanidin B1 
(PCB1)
procyanidin B2 
(PCB2) procyanidin C 
(PCC)
EC-(4β→6)-EC-(4β→8)-EC-(4β→8)-EC 
(PC 4-1)
cinnamtannin A2 
(PC 4-2)
Fig. appendix A-1, Chemical structures of major polyphenols in BE.  
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Mutagenic assay 
The mutagenicity of BE was assayed according to the method of Ames [Maron and 
Ames, 1983] using S. typhimurium strains TA 98 and TA 100. A solution of 0.1 mL of BE at 
various concentrations (final 5, 50, 500 and 5000 μg/plate), DMSO as vehicle control, or 
mutagen was added to the mixture of 0.5 mL of S9 mix (S9+) or 0.1 M phosphate buffer 
(S9-), and 0.1 mL of S. typhimurium TA 98 or TA 100 overnight culture. As the mutagens, 
2-AA (0.1 μg/plate in TA 98 and 0.01 μg/plate in TA 100) and AF-2 (0.5 μg/plate in TA 98 
and 1 μg/plate in TA 100) were used. After pre-incubation at 37℃ for 30 min, 2 mL of molten 
top agar supplemented with l-histidine and (+)-biotin at 55◦C was added to the mixture. The 
solution was then gently mixed and poured onto minimal glucose agar plates. The plates were 
turned upside down and incubated at 37◦C for 48 h, and colony counts were determined. 
Three independent experiments were performed using triplicate plates in each experiment. 
 
Cytotoxicity assay 
The cytotoxicity of BE was also determined using S.  typhimurium strains TA 98 and 
TA 100 as described by Ames et al. [Maron and Ames, 1983] with slight modification. Cells 
of Salmonella strains were cultured overnight at 37℃. Aliquots of cell suspensions (0.4 mL 
each) were supplemented with 0.4 mL of BE at 5000 μg/plate or DMSO as vehicle control, 
with or without S9 mix, respectively. The mixtures were incubated at 37◦C for 30 min. The 
cells were washed 3 times with saline by centrifugation at 3000×g for 20 min and 
resuspended in 0.4 mL of 0.1 M phosphate buffer (pH 7.4). A 0.1 mL aliquot of the cell 
suspension was added to 2 mL of molten soft agar and poured onto minimal glucose agar 
medium. In parallel, a portion of the same volume of cell suspension was diluted 106-fold 
with saline and 0.1 mL aliquots were added to 2 mL of molten soft agar containing 5 mM 
L-histidine and poured onto minimal glucose agar medium. After incubation at 37◦C for 48 h, 
the revertant and surviving colonies were counted. Three independent experiments were 
performed using triplicate plates in each experiment. 
 
Anti-mutagenic assay 
The anti-mutagenicity of BE and its polyphenols was investigated using the Ames test as 
described previously [Maron and Ames, 1983]. B(a)P was used as an indirect mutagen, which 
required the S9 mix for metabolic activation, at 5 μg/plate for both TA 98 and TA 100, while 
95 
 
 
4NQO was used as a direct mutagen at 1 μg/plate for TA 98 and 0.5 μg/plate for TA 100. In 
the assay, 0.1 mL of BE, PC-rich BE, or C3G at different concentrations was added to 0.02 
mL of mutagen solution and 0.5 mL of S9 mix (S9+) or 0.1 M phosphate buffer (S9-). 
Subsequently, 0.1 mL of bacterial cells was added to the mixture and incubated at 37◦C for 30 
min. The following procedure was carried out according to that for the mutagenic assay as 
described above. Data are presented as the mean of three independent experiments of 
triplicate plates.  
For the anti-mutagenic assay, the inhibition of mutagenicity was calculated by using the 
following equation (A: number of revertants/plate induced by mutagen alone, B: number of 
spontaneous revertants, C: number of revertants/plate induced by the compound plus 
mutagen) Inhibition (%) = [(A-C)/ (A-B)] × 100. 
 
Statistical analysis 
The data are expressed as the mean ± SE. Analysis of variance (ANOVA) was conducted. 
Tukey’s multiple-range test was used to estimate the significance of differences among groups. 
The level of statistical significance was set at p<0.05. 
 
RESULTS 
Mutagenic assay of BE 
The author first investigated BE mutagenicity by performing the Ames test with S. 
typhimurium strains TA 98 and TA 100. As shown in Table appendix A-2, in the presence of 
Table appendix A-2. Mutagenicity of BE 
 
 
Compounds 
Number of revertant colonies 
TA 98 TA 98  TA100 TA100 
S9+ S9-  S9+ S9- 
2-AA 
AF-2 
BE 
(μg/plate) 
 
 
Vehicle 
 
 
5000 
500 
50 
5 
63±12* 
- 
31±2 
26±3 
24±2 
25±2 
22±3 
- 
419±7* 
15±2 
17±2 
19±3 
19±5 
18±2 
 476±9* 
- 
210±14 
202±5 
172±17 
170±10 
177±7 
- 
580±13* 
268±18 
217±7 
202±5 
202±6 
210±5 
Vehicle: DMSO (100 μL/plate); 2-AA: 2-aminoanthracene (0.1 μg/plate in TA 98 and 0.01 μg/plate in TA 
100); AF-2: 2-(2-furyl-3-(5-nitro-2-furyl) acrylamide (0.5 μg/plate in TA 98 and 1 μg/plate in TA 100). 
*The number of revertant colonies was more than twice that of the vehicle. Values are expressed as mean 
± SE (n=3). 
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S9 mix (S9+), the positive control 2-AA showed mutagenic activity compared with the 
DMSO control, which had 22 ± 3 and 177 ± 7 spontaneous revertants per plate in strains TA 
98 and TA 100, respectively. In the absence of S9 mix (S9-), the positive control AF-2 also 
showed mutagenic activity compared with the DMSO control, which had 18 ± 2 and 210 ± 5 
spontaneous revertants per plate in strains TA 98 and TA 100, respectively. However, these 
spontaneous mutation frequencies did not change under treatment with BE, even at the 
highest concentration of 5000 μg/plate.  
 
Cytotoxicity of BE 
BE cytotoxicity was assessed by the Ames test using S. typhimurium strains TA 98 and 
TA 100. As shown in Table appendix A-3, in the absence of L-histidine, BE at 5000 μg/plate 
did not change spontaneous revertants with or without S9 mix in both TA 98 and TA 100. In 
the presence of L-histidine, BE at 5000 μg/plate also did not change spontaneous surviving 
colonies, with or without S9 mix, in both strains.  
 
Anti-mutagenicity of BE and its polyphenols against B(a)P- and 4NQO-induced 
mutagenesis in S. typhimurium TA 98 and TA 100. 
The anti-mutagenic activities of BE, PC-rich BE and C3G on the indirect mutagen B(a)P 
(5 μg/plate) was evaluated. As shown in Fig. appendix A-2A, BE, PC-rich BE and C3G 
dose-dependently inhibited B(a)P-induced mutagenesis in the presence of S9 mix. In addition, 
they also exhibited strong inhibitory effect on 4NQO (1 μg/plate for TA 98 and 0.5 μg/plate 
for TA 100)-induced mutagenesis in the absence of S9 mix (Fig. appendix A-2B). 
Anti-mutagenic activity was in the rank order: C3G>BE>PC-rich BE. These results indicate 
that C3G is one of the active compounds in BE that prevents B(a)P- and 4NQO-induced 
mutagenesis. To clarify the antimutagenic effects of other polyphenols present in BE, the 
Table appendix A-3. Cytotoxicity of BE 
 
Compound (μg/plate) 
Number of revertant colonies 
       TA98          TA100 
S9+ S9-  S9+ S9- 
His+   Vehicle 638±23 47±4  534±13 717±22 
+BE  5000 689±8 51±5  603±35 712±43 
His-   Vehicle 20±2 21±3  169±19 195±18 
+BE  5000 18±5 21±1  170±17 221±4 
 Vehicle: DMSO; (100 μL/plate). Values are expressed as mean ± SE (n=3). 
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anti-mutagenic effect of each compound at 5 μM (concentration in pre-incubated solution, 
720 μL) was determined against the mutagenicity of B(a)P and 4NQO. In TA 98, the 
inhibition of C3G, catechin, epicatechin, PCB1, PCB2, PCC, PC4-1 and PC4-2 on 
B(a)P-induced mutagenesis was 40%, 16%, 20%, 34%, 33%, 41%, 59% and 52%, 
respectively, and the inhibition against 4NQO-induced mutagenesis was 37%, 23%, 23%, 
29%, 26%, 37% 44% and 39%, respectively. In TA 100, the inhibition of these compounds on 
B(a)P-induced mutagenesis was 43%, 17%, 25%, 30%, 28%, 48%, 57% and 59%, 
respectively, and the inhibition on 4NQO-induced mutagenesis was 36%, 20%, 18%, 28%, 
28%, 38%, 56% and 54%, respectively (Fig. appendix A-3). From these results, procyanidins, 
in addition to C3G, showed anti-mutagenic activity. In particular, the procyanidin trimer and 
tetramer showed strong anti-mutagenic activity, while catechin and epicatechin showed weak 
activity.  
 
 
(A) TA 98 TA 100
(B)
Dose (µg/plate)
TA 98 TA 100
Dose (µg/plate)
0
20
40
60
80
100
0.1 1 10 100 1000 10000
In
hi
bi
tio
n 
%
 a
0
20
40
60
80
100
0.1 1 10 100 1000 10000
0
20
40
60
80
100
0.1 1 10 100 1000 10000
In
hi
bi
tio
n 
%
 a
0
20
40
60
80
100
0.1 1 10 100 1000 10000
 
Fig. appendix A-2. Anti-mutagenicity of BE, PC-rich BE and C3G against (A) B(a)P- 
and (B) 4NQO-induced mutagenesis in Salmonella typhimurium TA 98 and TA 100. B(a)P 
was used at 5 μg/plate while 4NQO was used at 1 μg/plate for TA 98 and 0.5 μg/plate for TA 100. 
Diamonds, BE; squares, PC-rich BE; triangles, C3G. Results are expressed as the mean ± SE (n=3).   
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DISCUSSION  
In the present study, the author demonstrated that BE exhibited neither mutagenicity nor 
cytotoxicity toward S. typhimurium TA 98 and TA 100 even at the highest concentration (5000 
μg/plate) used in this study to (Table appendix A-2 and 3). In previous acute and chronic oral 
toxicity studies, the author also found that BE did not result in mortality or poisoning in rats 
and mice [Fukuda et al., 2011]. These results indicate that BE is safe for consumption or for 
use as a food material. With respect to anti-mutagenicity, BE, C3G and PC-rich BE exhibited 
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Fig. appendix A-3. Anti-mutagenicity of C3G, (+)-catechin, (-)-epicatechin and 
procyanidins against (A) B(a)P- and (B) 4NQO-induced mutagenesis in Salmonella 
typhimurium TA 98 and TA 100. Each polyphenol was added to the pre-incubation solution at 5 
μM. B(a)P was used at 5 μg/plate while 4NQO was used at 1 μg/plate in TA 98 and 0.5 μg/plate in TA 
100. Results are expressed as the mean ± SE (n=3). Means with different letters differ significantly 
(p<0.05), as determined by Tukey’s multiple-range test. 
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a dose-dependent anti-mutagenic activity with or without the S9 mix, in TA 98 (frame-shift 
mutation) and TA 100 (single base-substitution mutation) (Fig. appendix A-2). The author’s 
results indicate that C3G is one of the active compounds in BE that prevents mutagenesis. 
Moreover, procyanidins especially the dimer, trimer and tetramer, but not catechin and 
epicatechin (monomer), contributed to the anti-mutgaenic activity of BE (Fig. appendix A-3). 
Anti-mutagenic activity was in the rank order: tetramer>trimer>dimmer>monomer. The 
previous study showed that procyanidins prevented B(a)P-induced DNA damage via 
decreasing the expression of CYP1A1 and increasing the expression of glutathione 
S-transferases, depending on the degree of procyanidin polymerization [Zhang et al., 2013]. 
This result indicates that polymers are more potent than monomers in modulating the 
drug-metabolizing enzyme system, suggesting that polymers have strong effects on the 
prevention of chemically -induced mutagenesis and/or carcinogenesis, although the 
bioavailability of polymers is lower than that of monomers. From these results, C3G and 
procyanidins, the main components in BE, have the potential to protect against 
mutagen-induced DNA damage. 
The mutagens used in this study were the indirect mutagen B(a)P and the direct mutagen 
4NQO. B(a)P is a five-ring polycyclic aromatic hydrocarbon whose metabolites are 
mutagenic and highly carcinogenic. Numerous studies have documented B(a)P involvement 
in increased cancer risk [Xiong et al., 2001; Sinha et al., 2005]. It is known that B(a)P leads to 
cancer through several enzymatic reactions [Jiang and Whitlock, 2007]. The most important 
enzyme is cytochrome P4501A1 (CYP1A1), and B(a)P induces CYP1A1 through an aryl 
hydrocarbon receptor mediated pathway [James et al., 1999]. Induced CYP1A1 plays a role in 
metabolic activation of B(a)P to form its epoxides. The formed epoxides generate radicals and 
DNA -adducts [Lodovici et al., 2004]. Recent study showed that procyanidins and C3G from 
black soybean seed coat, prevented B(a)P-induced DNA damage via modulation of 
drug-metabolizing enzymes in HepG2 cells and ICR mice [Zhang et al., 2013]. Previous 
studies have shown that procyanidin -rich cacao polyphenol extract suppresses 
3-methylcholanthrene-induced CYP1A1 expression in C57BL/6 mice [Mukai et al., 2008]. 
Moreover, anthocyanin -rich pomegranate juice prevented procarcinogen activation through 
the inhibition of CYP activity [Faria et al., 2007]. Besides, it was reported that certain 
polyphenols can form complexes with B(a)P and reduce its mutagenicity  [Gupta et al., 
2002; Mejia et al., 1999]. Thus, the anti-mutagenic activity of C3G and procyanidins of BE 
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may involve modifying the expression of cytochrome P4501A1 or forming complexes with 
B(a)P thereby inhibiting the metabolic activation of B(a)P and formation of DNA -adducts. 
Another mutagen, 4NQO, is a quinoline derivative and a tumorigenic compound. It is 
well-known that the mutagenic action of 4NQO is responsible for the generation of DNA 
-adducts [Galiegue-Zouitina et al., 1986] and intracellular oxidative stress that undergoes 
redox recycling [Nunoshiba and Demple, 1993]. From the author’s results, the antimutagenic 
activity of C3G and procyanidins of BE may be attributed to protection against the production 
of DNA -adducts or scavenging of superoxide radicals and other reactive oxygen species 
induced by 4NQO. Further study is required to clarify this issue. 
In conclusion, BE exhibited neither mutagenicity nor cytotoxicity against S. typhimurium. 
In contrast, C3G and procyanidins, the main BE polyphenols, contributed to strong 
anti-mutagenicity against B(a)P- and 4NQO-induced DNA damage. Therefore, BE is a safe 
and effective material for use in functional foods and medicines to prevent or treat 
chemically-induced carcinogenesis.  
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Appendix B 
Black soybean seed coat polyphenols prevent B(a)P-induced DNA damage through 
modulating drug-metabolizing enzymes in HepG2 cells and ICR mice 
INTRODUCTION 
B(a)P is a polycyclic aromatic hydrocarbon and widespread in the environment 
[Hattemer-Frey and Travis, 1991]. It is well documented that B(a)P requires metabolic 
activation to generate an electrophilic intermediate by CYP1A1-dependent monooxygenase 
enzymes [Gelboin, 1980; Schoket et al., 2001]. Through metabolic activation, B(a)P converts 
to its ultimate carcinogens, (+)-anti-7,8-dihydroxy-9,10-tetrahydrobenzo[a]pyrene 
[(+)-anti-BaPDE] [Gelboin, 1980; Buening et al., 1978; Slaga et al., 1979], which covalently 
binds to DNA to form B(a)P-DNA adducts; this is a critical event in B(a)P-induced DNA 
damage. Although, the constitutive level of CYP1A1 in mammal liver is low, B(a)P induces 
CYP1A1 expression through the action of an aryl hydrocarbon receptor (AhR) [Whitlock, 
1999; Drahushuk et al., 1998]. After binding the ligands to AhR, the receptor protein 
translocates into the nucleus and forms a heterodimer with AhR nuclear translocator (Arnt) 
[Denison et al., 1986; Elferink et al., 1990]. This AhR/Arnt heterodimer functions as a 
transcription factor. The heterodimer binds to the dioxin responsive element (DRE) and 
induces the expression of various proteins including CYP1A1 [Whitlock, 1999]. Thus, the 
reduction of CYP1A1 expression should be a feasible way to prevent B(a)P-induced DNA 
damage. 
(+)-anti-BaPDE, the final carcinogenic metabolite of B(a)P [Gelboin, 1980], has been 
known to induce mutagenicity in vitro and carcinogenicity in vivo [Buening et al., 1978; 
Slaga et al., 1979; Celotti et al., 1993]. To date, several mechanisms exist that can convert 
(+)-anti-BaPDE into less harmful compounds to protect against DNA damage [Singh et al., 
1998; Robertson et al., 1986; Hu et al., 1996; Harvey, 2011]. Among them, the most 
important mechanism of (+)-anti-BaPDE inactivation seems to be its conjugation with 
glutathione, a reaction catalyzed by the glutathione S-transferase (GST) family. GSTs are one 
of the most important detoxifying enzymes related to the detoxification system. It is known 
that GSTs catalyze the conjugation of a wide variety of xenobiotics through conjugation with 
glutathione thereby reducing their gene toxicity and protection against carcinogen-induced 
DNA damage [Frova, 2006]. GST expression is regulated by multiple factors including 
nuclear factor-erythroid 2-related factor 2 (Nrf2) that binds to antioxidant response elements 
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(ARE), which are specific nucleotide sequences present in the promoter region of the gene 
encoding for GSTs [Zhu et al., 2005]. Accordingly, an increase in the expression of GSTs 
should be another possible mechanism to prevent B(a)P-induced DNA damage. 
In appendix A, the author had showed that BE polyphenols showed strong 
anti-mutagenicity against B(a)P- and 4NQO-induced DNA damage in Salmonella 
typhimurium stains. In appendix B, the micronucleus (MN) assay was performed to 
investigate the protective effects of BE and its components on B(a)P-induced DNA damage in 
HepG2 cells. To clarify the underlying protective mechanism, the author examined the effects 
of BE and its components on B(a)P-induced CYP1A1 expression and the specific binding 
between AhR and DRE in HepG2 cells and ICR mice. The author further examined the effects 
of BE and its components on GSTα, µ and π expression and the specific binding between 
Nrf2 and ARE. 
 
MATERIAL AND METHODS 
Materials 
Cytochalasin B, Giemsa solution were purchased from Sigma (St. Louis, MO, USA). 
Anti-CYP1A1 (Daiichi Pure Chemicals Co. LTD Tokyo, Japan), anti-GSTα (Alpha 
Diagnostic International, Texas, USA), anti-GSTµ (Proteintech Group, Inc., Chicago, IL, 
USA) and anti-GSTπ (Assay Designs, Michigan, USA) were used in this study. For the 
electrophoretic mobility shift assay (EMSA), oligonucleotide probes were synthesized as 
follows: DRE: 5’-GAT CCG GAG TTG CGT GAG AAG AGC CA-3’ (coding) and 5’-GAT 
CTG GCT CTT CTC ACG CAA CAC CG-3’ (non-coding) and ARE: 5’-TCT AGA GTC 
ACA GTG ACT TGG CAA AAT CTG A-3’ (coding) and 5’-TGA GAT TTT GCC AAG 
TCA CTG TGA CTC TAG A-3’ (non-coding). All other reagents used were of the highest 
grade available from a commercial source. 
 
HepG2 cells culture and treatment 
HepG2 cells were cultured in Dulbecco’s modified Eagle’s medium (Nissui 
Pharmaceutical, Tokyo, Japan) containing 10% fetal bovine serum (Sigma, USA), 4 mM 
L-glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin under a humidified 
atmosphere of 95% air and 5% CO2 at 37 °C. After seeding in 6 cm dishes, the cells (90% 
confluent) were treated with BE (4.85 µg/mL equivalent to 10 µM of C3G) or its components 
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(10 µM) for 1 h. These cells were exposed to B(a)P (5 µM) or vehicle dimethyl sulfoxide 
(DMSO) for another 24 h. Thereafter, a post-nuclear fraction was extracted for western 
blotting analysis, whereas nuclear protein was prepared to measure the DNA-binding activity. 
Preparation of these fractions was performed according to the previous report [Nishiumi et al, 
2008]. 
 
Animal treatment 
Animal treatment in this study conformed to the “Guidelines for Care and Use of 
Experimental Animals”, Rokkodai Campus, Kobe University (Permission # 24-11-01). Male 
ICR mice (6-weeks-old) were purchased from Japan SLC, Shizuoka and maintained in a 
temperature-controlled room (23 ± 2 °C) with a 12:12-h light/dark cycle (lights on at 9:00 am). 
For the first experiment, twelve male ICR mice (20-25 g) were divided at random into three 
groups of four each, i.e., the BE, PC-rich BE and water groups. All mice were orally 
administered BE and PC-rich BE (1 g/kg of body weight) suspension in deionized water or 
the vehicle alone (10 mL/kg of body weight) as a control. After 24 h, the liver was removed 
and used for experiments. For the second experiment, 24 male ICR mice (6 weeks old) were 
randomly divided into three groups of eight each for BE, PC-rich BE and water groups. All 
mice were orally administered BE and PC-rich BE (1 g/kg of body weight) suspension in 
deionized water or vehicle alone (10 mL/kg of body weight) as a control for 1 day or 3 
consecutive days. These mice were further divided into two subgroups of 4 each for BE, 
PC-rich BE and water groups. One subgroup was given B(a)P (10 mg/kg of body weight) in 
corn oil through an intraperitoneal injection 1 h after the last administration of BE, PC-rich 
BE or water, whereas the other subgroup was given corn oil (5 mL/kg of body weight) as a 
vehicle control. After 25 h, the mice were sacrificed, and livers were removed for use in 
further experiments. Hepatic nuclear and post-nuclear fractions were prepared according to a 
previous report [Nishiumi et al., 2008] and subjected to western blotting analysis and EMSA 
as follows. 
 
MN assay 
The MN assays were performed according to the previously described method [Darroudi 
and Natarajan, 1993]. Briefly, HepG2 cells were first grown for 24 h and then washed twice 
with PBS. To estimate genotoxicity, the cells were exposed to BE at concentrations of 0, 6.25, 
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12.5 and 25 µg/mL for another 24 h. As a positive control, B(a)P at 2 µM was used. In the 
case of the anti-genotoxicity test, the cells were pre-treated with BE at concentrations of 0, 1, 
5, 10 and 20 µg/mL for 24 h then exposed to B(a)P at 40 µM for another 2 h. After washing 
the cells, cytochalasin B (final concentration 3.0 µg/mL) was added to the medium for 24 h. 
For fixation, the cells were trypsinized and treated with cold hypotonic KCl solution (5.6 g/L) 
and subsequently air-dried preparations were made. To detect MN in the binucleated cells, the 
fixed cells were strained with 5.0% aqueous Giemsa solution. For each experiment, the 
percentage of MN frequency was determined in at least 1000 binucleated cells from triplicate 
independent cultures. To estimate cell division, the percentage of binucleated cells was also 
determined in the same culture dishes [Ehrlich et al., 2002] 
 
Western blotting analysis 
The post-nuclear fraction from HepG2 cells and the cytosolic fraction from ICR mice 
liver were used for the detection of CYP1A1 and GSTs by 10 and 12% of sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), respectively. The proteins were 
transferred onto a PVDF membrane (GE Healthcare Bio-Science Co., Piscataway, NJ, USA). 
The membrane was treated with commercial blocking solution (Blocking One, Nacalai 
Tesque) for 30 min at room temperature. The membrane was incubated with primary 
antibodies for CYP1A1 (1:20000), GSTα (1:50000), GSTβ (1:20000) and GSTπ (1:20000) 
overnight at 4 °C, followed by the corresponding HRP-conjugated secondary antibody for 1 h 
at room temperature. The blots were developed using ImmunoStar® LD (Wako) Western 
Blotting Substrate and detected with Light-Capture II (ATTO, Tokyo, Japan). The densities of 
specific bands were determined using Image J image analysis software. 
 
EMSA 
EMSA was performed to determine the DNA-binding activity of DER and ARE. Briefly, 
nuclear extract (10 μg of protein) from the HepG2 cells or liver from the ICR mice was 
incubated with 500 ng of poly[dI-dC] and a 32P-labeled DRE or 32P-labeled ARE probe (30 
kcpm, 10 fmols) in HEDG buffer for 15 min. The mixture was then loaded onto a 4% 
nonstacking polyacrylamide gel in TBE buffer (25 mM Tris, 22.5 mM borate and 0.25 mM 
EDTA). After electrophoresis, the AhR/DRE and Nrf2/ARE complexes were visualized by 
autoradiography and quantitatively analyzed by Gel-Pro Analyzer (Media Cybernetics, 
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Bethesda, MD, USA).  
 
Statistical analysis 
The data are expressed as the mean ± SE of at least three independent determinations for 
each experiment. Dunnett’s test was used to determine the significance of differences between 
the treated and control groups. The level of statistical significance was set to p<0.05. 
 
RESULTS 
Genotoxic and anti-genotoxic activities of BE in HepG2 cells 
Genotoxicity of BE was evaluated by MN assay. As shown in Fig. appendix B-1A, none 
of the tested concentrations led to increased MN frequencies compared with the background 
level 19 MN/1000 BNC. In addition, BE at concentrations up to 25 µg/mL did not 
significantly alter the number of binucleated cells (Fig. appendix B-1B). The effects of BE on 
B(a)P-induced MN are shown in Fig. appendix B-2A. It was found that BE at 5, 10 and 20 
µg/mL significantly decreased the level of B(a)P-induced MN in HepG2 cells. To clarify the 
main active compounds in BE, the author next evaluated the effects of BE and its polyphenols 
on B(a)P-induced MN frequencies. Fig. appendix B-2B showed that treatment with BE and 
PC-rich BE (4.85 µg/mL equivalent to 10 µM C3G), C3G, EC and other PCs (10 µM each) 
significantly decreased MN frequencies induced by B(a)P. 
 
BE inhibits B(a)P-induced CYP1A1 expression and AhR transformation in HepG2 cells 
and livers of ICR mice 
To clarify the mechanism of the inhibitory effects of BE and its polyphenols on 
B(a)P-induced MN frequencies, the author investigated the effects of BE and its polyphenols 
on the expression of CYP1A1 and the upstream event AhR transformation in vitro and in vivo. 
For the in vitro experiment, the author isolated the post-nuclear fractions from the HepG2 
cells that were treated with 5 µM B(a)P for 24 h as well as the vehicle-treated control cells. 
Results from western blotting analysis showed that CYP1A1 expression was dramatically 
induced following B(a)P treatment (Fig. appendix B-3A). The author found that 
B(a)P-induced CYP1A1 expression was significantly suppressed by BE and PC-rich BE at 
4.85 µg/mL by 43 and 53%, respectively. Moreover, the author confirmed that BE and 
PC-rich BE, themselves did induce any changes to CYP1A1 expression. When AhR 
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transformation was evaluated by EMSA, B(a)P significantly promoted the transformation as 
expected (Fig appendix B-3B). BE and PC-rich BE at 4.85 µg/mL suppressed the 
B(a)P-induced transformation by 48 and 45%, respectively. To make clear the effective 
components, the author determined the effects of BE components C3G, catechin, EC and 
procyanidins (PCB1, PCB2, PCC, PCD1 and PCD2) on B(a)P-induced CYP1A1 expression 
in HepG2 cells. As shown in Fig. appendix B-3C, C3G, PCB1, PCB2, PCC, PCD1 and PCD2 
down-regulated CYP1A1 expression by 54, 36, 47, 39, 33 and 32%, respectively, compared 
with the control group, whereas catechin and EC did not show significant inhibitory effect.  
 
 
 
 
 
 
Fig. appendix B-1. Effects of BE on MN formation (A) and cell division (B) in HepG2 
cells. The cells were exposed for 24 h to BE or B(a)P (2 µM) as a positive control followed by 
subcultivation for 24 h in the presence of cytochalasin B (3 µg/mL). (A) Bars represent MN numbers 
found in three cultures (in each culture, 1000 binucleated cells were evaluated for MN induction). 
(B) Number of binucleated cells (%) relative to the number of mono-, tri- and tetranucleated cells. 
The results are represented as the mean ± SE (n=3). *Indicates significant difference from the 
corresponding control by Dunnett’s test (p<0.05). 
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To confirm the in vitro results, the author also performed in vivo experiments. After the 
mice were orally administered BE and PC-rich BE at 1 g/kg of body weight followed by an 
intraperitoneal injection of B(a)P at 10 mg/kg of body weight, both CYP1A1 expression and 
AhR transformation in mice liver were significantly decreased by approximately 40%, which 
was evaluated by western blotting and EMSA, respectively (Fig. appendix B-4). 
 
 
 
 
 
Fig. appendix B-2. Effects of BE (A) and its polyphenols (B) against B(a)P-induced MN 
formation in HepG2 cells. The cells were treated with BE at various concentrations (A), or BE 
and PC-rich BE at 4.85 µg/mL and their major polyphenols at 10 µM (B) for 24 h. Then, the cells 
were exposed to B(a)P at 40 µM for further 2 h. Subsequently, the cells were treated with 
cytochalasin B (3 µg/mL) for another 24 h. Bars represent MN numbers found in three cultures (in 
each culture, 1000 binucleated cells were evaluated for MN induction). The results are represented as 
the mean ± SE (n=3). *Indicates significant difference from the corresponding positive control by 
Dunnett’s test (p<0.05). 
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Fig. appendix B-3. BE (A and B) and its polyphenols (C) suppress CYP1A1 expression 
(A and C) and AhR transformation (B) induced by B(a)P in HepG2 cells. The cells were 
treated with BE (4.85 µg/mL equivalent to 10 µM of C3G) or its components (10 µM) for 1 h. 
Subsequently, the treated cells were exposed to B(a)P (5 µM) or DMSO for 24 h. CYP1A1 
expression was determined by western blotting analysis, whereas AhR transformation was estimated 
by EMSA. The density of each band was quantified, and the value in the positive control 
[B(a)P-treated cells] was set to 100%. The results are represented as the mean ± SE (n=3). *Indicates 
significant difference from the corresponding positive control by Dunnett’s test (p<0.05). 
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Fig. appendix B-4. BE and PC-rich BE suppress B(a)P-induced CYP1A1 expression 
(A) and AhR transformation (B) in ICR mice. Mice were orally administered BE and 
PC-rich BE at 1 g/kg of body weight or water (10 mL/kg of body weight) as a vehicle control for 3 
consecutive days. Half of the mice were given B(a)P (10 mg/kg of body weight) in corn oil through 
an intraperitoneal injection 1 h after the administration of BE and PC-rich BE, whereas the 
remaining were given corn oil (5 mL/kg of body weight) as a vehicle control. After 25 h, hepatic 
nuclear and post-nuclear fractions were prepared and subjected to EMSA for AhR translocation and 
western blotting analysis for CYP1A1. The density of each band was quantified, and the value in 
the positive control was set to 100%. The results are represented as the mean ± SE (n=4). *Indicates 
significant difference from the corresponding positive control by Dunnett’s test (p<0.05).  
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Fig. appendix B-5. BE (A and B) and its polyphenols (C) enhance GSTα, µ and π 
expression (A and C) and DNA-binding activity of Nrf2 (B) in HepG2 cells. The cells 
were treated with BE (4.85 µg/mL equivalent to 10 µM of C3G) or its components (10 µM) for 24 
h. DMSO (final 0.25%) and t-BHQ (30 µM) were used as the vehicle and positive controls, 
respectively. Nuclear and post-nuclear fractions were prepared and subjected to EMSA for Nrf2 and 
western blotting analysis for GSTs. The density of each band was quantified, and the value in the 
vehicle control was set to 100%. The results are represented as the mean ± SE (n=3). *Indicates 
significant difference from the corresponding vehicle control by Dunnett’s test (p<0.05). 
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BE enhances GST expression and DNA-binding activity of Nrf2 in HepG2 cells and 
livers of ICR mice 
Induction of GST isoforms is considered one of the crucial mechanisms to protect cells 
against B(a)P-induced DNA damage. Nrf2 has been described as the main transcription factor 
that binds to the ARE sequence promoter region of the gene encoding for GSTs [Zhu et al., 
2005]. The author performed both in vitro and in vivo experiments to evaluate the effects of 
BE on GST expression and Nrf2 transformation. For the in vitro experiments, HepG2 cells 
were treated with BE and PC-rich BE at 4.85 µg/mL for 24 h. Western blotting results showed 
that GSTα, µ and π expression were significantly enhanced by 2-3 fold compared with the 
control group (Fig. appendix B-5A). The EMSA results also showed that these proteins 
increased DNA-binding activity of Nrf2 (Fig. appendix B-5B). To determine the effects of 
various components, the author tested the effects of the BE components C3G, catechin, EC 
and procyanidins (PCB1, PCB2, PCC, PCD1 and PCD2) on GST expression in HepG2 cells. 
As shown in Fig. appendix B-5C, C3G, EC, PCB1, PCB2, PCC, PCD1 and PCD2 
up-regulated GST expression approximately 1.5- to 3-fold compared with the control group. 
Similar results were also found from the in vivo experiments. After the mice were orally 
administered BE and PC-rich BE at 1 g/kg of body weight for 1 day or 3 consecutive days, 
BE and PC-rich BE significantly increased GSTα, µ and π expression in both 1-day and 3-day 
treatment (Figs. appendix B-6A and 6B, respectively). In addition, induction of GSTs in the 
3-day treatment was higher compared with that from the 1-day treatment (Figs. appendix-6A 
and 6B). As expected, these treatments were observed to increase the DNA-binding activity of 
Nrf2 (Figs. appendix-6C). 
 
DISCUSSION  
In the present study, the author first confirmed that BE was non-genotoxic (Fig. appendix 
B-1). In contrast, BE showed a dose-dependent anti-genotoxic activity against B(a)P-induced 
MN frequencies (Fig. appendix B-2A). This anti-genotoxic activation was involved in the 
modulation of drug metabolizing enzyme expression by BE: On the one hand, BE suppressed 
the expression of CYP1A1 by inhibiting AhR transformation both in vitro and in vivo (Figs. 
appendix B-3 and 4). On the other hand, BE enhanced DNA-binding activity of Nrf2 and 
subsequent induction of GSTs expression both in vitro and in vivo (Figs. appendix B-5 and 6). 
The author’s finding demonstrated that PCs (dimmer, trimer and tetramer) and C3G, which 
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are the major polyphenols in BE, contributed to the anti-genotoxic activity of BE (Figs. 
appendix B-2B, 3C and 5C). From these results, polyphenols in BE have the potential to 
protect against B(a)P-induced DNA damage. 
 
 
 
 
 
 
 
Fig. appendix B-6. BE and PC-rich BE enhance GSTα, µ and π expression (A and B) 
and DNA-binding activity of Nrf2 (C) in ICR mice. Mice were orally administered BE and 
PC-rich BE at 1 g/kg of body weight or water (10 mL/kg of body weight) as a vehicle control for 1 
day (A) or 3 consecutive days (B). Hepatic nuclear and post-nuclear fractions were prepared and 
subjected to EMSA for Nrf2 and western blotting analysis for GSTs. The density of each band was 
quantified, and the value of the vehicle control was set to 100%. The results are represented as the 
mean ± SE (n=4). *Indicates significant difference from the corresponding positive control by 
Dunnett’s test (p<0.05). 
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B(a)P is a five-ring polycyclic aromatic hydrocarbon whose metabolites are mutagenic 
and highly carcinogenic. Numerous studies have documented B(a)P involved in an increase of 
cancer risk [Xiong et al., 2001; Sinha et al., 2005]. It has been known that B(a)P causes 
cancer through several enzymatic reactions [Jiang et al., 2007]. The most important enzyme is 
CYP1A1. B(a)P induces CYP1A1 through an AhR-mediated pathway [Whitlock, 1999; James 
and Whitlock, 1999]. Induced CYP1A1 plays a role in metabolic activation of B(a)P to form 
epoxides, which generate radicals and DNA-adducts [Lodovici et al., 2004]. Previous studies 
have demonstrated that procyanidin-rich cacao polyphenol extract suppresses 
3-methylcholanthrene-induced CYP1A1 expression in C57BL/6 mice [Mukai et al., 2008]. 
Anthocyanin-rich pomegranate juice prevents procarcinogen activation through the inhibition 
of CYP activity [Faria et al., 2007]. The author’s results showed that BE and its components 
suppressed CYP1A1 expression both in HepG2 cells and livers of ICR mice, and this 
suppression was involved in the inhibition of AhR transformation [Figs. Appendix B-3 and 4]. 
These results suggest that BE and its components down-regulated expression of CYP1A1 by 
inhibiting the binding between AhR and DRE to reduce metabolic activation of B(a)P. 
Moreover, it has been reported that certain polyphenols can form complexes with B(a)P and 
reduce its mutagenicity [Gupta et al., 2002; de Mejia et al., 1999]. Thus, the anti-genotoxic 
activity of PCs and C3G of BE are explained by modifying CYP1A1 expression or forming 
complexes with B(a)P to inhibit metabolic activation of B(a)P and formation of DNA adducts. 
The metabolic fate of the prototype carcinogen B(a)P has been extensively studied since 
the mid-1970s [Conney, 1982]. A series of investigations have clearly demonstrated that 
B(a)P epoxides, especially (+)-anti-7,8-dihydroxy-9,10-tetrahydrobenzo[a]pyrene, are highly 
reactive towards DNA and are classified as the ultimate carcinogenic metabolites of B(a)P 
[Gelboin, 1980; Buening et al., 1978; Slaga et al., 1979]. It is been known that B(a)P epoxides 
inactivation seems to be by conjugation with GSH, a reaction catalyzed by GSTs [Frova, 
2006]. The main physiological activity of the detoxification enzyme GST family is to protect 
the cells against carcinogens, toxins and free radical oxidants [Lo and Ali-Osman, 2007]. 
Thus, GSTs have been recognized as important target molecules for a number of 
chemopreventive and cytoprotective agents, including dietary factors [Lii et al., 2006]. 
Previous studies have shown that naturally occurring flavonoid procyanidin B2 inhibits 
oxidative stress by inducing Nrf2 nuclear translocation and GSTP1 expression 
[Rodriguez-Ramiro et al., 2012]. Anthocyanin from black rice, berry and potato prevent 
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oxidative stress and some toxins by inducing GST expression [Hou et al., 2010; Milbury et al., 
2007; Hwang et al., 2011]. Notably, BE and its component PCs and C3G also enhanced GST 
expression in both HepG2 and livers of ICR mice (Figs. Appendix B- 5 and 6). These results 
indicate that PCs and C3G in BE may help to convert B(a)P epoxides into less harmful 
compounds by inducing GST expression. It is well known that up-regulation of GSTs is 
mediated by activation of the nuclear translocation of Nrf2 and its binding to ARE sequence 
[Zhu et al., 2005]. The author’s findings have demonstrated that BE and PC-rich BE increased 
the DNA-binding activity of Nrf2 and its downstream GST expression (Figs. Appendix B-5 
and 6). Moreover, the increase in the DNA-binding activity of Nrf2 is correlated with an 
increase in GST expression. These results indicate that BE may reduce the toxicity of 
carcinogenic metabolites of B(a)P via enhancing detoxification enzyme GST expression. 
In conclusion, BE did not induce genotoxicity to HepG2 cells. On the contrary, BE 
revealed a strong anti-genotoxicity against B(a)P-induced DNA damage in HepG2 cells. The 
author found that PCs and C3G were the main active compounds in BE for the suppression of 
DNA damage. These suppression effects of DNA damage were involved in the modulation of 
drug metabolizing enzyme expression. The author found that the PCs and C3G were the main 
active compounds in BE for down-regulation of CYP1A1 and up-regulation of GST 
expression, indicating that these compounds can effectively protect against B(a)P-induced 
DNA damage in liver cells. Collectively, BE is not only a safe and effective functional food 
but also has medicinal properties for the prevention and treatment of chemical-induced DNA 
damage and cancers.  
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Appendix C 
Black soybean seed coat polyphenols inhibit AAPH-induced production of 8-OHdG in 
HepG2. 
INTRODUCTION 
Reactive oxygen species (ROS) are well-established physiological molecules controlled 
by antioxidative defense systems. Cells are naturally provided with an extensive array of 
protective enzymes to scavenge ROS [Halliwell, 1994]. However, when environmental stress 
occurs, ROS levels can increase dramatically [Devasagayam et al., 2004]. Oxidants produce 
extensive oxidative damage to DNA, which, in turn contributes to malignant tumors, diabetes 
and other degenerative diseases [Sun, 1990; Poulsen et al., 1998]. 
8-Hydroxy-2’-deoxyguanosine (8-OHdG) is one of the biomarkers of oxidative DNA damage 
[Helbock et al., 1999]. An accumulation of 8-OHdG has been shown to lead to G: C-to-T: A 
transversion mutations that are prevalent in mutated in tumor suppressor genes [Shibutani et 
al.,1991; Hussain et al.,1998]. In recent years, the 8-OHdG lesions can be detected and 
analyzed with high sensitivity by liquid chromatography-mass spectrometry-mass 
spectrometry (LC-MS/MS). Determination and analysis 8-OHdG can be performed in cells, 
animal organs and human samples as a biomarker of oxidative stress and carcinogenesis 
[Valavanidis et al., 2009]. 
The appendix A and B showed that BE and its components inhibited mutagens-induced 
DNA damage effectively. In appendix C, the author, further, investigated the protective effect 
of BE and its polyphenols on oxidative DNA damage by estimating the levels of 8-OHdG in 
HepG2 cells.  
 
MATERIAL AND METHODS 
Materials 
8-OHdG, and a ROS generator, 2,2’-azobis(2-amidinopropane) dihydrochloride (AAPH), 
were purchased from Wako Pure Chemical Industries. 8-mercaptoguanosine (8-SHG) was 
purchased from Sigma (St. Louis, MD). Other materials were described in appendix A and B. 
 
DNA Sample preparation  
The HepG2 cells were seeded at a density of 5×105 cells/mL on a 60 mm plastic dish. 
After a 5 day culture, the cells were incubated with 4.85 µg/mL (equivalent to 10 µM of C3G) 
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BE and PC-rich BE or 10 µM each polyphenol for 1 or 24 h and then exposed to 25 mM 
AAPH at 37°C for 3 h. Then, the incubated HepG2 cells were submitted for isolation of the 
nuclei according to a previous method [Kanazawa et al., 2006] with some modification. 
Briefly, the cells scraped with 100 µL of PBS were washed three times with ice-cold PBS and 
centrifuged at 1000×g for 3 min at 4 °C. The pellet was gently homogenized in an ice-cold 5 
mM HEPES buffer (pH 7.5) containing 0.25 M sucrose and 0.5 mM EGTA, and again 
centrifuged at 1000×g for 10 min at 4°C. The pellet was three times washed with the buffer, 
and repeating the centrifugation. After washing with ice-cold PBS, the nuclei were lysed with 
400 µL of TE buffer (10 mM Tris-HCl, pH 7.4, and 1 mM EDTA) containing 0.5% sodium 
dodecyl sulfate (SDS). The lysate was treated with a final concentration of 0.5 mg/mL of 
ribonuclease A (Sigma) for 30 min at 50°C, and again with 0.5 mg/mL of proteinase K 
(Sigma) for 1 h at 50°C. By adding 0.5 M NaCl, DNA was then precipitated in 50% 
isopropanol and centrifuged at 17,000×g for 15 min. The pellet was dissolved in 35 mM 
sodium acetate containing 1 mM EDTA, mixed with a final concentration of 500 nM of 
internal standard 8-SHG and 0.2 mg/mL of nuclease P1 (Sigma) at 37°C for 30 min, and the 
reaction was stopped by adding 0.1 M Tris-HCl (pH 7.5). The DNA was treated with 3 units 
of alkaline phosphatase (Sigma) for 1 h at 37°C and centrifuged at 17,000×g for 10 min at 
4°C. The supernatant was filtered through a 0.45 µm membrane filter. DNA concentration in 
the filtered solution was quantified using the NanoDrop® ND-1000 spectrophotometer 
(NanoDrop, Wilmington, DE, USA) and the DNA concentration was adjusted to 40 ng/µL. 
 
Measurement of 8-OHdG 
The formation of 8-OHdG was detected and quantified by LC-MS/MS (4000 Q TRAP®, 
AB Sciex, Foster City, CA, USA) using electrospray ionization. HPLC separation was done 
with a gradient system using the mobile phase consisted of Solvent A (0.1% formic acid in 
de-ionized water) and Solvent B (acetonitrile). The samples were performed on a 5C18-MS-II 
2.0 ID×15 mm column (Chemicals Evaluation and Research Institute, Tokyo, Japan) at a flow 
rate of 0.2 mL/min. The column oven was maintained at 40°C. The filtered samples were 
injected (5 µL) on column with initial conditions set to 0% Solvent B for 1 min. and then the 
concentration of Solvent B was increased linearly to 80% by 13 min. This condition was held 
for 1 min before returning to the initial mobile phase composition that maintained for the 
remainder of the assay and returned to initial conditions prior to the next injection. The total 
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run time, including column re-equilibration, was 20 min. Detection of 8-OHdG and 8-SHG 
was carried out under the positive electrospray ionization mode. The conditions for detection 
were obtained by direct infusion of a standard solution in line with the HPLC, set to initial 
mobile phase conditions. The cone and collision settings were established individually for 
8-OHdG and 8-SHG to be used for multiple reaction monitoring (MRM) detection. Peak area 
of 8-OHdG was corrected by the area of the internal standard, 8-SHG. 
 
Statistical analysis 
The data are expressed as the mean ± SE. Dunnett’s test was used to determine the 
significance of differences between sample group and control group in LC-MS/MS analysis. 
The level of statistical significance was set to p<0.05. 
 
RESULTS 
Establishment of analytical procedure by LC-MS/MS 
To quantify 8-OHdG and 8-SHG (as an internal standard), the author first established the 
measurement conditions in LC-MS/MS. The MRM channels for 8-OHdG and 8-SHG were 
found to be 284/168 m/z and 317/185 m/z, respectively, corresponding to the [M + H] + 
parent ion and daughter fragment (the data was not shown). The detection limit was 
determined to be 1 nM (signal-to-noise ratio > 10:1) of 8-OHdG. In order to confirm the 
8-SHG can be used as the internal standard to measure 8-OHdG from cells samples, the 
author, first, measured 8-OHdG (500 nM) and 8-SHG (500 nM) simultaneously, and found 
the retention time of them was 7.56 min and 7.73 min, respectively  (shown in Fig. appendix 
C-1). Then the 8-OHdG in DNA samples 40 ng/µL from AAPH-treated cells were measured 
with or without internal standard 8-SHG (500 nM) under the same condition. Fig. appendix 
C-1B and C showed one of the typical results of DNA sample from AAPH-treated cells. The 
results exhibit that 8-OHdG and 8-SHG can be detected simultaneously, and there is no 
8-SHG existing in DNA samples from cells. Thus, the author identified 8-SHG can be used as 
the internal standard to detect the formation of 8-OHdG in DNA samples from HepG2 cells. 
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Fig. appendix C-1. LC-MS/MS chromatogram of reference compounds using multiple 
reaction monitoring (MRM) mode. (A) Simultaneous measurement of 8-OHdG (500 nM) and 
8-SHG (500 nM). (B) Measurement of DNA sample (40 ng/µL) from the AAPH-treated cells 
without internal standard 8-SHG. (C) Simultaneous measurement of DNA sample (40 ng/µL) from 
the AAPH-treated cells with internal standard 8-SHG (500 nM). Typical result was shown from 
three independent experiments. 
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Preventive effect of BE and its polyphenols on 8-OHdG formation 
Using the established methods, the author examined the potential protective effect of BE 
and its polyphenols on the AAPH-induced 8-OHdG formation in HepG2. BE and PC-rich BE 
(4.85 µg/mL equivalent to 10 µM C3G), C3G, (+)-catechin, EC, PCB1, PCB2, PCC, PC 4-1 
and PC 4-2 (10 µM each) significantly suppressed the formation of 8-OHdG by 60 %, 63%, 
Fig. appendix C-2. Inhibition effect of BE and its polyphenols on the AAPH-induced 
8-OHdG formation in HepG2. (A) BE and PC-rich BE at 4.85 µg/mL (equivalent to 10 µM 
C3G) and its polyphenols [C3G, (+)-catechin, EC, PCB1, PCB2, PCC, PC 4-1 and PC 4-2] at 10 
µM each were treated to HepG2 cells for 1 or 24 h. (B) HepG2 cells were treated with C3G, EC, 
PCB1 and PC 4-1 (1, 5, 10 and 30 µM) for 1h. Then these cells were exposed to 25 mM AAPH for 
another 3 h. Nuclei were isolated from these cells. DNA was extracted, purified and subjected to 
LC-MS/MS analysis. Three independent experiments were performed. *Significantly different from 
the 8-OHdG level in DNA sample from the corresponding control cells by Dunnett’s test (p<0.05). 
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76%, 75%, 83%, 71%, 76%, 68%, 60% and 66% for 1 h treatment compared with control. 
Furthermore, they showed higher inhibitory effect for the 8-OHdG formation by 35%, 45%, 
80%, 75%, 75%, 58%, 71%, 63%, 41% and 57% for 24 h treatment (Fig. appendix C-2A). 
The author further, examined the dose-dependent effect of C3G, EC, PCB1 and PC 4-1 against 
AAPH-induced 8-OHdG formation. As shown in Fig. appendix C-2B, these 4 compounds 
suppressed the formation of 8-OHdG dose-dependently. C3G and EC significantly decreased 
the AAPH-induced 8-OHdG formation from 10 µM, while PCB1 and PC 4-1 from 3 µM. 
 
DISCUSSION 
ROS-induced oxidative DNA damage has been implicated in mutagenesis and 
carcinogenesis. This oxidative DNA damage is mainly due to the formation of 8-OHdG [Sun, 
1990]. Accumulation of 8-OHdG has been exhibited in several carcinoma cells [Miyake et al., 
2004; Kondo et al., 2000; Musarrat et al., 1996]. Moreover, 8-OHdG in human muscle, lung 
and intestine are increasing with aging, smoking habit and chronic diseases, respectively 
[Hayakawa et al., 1991; Bizon et al., 2011; D'Inca et al., 2004]. Since 8-OHdG is one of the 
biomarkers to evaluate carcinogenesis, establishment of a high-sensitive analytical method for 
8-OHdG is important. The method LC-MS/MS was found to be demonstrably as reliable, 
sensitive and preciseto detective 8-OHdG. Owing to the complex nature of the sample extract, 
it is not uncommon for each of these methods to require several labor-intensive clean-up steps 
prior to analysis. For these reasons, isotopic labeled internal standards are necessary for 
quantification by mass spectroscopy. However, isotopic labeled internal standards are not 
stable and would not be cost-effective for a clinical laboratory [Hu et al., 2004]. Recently, 
8-SHG as a cheap and readily available non-isotopic internal standard was established for 
LC-MS/MS assay to detect 8-OHdG in urine [Crow et al., 2008]. In the present study, the 
author confirmed that 8-SHG also can be used as an internal standard to detection of 8-OHdG 
in the cells system (Fig. appendix C-1). Using this established method, the author found that 
PCs, C3G in addition to (+)-catechin and (-)-epicatechin inhibited the 8-OHdG formation. In 
particular, PCs presented a strong inhibition effect (Fig. appendix C-2). PCs in beverages, 
vegetable and fruits have been reported for the prevention activity against DNA damage. For 
example, PCs in wine protect against hydrogen peroxide-induced oxidative stress in Fao cells 
[Roig et al., 2002], PCs from apple juice reduce oxidative DNA damage in vivo [Barth et al., 
2005] and grape seed PC extract protects DNA from H2O2-induced DNA lesions [Llopiz et al., 
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2004]. Therefore, PCs should be the main active compounds in BE that suppressed ROS 
generator AAPH-induced DNA damage.  
In appendix C, the author established a method to detect 8-OHdG formation in HepG2 
cells. Using this method, it was found that PCs should be the main active compound in BE for 
suppression of 8-OHdG formation induced by a ROS generator AAPH. Therefore, BE 
effective material for functional food and a medicinal material for prevent oxidative DNA 
damage. 
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APPENDIX DISCUSSION  
DNA damage can lead to degenerative diseases [Reardon et al., 1992; Lee and Blair, 
2001]. Black soybean seed coats are rich in various polyphenols such as catechins, 
anthocyanins, procyanidins and other flavonoids. Constituents in black soybean seed coat 
extract (BE) have been reported to possess various physiological functions [Ignasius et al., 
2009; Kanamoto et al., 2011; Reardon et al., 1992; Lee and Blair, 2001]. In this study the 
author found that BE polyphenols prevent mutagens- and AAPH-induced DNA damage. 
In appendix A, Ames test was used to estimate mutagenic and antimutigenic potential of 
BE polyphenols. The results showed that BE neither exhibited mutagenicity nor any 
cytotoxicity in Salmonella tyhimurium. On the contrary, C3G and procyanidins, the main BE 
polyphenols contributed to a strong antimutagenicity against B(a)P- and 4NQO-induced DNA 
damage. To clarify the underlying preventive mechanism of BE on mutagens-induced DNA 
damage, in appendix B, the author investigated the potential protective effects of polyphenolic 
extracts from black soybean seed coat on B(a)P-induced DNA damage in HepG2 cells and 
ICR mice. BE did not bring any genotoxicity to HepG2 cells. On the contrary, BE revealed a 
strong anti-genotoxicity against B(a)P-induced DNA damage in HepG2. The author found 
that procyanindins and C3G should be the main active compounds in BE for suppression of 
DNA damage. These suppression effects of DNA damage was involved in modulation of 
drug-metabolizing enzymes expression. Procyanidins and C3G were the main active 
compounds in BE for down-regulation of CYP1A1 and up-regulation of GSTs expressions, 
indicating that these compounds can protect B(a)P-induced DNA damage in the HepG2 cells 
effectively. Moreover, the author established a method to detect 8-OHdG in the cells system. 
Using this established method, the author investigated the BE and BE polyphenols on 
AAPH-induced the formation of 8-OHdG. The results showed that BE polyphenols 
suppressed 8-OHdG formation effectively. Procyanidins should be the main active 
compounds in BE for suppression of 8-OHdG formation induced by a ROS generator AAPH 
in HepG2 cells. 
Together all, BE is not only a safe and effective material for functional food but also a 
medicinal material for prevention and treatment of chemical-induced DNA damage.  
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